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ABSTRACT 
The studies discussed herein were conducted to develop a vaccine for use in alleviating 
Mycoplasma hyorhinis associated disease in swine. This goal necessitated the development 
of a consistent and robust challenge model. We exploited M. hyorhinis’ affinity to infect 
tissue culture and have generated a cell-associated challenge material. This material was then 
administered in a consecutive-day, variable route model resulting in a high degree of 
lameness, arthritis and polyserositis in caesarian derived, colostrum deprived pigs. We 
further demonstrated an age limitation of the pigs for susceptibility to M. hyorhinis infection 
in this model. An inactivated whole-cell vaccine was developed and efficacy was evaluated 
in the challenge model. Vaccination provided significant reductions of pericarditis, arthritis 
and lameness as well as a significant increase in weight gain compared to a placebo control 
group. Lastly, a comparative proteomic analysis was performed between a broth-derived 
culture and two cell-associated cultures of a single isolate of M. hyorhinis. Differential 
expression of several membrane-associated proteins was observed in the cell-associated 
cultures. The identified proteins provide insight into the infection process and are targets for 
future vaccine trials.
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CHAPTER 1. INTRODUCTION 
 
General Introduction 
 Mycoplasma hyorhinis (MHR) is a pathogen of swine which causes polyserositis and 
lameness in the production setting, leading to reduced performance or culling of affected 
animals. These outcomes result in economic losses to the pig producer. As compared with 
Mycoplasma hyopneumoniae, a major respiratory pathogen of swine, our understanding of 
the pathogenesis of MHR is poor. As no commercial vaccines are currently available, 
treatment of MHR-associated disease has been mainly through antibiotic therapy. The studies 
described here detail a disease model developed for use to evaluate vaccine candidates. A 
proteomic evaluation is also discussed which will aid in our understanding of MHR infection. 
 
Dissertation Organization 
 This dissertation is arranged into six chapters. The first chapter is a general 
introduction to MHR and includes a literature review. Chapters 2 and 3 detail the 
development and optimization of a disease model for MHR, as well as the age susceptibility 
of pigs to this model. Chapter 4 determines the efficacy of an inactivated, whole cell vaccine 
for protection against MHR-associated pericarditis and lameness. Chapter 5 details a 
comparative proteomic analysis between in vitro and ex vivo cultures of a single isolate of 
MHR for differential protein expression. The final chapter is a general conclusion with 
discussions for future research. Chapters 2 - 5 constitute research which has or will be 
submitted for publication and are presented in the style of the peer reviewed journal for 
which they were targeted. 
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Literature Review 
Porcine Mycoplasmas 
 Mycoplasmas are bacteria in the family Mycoplasmataceae and are in the class 
Mollicutes. This class of bacteria is distinguished by their small size (0.1 µm – 0.3 µm), very 
small genome with a low G + C content, and lack of a cell wall (1, 2). It is proposed that 
Mycoplasmas’ small, reductive genome de-evolved from a common Gram positive ancestor, 
possibly lactobacilli, streptococci, or staphylococci (1-3).  
 Three distinct mycoplasma species are considered pathogenic to swine, Mycoplasma 
hyopneumoniae (MHP), Mycoplasma hyosynoviae (MHS), and Mycoplasma hyorhinis  
(MHR) (4, 5). Other species of Mycoplasma, such as Mycoplasma flocculare (MF), can be 
found in this host but have yet to be associated with disease (1, 5-7). The most well-known 
and researched swine mycoplasma is MHP, the etiologic agent of enzootic pneumonia (EP) 
(4, 8-10). Phylogenetic analysis of 16S rRNA gene sequences cluster most of the 
Mycoplasma spp. into the Mycoplasmataceae family; the exceptions being the Mycoplasma 
mycoides subgroup (including Mycoplasma mycoides mycoides and Mycoplasma capricolum 
capricolum), which cluster to the Spiroplasmatacae-Entomoplasmatacease (SEM) family (1). 
The Mycoplasmataceae phylogeny divides into α-, β-, γ- and δ-mycoplasma branches, of 
which MHS clusters to the β branch and MHR, MHP and MF to the γ branch (1). 
 The three pathogens (MHR, MHP, and MHS) share some culture requirements and 
disease characteristics. Both MHR and MHP ferment glucose, whereas MHS hydrolyses 
arginine for energy requirements (1, 5). However, all three require an exogenous source of 
sterols and fatty acids as they lack the machinery to synthesize these fundamental membrane 
components (1, 11). Likewise, they lack the capability of de novo synthesis of nucleic acid 
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precursors and amino acids which they must acquire from their environment. 
Supplementation of growth medium with yeast extract and animal serum generally fulfill 
these requirements (5, 11). 
 These three species of Mycoplasma all colonize the upper respiratory tract and can be 
recovered from the nasal cavity and tonsil of affected pigs (4, 12-14). Although MHP is the 
major agent for EP, MHR has also been shown to cause pneumonia and both species are 
frequently isolated together from the lungs of pigs (5, 15-18). Similarly, both MHR and MHS 
cause lameness and arthritis and can be isolated from the joint fluids and synovial 
membranes of affected pigs, though infrequently together (5, 14, 18-21). Further, MHR also 
causes polyserositis and can be isolated from serosal tissues (i.e. pericardium, pleura, and 
peritoneum) (5, 18, 19, 21). 
 Treatment of mycoplasma infections in pigs has largely depended on antibiotics. Due 
to the lack of a cell wall, β-lactams are ineffective. Macrolides, tetracyclines, and 
fluoroquinolones have proven effective in reducing clinical signs, although continuous or 
pulse dosing is required (5, 10). These dosing procedures are expensive, often do not affect 
overall bacterial population and increase the risk of development of antibiotic resistance (5, 
10, 18, 22, 23). While whole-cell, inactivated commercial vaccines have been used to control 
MHP infections for several years, results of vaccination protocols have been mixed (5, 24-
26). There are currently no commercially available vaccines for MHR or MHS. The efficacy 
of an experimental MHR vaccine is discussed in Chapter 5 of this dissertation. 
 Management of production practices, biosecurity and air flow (i.e. all-in/all-out, gilt 
exposure, positive-pressure barns, etc.) have also proven effective in control of MHP, 
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especially in combination with vaccination and antimicrobial protocols (26). These measures 
have not been fully investigated in mitigation of MHR and MHS. 
 
Mycoplasma hyorhinis 
 
Characteristics of disease 
 Mycoplasma hyorhinis is ubiquitous in the pig population and can be found in the 
upper respiratory tract of both healthy animals and those showing clinical signs of MHR 
infection (14, 18, 21). Clinical signs vary greatly from severe systemic infection leading to 
polyserositis, arthritis and lameness, to mild clinical manifestations such as otitis media or 
ocular discharge (5, 17-21, 27-34). In addition to the nasal cavity, ears, tonsils, lungs, joints, 
and serous membranes of the visceral organs, MHR has also been detected in the brains of 
some pigs, although no definitive association to neurological disease has been made (5, 18). 
 The gross lesions of MHR (serofibrinous to fibrinopurulent pericarditis, pleuritis, and 
peritonitis) are similar to, and are often confused with, those of the bacterial swine pathogens 
Streptococcus suis and Haemophilus parasuis (5, 21, 35). Both MHR and H. parasuis are 
often co-cultured from affected animals (35). Gross observations thus necessitate 
confirmatory testing (i.e. culture, polymerase chain reaction (PCR), etc.) for a definitive 
diagnosis. Histological examination of synovial and serosal membranes usually show 
invasion by polymorphonuclear and mononuclear cells, hyperplasia of the cells in the 
synovial lining, and villous hypertrophy of the synovial membrane (5, 19, 21, 27, 28). 
Macroscopic and microscopic lesions can be exacerbated by viral co-infections such as 
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porcine reproductive and respiratory syndrome virus (PRRSv) and porcine circovirus type 2 
(PCV2), both members of the porcine respiratory disease complex (PRDC) (35, 36). 
 Pigs are reported to be most susceptible to MHR infection from weaning to 
approximately 10 weeks of age (5, 18, 21, 27, 37); whereas lameness associated with MHS 
tends towards animals older than approximately 12 weeks of age (5, 21, 37, 38). It is 
uncertain whether exposure of MHR in younger animals increases their susceptibility to 
MHS clinical disease later in life. It is suspected that piglets become exposed to MHR while 
on the sow and that variations in virulence between field strains of MHR, co-infections, 
genetic predisposition of the animals, and stress are triggers for MHR infections to progress 
from sub-clinical to clinical (18). Chronic arthritis has been observed in older animals 
affected with MHR (27, 30, 34). Age susceptibility to MHR infection is presented in Chapter 
4 of this dissertation. 
 Experimental reproduction of MHR-associated disease has varied greatly. Intra-nasal 
(IN) and intraperitoneal (IP) inoculations have been the administration methods of choice in 
past experiments, with IP showing the most consistent results (18, 27, 29, 30, 32, 33, 37, 39). 
Intra-tracheal (IT) administration has also been reported (36). With the exception of Chen et 
al. (36), the majority of the MHR challenge models were developed nearly 20 years ago, with 
some studies conducted in the early 1970’s. Some of these studies were conducted with very 
low numbers of animals (n=5, in some cases). Additionally, clinical signs could vary greatly 
between challenged animals with some animals showing polyserositis and no lameness, some 
showing both polyserositis and lameness, and some unaffected. Herd genetics, vaccine and 
antibiotic protocols, and mycoplasma strain variations have undoubtedly changed since the 
earliest MHR investigations and each may play a role in disease outcomes. An MHR 
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challenge model which consistently and effectively produces both polyserositis and lameness 
in a number of animals sufficient to provide power for statistical analyses in future vaccine 
trials is lacking. Chapter 3 of this dissertation addresses this need. 
 
Phase shifting and antigenic variation 
 Due to their metabolic requirements necessitating a parasitic lifestyle, MHR 
membrane components are vital for interactions with host cells and nutrient acquisition. 
Whereas Gram-positive bacteria have a thick peptidoglycan layer in their cell wall and 
Gram-negative bacteria have an inner and outer membrane separated by a periplasmic space, 
the lack of a cell wall in Mycoplasma leaves them more vulnerable to attack by the host 
immune cells. Mycoplasma hyorhinis possess a unique set of membrane-associated variable 
lipoproteins (Vlp) which can allow them to evade immune attack (1, 40-44). 
 To date, seven Vlp genes have been identified (vlpA – vlpG) with individual strains of 
MHR possessing different repertoires of these genes (45-49). Of the six MHR genomes 
sequenced to date, the tissue culture derivatives and the broth derived clonal variant are 
lacking one or more of the seven known vlp genes. 
 The Vlp system for MHR has been closely examined. Rosengarten and Wise (41) 
demonstrated heterogeneity in phenotypes of an in vitro cultured, clonal MHR isolate, with 
colony morphology varying in size and opacity. These colonies also demonstrated the 
phenomenon of sectoring for both morphologies. Immunoblotting revealed phase switching 
in lipoprotein expression (41). Further research has shown a diverse population of Vlp’s with 
phenotypes varying in both their size and their expression (41, 43). The source of variability 
has been attributed to high-frequency, random mutations in these chromosomally clustered 
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vlp genes. Indel mutations in each of the vlp promoters lead to variability in the transcription 
of each gene and thus, phase variation in Vlp expression (40, 43, 50, 51). Similarly, random 
mutations can affect the size of each Vlp via intragenic recombination in tandem sequence 
repeats present in 3’ regions of the vlp genes (40, 43). Citti et al. (43) established that the 
longer Vlp size variants were able to negate complement-independent antibody inhibition in 
vitro and these variants were selected for when cultured in the presence of these antibodies 
(43). Thus, at least some of the Vlp’s are capable of providing protection for MHR against 
humoral attack. The lack of this selective pressure may be a reason for their absence in the 
sequenced in vitro (cell- and broth-derived) isolates (46-48).  
 The variable lipoproteins represent a heritable system in MHR leading to a diverse 
population and capable of providing protection for the mycoplasma. 
  
Pathogenesis and virulence factors 
 As with the other swine mycoplasmas, pathogenesis for MHR is not fully understood. 
It is thought the pathogen enters the host via the respiratory route as MHR colonizes the 
upper respiratory tract. Few specific colonizing factors have been identified. Proteins 
involved in attachment to ciliated epithelial cells have been described for MHP (52) and 
include the well-studied protein P97. There is a functional ortholog of this protein, P95, in 
MHR which may play a similar role for this species (53). 
 As described above, the Vlp system has been implicated in immunoevasion and 
immunosuppression. Presentation of highly variable surface antigens to the host requires a 
similar, constantly changing supply of antibodies to combat. As Citti et al. demonstrated 
(43), these lipoproteins appear to also be decoy antigens, preventing antibody inhibition.  
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 Adsorption to mammalian cells in vitro has been well documented for several species 
of Mycoplasma (54, 55). The process of adsorption for MHR has been shown to involve cap 
formation (56) and can be independent of sialic acid binding (57). A trypsin sensitive protein 
of approximately 71 kDa has been linked with MHR adhesion to mammalian cells (58). 
Adhesins for the human pathogen Mycoplasma pneumoniae have shown sequence homology 
to mammalian structural proteins (59). It is this molecular mimicry which may be involved 
with autoimmune-like disease manifestations and overwhelming inflammatory responses in 
the host following infection with M. pneumonia (59). These responses are similarly observed 
in systemic MHR infections and may indicate such mimicry exists in this species. The 
exchange of membrane components has been observed between adherent MHR and 
experimentally infected cells which may lead to modifications in the host cells’ functions for 
metabolism and interactions with the extracellular matrix (60, 61).  
 Intracellular growth has been established in several in vitro cell lines (48, 57, 62, 63). 
Receptor-mediated endocytosis has been suggested as one means of entry following adhesion 
to the cell surface (63, 64). Interactions between the high-affinity MHR transport protein p37 
and host cell Annexin A2 have been implicated for mammalian cell invasion (65). Yuan et 
al. (2016) inhibited  MRH infection of gastric cells by interrupting this interaction via 
competitive binding (66). Despite these studies, the exact mechanisms required for cellular 
invasion remain vague. 
 There are conflicting reports as to MHR survival upon cellular invasion. Hu et al. 
suggests an endosomal niche by disruption of late endosomal formation and inhibition of 
autophagocytosis (63). Yet Chernov et al. suggest that MHR avoids the endosomal pathway 
altogether and persist within the exocyst, also providing a means for escape (67). This later 
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group further demonstrated variations in methylation of CG and GATC sites between 
internalized and external MHR and proposed preferential selection of methylation patterns by 
MHR based on environment (67).   
 Some mechanisms for nutrient acquisition have been identified. With no ability for de 
novo nucleic acid synthesis, MHR uses enzymes such as cytidine deaminase, pyrimidine 
nucleoside phosphorylase, purine nucleoside phosphorylase, and thymidine phosphorylase 
(68-70) to catabolize the building blocks for DNA synthesis. Membrane associated nucleases 
(71) and oligonucleotide transporters (64) have been identified which aid in the acquisition 
and transport of required molecules. None of the mycoplasmas can synthesize or modify 
long-chain fatty acids and must acquire them from the environment. Mycoplasma hyorhinis 
shows a slight affinity for palmitic acid over oleic acid when these fatty acids are 
radiolabeled and measured after incorporation into membrane lipids (11). There are enzymes 
in the MHR repertoire for de novo phospholipid generation and include triacylglycerol lipase, 
glycerol-3-phosphate acyltransferase, and cardiolipin synthetase. The fatty acid transporters 
have not been fully identified. However, such proteins have been associated with virulence in 
M. pnemoniae (72). 
 
Immune response 
 With pathogenesis poorly defined, researchers have looked to immunological 
responses in the host to aid in defining the infection process for MHR. 
 Serum-based ELISA’s are generally the most economical of diagnostic assays for 
both the producer and testing labs due to the relative ease of sample collection and well 
established assay principles. However, serological assays for MHR and MHS have not been 
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widely available. There are no less than four commercial ELISA’s for MHP. Although there 
has been a poor correlation to results from these assays and the severity of MHP disease, they 
provide a good indication of herd status (73-75). Neto et al. demonstrated that cross-
reactivity among MHR, MHP, MHS, and MF antibodies was possible in similarly prepared 
assays (73). These facts have made the development of a reliable ELISA-based assay for the 
detection of MHR antibodies difficult. 
 Ross et al. demonstrated that complement-fixing antibodies to MHR could be 
detected in the serum of experimentally infected pigs as early as two weeks post-inoculation 
and up to one year after, with the majority of these antibodies being IgG (34). They further 
showed these same antibodies could also be detected in the synovial fluid from arthritic joints 
of the infected pigs and, generally, in higher quantities than those found in serum which is in 
accordance with the results of Barden and Decker (34, 76). Recently, MHR IgA antibodies 
have also been shown to be detectable in pen-based oral fluids (73). The establishment of a 
humoral response to MHR infection in swine is clear. The passive transfer and length of 
maternal immunity have not yet been studied. The prolonged detection of these MHR 
antibodies may likely indicate a chronic infection in the animal. 
 Acute septic arthritis by Staphylococcus aureus may provide insight into the chronic 
arthritis noted with MHR. There is no basement membrane underlying the synovial 
membrane which is well-vascularized and provides a point for bacterial entry (77). 
Extracellular matrix host proteins such as collagen and fibronectin facilitate adhesion (77). 
Following adhesion, S. aureus can be internalized by the host cell by methods such as 
receptor-mediated endocytosis. Once inside the cell, the bacteria can either induce apoptosis 
or persist within the host cell. Apoptosis may lead to the damage observed with septic 
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arthritis while persistence in the cell can allow for immunoevassion of inflammatory cells 
(77). The local inflammatory response in the joint begins with a cytokine response including 
the release of IL-1β and IL-6 into the synovial fluid, activating the acute-phase liver proteins 
which bind the bacteria for opsonization and complement activation. The inflammatory 
response continues with the release of TNFα and IL-8 as well as the reactive oxygen species 
nitric oxide (77). 
 Access to the synovial membranes by MHR is likely similar to S. aureus with a 
hematogenous entry. Mycoplasma hyopneumoniae has defined heparin, fibronectin and 
plasminogen binding factors (78, 79) and such similar mechanisms may be likely found in 
MHR as putative adhesions. Invasion into the host cell via receptor mediated endocytosis 
(63-65) and intra-cellular survival are discussed above. Similar to the S. aureus response, in 
pigs bred for a high immune response and experimentally inoculated with MHR, an increase 
in the expression of IL-8, IL-10 and TNFα were observed in mononuclear cells of the 
synovial membranes (80). Human monocytes have also been shown to secrete TNFα when 
experimentally infected with MHR in vitro (81). 
 Obara et al. has provided evidence that human gastric cells infected in vitro with 
MHR undergo drastic physical changes which can be attributed, in part, to the bacteria’s 
endonucleases, as well as increased cellular nitric oxide (NO) and up-regulation of the 
inducible nitric oxide synthase (iNOS) (82). The final outcome of this increase in NO is 
anoikis, defined as apoptosis due to a cell’s detachment from the extracellular matrix and 
inability to persist without cell-to-cell signaling. Anoikis increased as NO levels increased, 
and detachment from the matrix was shown to be due to NO attenuation of E-cadherin, an 
epithelial adhesion molecule (82). The effect of anoikis in the joint of an infected pig may 
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lead to an accumulation of dead epithelial cells in the affected area. Removal of this material 
would require an inflammatory response and can be difficult to accomplish in cartilaginous 
tissue, prolonging the inflammation and leading to arthritic-like symptoms (83). 
 Nitric oxide (NO) promotes interferon gamma (IFN-γ) in T helper 1 (Th1) cells and 
drives T-cell differentiation towards the Th1 phenotype (84). The result is an imbalance in 
Th1 and Th2 cells, a hallmark of chronic inflammatory diseases such as rheumatoid arthritis 
(84). This T-cell disparity further results in lower B cell activation and may provide one 
explanation for the discrepancies observed between serological assays and disease severity as 
described for MHP. 
 Toll-like receptors (TLR) play a crucial role for innate immunity. The two TLR’s 
associated with lipoproteins, TLR2 and TLR6, have been shown to play a role in MHP-
associated disease (85). In vitro studies have shown a pro-inflammatory response to MHR 
infection to be at least partially associated with TLR2 (86); however, TLR4, which is 
normally associated with and binds to lipopolysaccharide (LPS), has also been shown to 
activate inflammatory genes (87, 88). This TLR4 association has been demonstrated to be 
mediated through the MHR protein p37 (87, 88). 
 There has been some debate as to whether enhancement to cell-mediated or humoral 
immunity is more beneficial in response to mycoplasma infection. Investigations with the 
mouse model for M. pulmonis led Cartner et al. to hypothesize that innate immunity is 
preferred for protection of the lungs and respiratory mycoplasmas but humoral immunity 
provided for the best protection against systemic mycoplasmal disease (89). By this measure, 
a strong antibody response in pigs would help alleviate systemic MHR infection. 
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Tissue culture 
 Mycoplasma hyorhinis has been a well-known contaminant of mammalian tissue 
cultures for over 50 years (48, 56, 57, 62, 86, 90-94). This fact has been utilized to cultivate 
previously “non-cultivatable” strains of MHR (91). The growth factors involved in such 
cultivation techniques have not yet been definitively identified. Tissue culture has been used 
to demonstrate the invasive ability of some Mycoplasma species, including MHR, which 
were previously thought to remain on the surface of mammalian cells (48, 57, 62, 64). There 
have been many proposed sources for covert MHR tissue culture contamination. These 
include animal derived culture reagents (e.g. porcine trypsin), media supplementation (e.g. 
animal serum), or the humans that work with such cell lines (90, 95). 
 The insidious nature of undetected mycoplasma contamination has led to a 
commercial niche devoted entirely to detection and eradication of such contamination. The 
United States Department of Agriculture (USDA) requires testing for the detection of 
mycoplasma contamination in vaccine components per title 9, Code of Federal Regulations 
(CFR), section 113.28 to ensure purity of vaccines. Such rigorous screening is not necessarily 
employed in all laboratories. Contamination by mycoplasmas such as MHR has been shown 
to alter normal growth traits in primary and immortal cell lines (86, 90, 95). Investigators 
must keep this in mind and ensure tissue culture-based experiments are not misinterpreted 
due to undetected mycoplasma contamination. 
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Cancer 
 Recent research has focused on the putative link between MHR and human cancers. 
Antibodies to MHR, specifically targeted to the p37 protein, have been found in prostate 
cancer patients (96). It has not been definitively demonstrated whether MHR infection in 
these patients has resulted in the cancer or, conversely, if it is the cancer that has suppressed 
these individuals enough to allow for MHR infection to occur. As described above, MHR can 
easily infect mammalian cells in vitro; however, isolation from human in vivo samples has 
not been established. It should be said that MHR is considered a pathogen of swine and 
therefore a medical practitioner would have little reason, until recently, to attempt recovery 
of this bacteria in diagnostic samples. In vitro studies using cancer cells have shown that 
MHR can increase cell migration and invasion and has been positively correlated to tumor 
metastasis in gastric cancer tissues (88, 97, 98). These studies have focused in particular on 
the MHR p37 protein. 
 A member of a high affinity transport system, p37 has been structurally examined and 
found to bind thiamine pyrophosphate (TPP) (99). It is not known what role this 
sequestration of thiamine plays in cell culture systems or in the host. Inoculation of cell 
cultures with p37 have been shown to activate NF-κB, a transcription factor for several 
inflammatory and cancer-associated genes (65, 87, 88, 100). The exact mechanism that 
allows for increase invasivity of cancer cells is unknown. 
 Besides the implications with oncogenesis, MHR has also been shown to interfere 
with cancer therapies. Purine and pyrimidine nucleoside analogues have been used for 
treatment of cancers (68, 70, 101, 102). Mycoplasma hyorhinis possess enzymes which can 
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catabolize these nucleoside analogues, thus, inactivating these drugs and adversely affecting 
their efficacy (68-70, 102). 
 The possibility of human MHR infection and the ensuing implications with cancer 
necessitates caution when handling the organism in the laboratory and potentially infectious 
tissue in production and diagnostic settings. 
 
Summary with Hypothesis and Goals 
 The lack of a commercially available vaccine to aid in MHR disease management has 
relegated producers to a heavy regime of antibiotics to alleviate disease parameters. The 
overall goal of this research is to provide a viable MHR vaccine candidate. As such, a robust, 
consistent and reproducible disease model was needed to fully evaluate these candidates in a 
manner acceptable to regulatory authorities. 
 The central hypothesis is that MHR infected tissue culture resembles in vivo infection 
and, therefore, protein expression would more closely mimic that expressed in the pig and 
would provide for both virulent challenge material and efficacious vaccine antigen. 
 The experiments discussed in Chapter 2 detail challenging caesarian-derived, 
colostrum-deprived (CDCD) pigs with cell-associated MHR. The observation of lameness 
during the challenge period and the presence of pericarditis at necropsy were noted. The dose 
and route of administration of this material were optimized. The experiment described in 
Chapter 3 then examined the susceptibility of CDCD animals to this challenge model at 
incremental increases in age, from seven weeks through sixteen weeks of age. 
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 In Chapter 4, three doses of an inactivated, whole-cell vaccine were administered to 
pigs and compared to a product matched, mycoplasma-free placebo for efficacy in the 
previously established challenge model. Pigs were evaluated for lameness and pericarditis. 
 Chapter 5 is a proteomic analysis comparing two ex vivo cultures of MHR to a broth 
culture for differential protein expression. Madin-Darby canine kidney cells (MDCK) and 
McCoy mouse fibroblast cells were infected with a single isolate of MHR. These cultures 
were then examined by liquid chromatography, tandem mass spectrometry (LC-MS/MS) 
along with a standard broth culture of the same MHR isolate. 
 The final chapter is a general conclusion and includes discussions for future work. 
The tissue culture-associated, inactivated whole-cell vaccine provided significant reductions 
of both lameness and pericarditis. This vaccine will help alleviate disease in the production 
setting. It will also provide a benchmark for future vaccine trials, evaluating target candidates 
identified by the proteomic analysis. 
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Abstract 
 Mycoplasma hyorhinis (MHR) causes polyserositis and lameness in grower pigs. 
While herd-specific vaccines are being marketed, no fully licensed vaccine is available in the 
regional or global market. In order to evaluate suitable vaccine candidates, we have 
developed a challenge model in caesarean-derived colostrum-deprived pigs using cell-
associated MHR which results in both severe pericarditis and lameness. We investigated the 
administration of MHR to seven-week-old pigs over three days using three different routes 
compared to a single day administration using three different routes. Pigs were monitored for 
twenty-one days for signs of lameness and well-being. At study termination, pigs were 
examined for evidence of Mycoplasma-associated polyserositis and arthritis. Results indicate 
that clinical manifestation of disease was more dependent on the route of administration than 
the total given dose. A single intravenous (IV) administration resulted in extensive 
polyserositis while a single intranasal (IN) administration showed little-to-no signs of 
disease. A single intraperitoneal (IP) administration did not induce the same level of 
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polyserositis as observed in the IV group, but did result in an increased incidence of lameness 
compared to this group. Further, pigs administered MHR by IP (Day 0), IV (Day 1), and IN 
(Day 2) routes on three consecutive days showed a more robust disease manifestation, 
resulting in both polyserositis and lameness. Optimization of this group showed that 
elimination of the third-day IN challenge had no detrimental effect on clinical outcomes. The 
consecutive-day administration of cell-associated MHR will allow for simultaneous 
evaluations of both polyserositis and lameness in future vaccine trials. 
Introduction 
 Mycoplasma hyorhinis (MHR) is commonly found in the upper respiratory tract of 
pigs and can cause respiratory disease, polyserositis, and polyarthritis in animals typically 
around seven weeks of age (1, 2). The mechanisms of pathogenesis of this ubiquitous 
organism, including translocation from colonized upper airway to systemic dissemination in 
the animal, and the mode of targeting of specific organs, are currently unknown. 
 Reduced productivity due to MHR-associated disease has economic consequences in 
the swine production setting (3). Prophylactic and therapeutic antibiotic treatment can 
mitigate Mycoplasma infections (2, 3), but there is a desire in the swine industry to move 
away from such treatments (4, 5). There are currently no licensed, commercially available 
vaccines for MHR. In order to develop and evaluate potential vaccine candidates, a robust 
and effective challenge model needs to be established. As the pathogenesis of MHR is poorly 
understood, such a model would also help to increase our understanding of the infection 
process and development of disease. Previous experimental inoculation protocols for swine 
Mycoplasmas using standard, broth-derived material have resulted in varying degrees of 
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polyserositis and lameness (6, 7). However, the low number of animals tested and the 
inconsistency of affected animals necessitated further investigation. To this end, we have 
developed a suitable model, which consistently results in pericarditis and lameness in 
caesarean-derived colostrum-deprived (CDCD) pigs following infection with tissue-culture 
derived MHR. 
Materials and Methods 
 Two studies are discussed herein. The objective of Study 1 was to evaluate three 
different single routes of administration and two multiple route, consecutive-day 
administration of MHR for production of polyserositis and lameness. The objective of Study 
2 was to compare the multiple route, consecutive-day administration with and without the 
third-day, IN challenge for production of polyserositis and lameness. 
Challenge material 
 The MHR challenge isolate originated from the joint fluid of a clinically affected pig. 
After initial isolation and speciation, the bacteria were grown in modified Friis media (8) 
using established methods. To generate the infection dose of MHR, confluent monolayers of 
MDCK (Madin-Darby canine kidney) cells were infected as follows. Media for cell 
maintenance was minimum essential media (MEM; Gibco/Thermo Fisher Scientific Inc., 
Waltham, MA) supplemented with 5% fetal bovine serum (FBS; SAFC, St. Louis, MO). 
Prior to infection, media was removed, and cells were rinsed with 0.1 M phosphate buffered 
saline (PBS; Thermo Fisher Scientific Inc., Waltham, MA). Mycoplasma hyorhinis were then 
added to the tissue culture at approximately 10% (v/v) of the total final volume and allowed 
to incubate at 37°C for at least two hours prior to adding pre-warmed media consisting of 
 28  
MEM supplemented with 2% FBS. Harvest of the infected cell layer was performed after 
observation of cytopathic effect (CPE), generally occurring around four to seven days post-
infection, by freezing the infected cells at ≤ -60°C, thawing at 37°C, and then collecting the 
lysed cell-suspension. MHR challenge stocks were combined with sterile glycerol (10%, v/v) 
prior to dispensing into working volumes and stored at ≤ -60°C until challenge. Challenge 
doses of MHR were quantified by color changing units (CCU). 
Animal information 
 CDCD piglets were purchased from a commercial Class A dealer and were a 
commercial cross breed. Both gilts and intact barrows were used. Animals were determined 
to be free from MHR and M. hyosynoviae (MHS) colonization as determined by real-time 
PCR analysis of nasal swabs (eSwab™, Copan; Murrieta, CA) collected prior to challenge. 
Nasal swabs from Study 2 animals were also negative for M. hyopneumoniae (MHP) by real-
time PCR; Study 1 animals were not tested. Pre-challenge sera were determined to be free 
from MHP antibodies by ELISA (IDEXX, Westbrook, ME). All animals were seven weeks ± 
5 days of age at the time of initial inoculation. All animals were deemed to be in good health 
and nutritional status before the studies were initiated. No biologicals or pharmaceuticals 
other than the challenge material were administered to the test animals after arrival at the 
study site. Non-medicated feed was used throughout the duration of each study. Feed rations 
were appropriate for the age, condition, and species of test animal. Water was provided ad 
libitum throughout each study. Both studies were performed in BSL-2, USDA inspected 
facilities following the Guide for the Care and Use of Agricultural Animals in Agricultural 
Research and Teaching (9). 
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 For Study 1, pigs were blocked by litter and randomly assigned to five groups of ten 
animals each for experimental challenge, labeled groups 1-5. One group of six pigs was used 
for non-infected, negative controls and labeled group 6. Animals were housed in three rooms 
in pens on raised decks with metal slated floors. To reduce the chance of nasal shedding, 
those groups receiving IN challenge at any time (group 3-5) were house in one room and 
grouped by pen. Those groups not receiving IN challenge (group 1 and 2) were housed in 
another room and grouped by pen. The negative controls (group 6) were housed in a separate 
room in a single pen. 
  For Study 2, pigs were blocked by litter and randomly divided into two groups of 28 
animals each for experimental challenge, labeled group 1 and 2. A third group of eight pigs 
was used for non-infected, negative controls. Animals were housed in two rooms in pens on 
raised decks with metal slated floors. Challenged animals (group 1 and 2) were housed in one 
room, co-mingled in four pens and the negative control animals (group 3) in a separate room 
in one pen. 
Experimental inoculation 
  The inoculation procedure for Study 1 was as follows. At study day 0 (D0), pigs in 
group 1 received 40 mL of MHR by intraperitoneal (IP) route at a dose of 1.59 × 109 
CCU/pig. Pigs in group 2 received 20 mL of MHR by intravenous (IV) route at a dose of 
7.96 × 108 CCU/pig. Pigs in group 3 received 20 mL of MHR by intranasal (IN) route (10 
mL/nostril) at a dose of 7.96 × 108 CCU/pig. Pigs in group 4 received MHR at 40 mL/IP 
(1.59 × 109 CCU/pig) on Day 0, 20 mL/IV (8.53 × 108 CCU/pig) on Day 1, and 20 mL/IN 
(4.18 × 108 CCU/pig) on Day 2, for a total dose of 2.86 × 109 CCU/pig.  Pigs in group 5 
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received MHR at 20 mL/IP (7.96 × 108 CCU/pig) on Day 0, 10 mL/IV (4.27 × 108 CCU/pig) 
on Day 1, and 10 mL/IN (2.09 × 108 CCU/pig) on Day 2, for a total dose of 1.43 × 109 
CCU/pig; half the dose of group 4.  Animals in group 6 received no treatment. The challenge 
scheme for Study 1 can be seen in Table S1 in the Appendix A. 
  The inoculation procedure for Study 2 is as follows. Pigs in group 1 received MHR at 
20 mL/IP (1.12 × 109 CCU/pig) on Day 0, 10 mL/IV (6.76 × 108 CCU/pig) on Day 1, and 10 
mL/IN (1.00 × 108 CCU/pig) on Day 2, for a total dose of 1.90 × 109 CCU/pig. Pigs in group 
2 received MHR at 20 mL/IP (1.12 × 109 CCU/pig) on Day 0 and 10 mL/IV (6.76 × 108 
CCU/pig) on Day 1, for a total dose of 1.80 × 109 CCU/pig. The challenge scheme for Study 
2 can be seen in Table S2 in the Appendix A. 
Clinical observations 
 Pigs were observed daily from the first day of challenge through study termination for 
clinical signs of disease, respiratory distress, and lameness. Respirations and coughing were 
scored as ‘normal’ (=0) or ‘abnormal’ (=1). Lameness was scored as ‘normal’ (=0), ‘mild’ 
(=1), ‘moderate’ (=2), ‘moderately severe’ (=3), ‘severe’ (=4), or ‘recumbent” (=5). 
Definitions for the lameness categories were as follows:  normal—no visible lameness; 
mild—not constantly lame when walking, walking at a normal speed, weight bearing while 
walking and standing, lameness indicated by intermittent reduced weight bearing on one limb 
or shortening of the stride; moderate— lameness constant and observed throughout every 
step at a walking pace, bearing some weight on the leg at a walk and standing but short-
striding one or more legs while walking, walking at a normal speed; moderately severe—
non-weight bearing on the leg the first few steps after standing, constant, obvious lameness 
 31  
while at a walking pace, putting very little weight on the leg at a walk or while standing, 
requiring the pig to slow its speed of walking; severe— will stand (may require assistance) 
for at least 3 minutes, non-weight bearing on one or more legs at walk or standing, still able 
to three-legged walk; and recumbent— will not stand even with assistance. A pig was 
considered lame if it received a score ≥ 1 on two or more consecutive observation days. The 
clinical observation scoring systems can be seen in Table S3 in the Appendix A. 
 Weight measurements were collected just prior to challenge and just prior to 
euthanasia. At study termination, all pigs were anesthetized and then euthanized by 
electrocution. 
 The experimental schedules of events are summarized in Table S4 and S5 in the 
Appendix A for Study 1 and 2, respectively. 
Gross pathological examination and sample collection 
 After euthanasia, a necropsy and gross pathological examination were performed for 
all animals. The thoracic and abdominal cavities were examined for evidence of polyserositis 
(pleuritis, pericarditis, and peritonitis). In Study 1, heart tissue was collected from all pigs 
and tested for MHR and MHS by real-time PCR. Affected lung tissue was also collected. If 
no affected lung tissue was present, a section of the right diaphragmatic lobe was collected. 
Lung tissue was tested for MHR and MHS by real-time PCR. In Study 2, in lieu of tissue 
collection, pericardial swabs (eSwab™, Copan; Murrieta, CA) were taken from all pigs, and 
pleural swabs were taken from those animals exhibiting pleuritis. All swabs were tested for 
MHR, MHS and MHP by real-time PCR in both studies. The elbows, stifles, carpi and tarsi 
were opened and examined for signs of arthritis (e.g. excess synovial fluid, abnormal 
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synovial fluid, abnormal synovial membranes, abnormal articular surfaces). For each 
individual pig, a single, common swab (eSwab™, Copan; Murrieta, CA) was used to sample 
the articular surfaces of both elbows and both stifles. A second swab was used to sample the 
articular surfaces of all four carpi and tarsi.  All joint swabs were tested for MHR, MHS, and 
MHP by real-time PCR. 
Histopathology 
 For Study 1 only, lung and heart tissues were collected from all pigs and fixed in 10% 
neutral buffered formalin. Samples were submitted to Iowa State University Veterinary 
Diagnostic Laboratory (ISU-VDL) for histological examination (haematoxylin and eosin 
staining). Pleuritis was scored as none (=0), mild (=1), moderate (=2), or severe (=3) as were 
peribronchiolar/septal infiltrates. Heart tissue was scored for lymphocytic inflammation (0 = 
no inflammation, 1 = mild accumulation of lymphocytes, 2 = moderate accumulation of 
lymphocytes, 3 = severe accumulation of lymphocytes) and fibrosis of the epicardium (0 = 
no fibrosis, 1 = mild, 2 = moderate, 3 = severe). 
Real-time PCR 
 Total nucleic acid extractions were performed with a Qiagen BS96 Vet 100 BioSprint 
using the One-For-All Vet Kit (384) (Qiagen, Venlo, Limburg). Mycoplasma species-
specific regions of the 16S rRNA gene were then detected by real time PCR. The PCR mix 
contained 2x SsoAdvanced™ probe supermix (BioRad, Hercules, CA), 80 µM of each 
primer, 50 µM of probe, and 2 μL of DNA in a total volume of 20 μL. See Table 2.1 for 
primers, probes and control oligonucleotides sequence information. DNA amplification was 
carried out using a BioRad CFX96 Real Time System (BioRad, Hercules, CA) with the 
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following conditions: 2 min at 95°C then 35 cycles of 5 sec at 95°C and 5 sec at 58°C. Pure 
cultures of MHR and MHS were used as positive controls. For quantification, Ct values of 
the samples were compared to the standard curve. The standard curve was elaborated with 
serial dilutions of a synthesized control oligonucleotide of known DNA concentration. A Ct 
value of < 35 was considered positive. The detection limit of these assays is ~1000 genomic 
copies/mL of sample. The method for MHP detection by real-time PCR has been previously 
described (10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1.  List of Primers, Probes, and Control Oligo Sequences 
PCR Name Sequence 
M. hyorhinis MycoR-probe 
5’-6-FAM-
AGCTGTGAAGCTCCTTTCTATTACTCATC-
BHQ_1/-3’ 
 MHR-F 5’-GCTAATACCGGATATAGTTATTT-3’ 
 MHR-R 5’-GCACCCCCATTTTTAAG-3’ 
 Control 
5’-TTGGAAACAATAGCTAATACCGGATAT 
AGTTATTTATCGCATGATGAGTAATAG 
AAAGGAGCTTCACAGCTTCACTTAAAA 
ATGGGGGTGCGGAACATTAGTTA-3’ 
 
M. hyosynoviae MycoS-probe 
5’-Cy5-
AAGCAAACGCTTCTTTCATAACGAAATC-
BHQ_2-3’ 
 MHS-F 5’-TTAATGCCGGATAAGTATGAA-3’ 
 MHS-R 5’-GCACCCTCATCTCTTAG-3’ 
 Control 
5’-GGAAACATTGGTTAATGCCGGATAAG 
TATGAAATCGCATGATTTCGTTATGAA 
AGAAGCGTTTGCTTCACTAAGAGATGA 
GGGTGCGGAACATTAGC-3’ 
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Bacteriology 
 To exclude contribution by extraneous bacterial pathogens in the study animals, all 
samples collected at the time of necropsy were cultured onto sheep blood agar 
(Remel/Thermo Fisher Scientific Inc., Waltham, MA) with a Staphylococcus “nurse” streak 
for aerobic and anaerobic growth. Plates were incubated at 37° C for two days and examined 
daily for growth. Further isolation, if necessary, was performed on colonies of interest and 
identification was performed by ISU-VDL. 
Statistical analysis 
 Statistical summaries were conducted by a BIVI statistician using SAS Version 9.4. 
Summary tables can be found in Appendix A. 
 For Study 1, treatment was confounded by housing and results are therefore 
summarized by treatment group. Individual average daily gain during the 21-day period was 
calculated by subtracting day 0 weight from day 21 weight and dividing by 21. Day 0 weight, 
day 21 weight, and average daily gain for each treatment group was summarized using the 
MEANS procedure of SAS. Means, standard errors, and 95% confidence intervals for each 
treatment were determined (Table S6). Polyserositis, any joint showing signs of arthritis, and 
PCR results were each scored as positive or negative. These variables were each summarized 
by treatment group using the FREQ procedure of SAS. The proportion positive, standard 
error and Clopper-Pearson Exact 95% confidence interval were determined for each 
treatment group (Tables S7, S8, and S9). Distributions of lameness scores were summarized 
by day and treatment group using the TABULATE procedure of SAS. A lameness score ≥ 1 
for any two consecutive days during the study was analyzed as a binomial outcome (positive 
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if true, negative if false). Results were summarized by treatment group using the FREQ 
procedure of SAS. The proportion positive, standard error and Clopper-Pearson Exact 95% 
confidence interval were determined for each treatment group (Table S10). Distributions of 
histological scores were summarized by treatment group using the TABULATE procedure of 
SAS. In addition, binomial outcomes were created for each variable (positive if score > 0, 
negative if score=0). These binomial outcomes were each summarized by treatment group 
using the FREQ procedure of SAS. The proportion positive, standard error and Clopper-
Pearson Exact 95% confidence interval were determined for each treatment group (Table 
S11). 
 For Study 2, treatment groups 1 and 2 were housed together and therefore, statistical 
comparisons include group 1 versus 2. Individual average daily gain during the 28-day period 
was calculated by subtracting day 0 weight from day 28 weight and dividing by 28. The 
analysis utilized the MIXED procedure of SAS. The model included the fixed effect of group 
and the random effects of litter and pen within group. Least squares means, standard errors, 
and 95% confidence intervals for each treatment were determined as well as comparisons of 
group 1 versus group 2 (Table S12). Polyserositis evaluations were summarized using the 
TABULATE procedure. Evaluations of peritonitis were all negative. Pericarditis and pleuritis 
were analyzed by room using the GLIMMIX procedure with binomial distribution and logit 
link. The model included the fixed effect of group and the random effects of litter and pen 
within group. Back transformed least squares means, standard errors, and 95% confidence 
intervals were determined as well as comparisons of group 1 versus 2 (Table S13). PCR 
swabs were analyzed as binomial outcomes. Pericardial, pleural, elbow/stifle, and 
carpal/tarsal swabs were each analyzed using the GLIMMIX procedure with binomial 
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distribution and logit link. The model included the fixed effect of group and random effects 
of litter and pen within litter. Back transformed least squares means, standard errors, and 
95% confidence intervals were determined as well as comparisons for group 1 versus 2 
(Table S14). Presence of arthritis for each location (left and right elbow, left and right stifle, 
and left and right tarsal) were analyzed using the GLIMMIX procedure with binomial 
distribution and logit link. The left and right carpal was free from arthritis in all animals. The 
model included the fixed effect of group and random effects of litter and pen within litter. 
Back transformed least squares means, standard errors, and 95% confidence intervals were 
determined as well as comparisons for group 1 versus 2 (Table S15). In addition, the 
presence of arthritis at any location was also analyzed using a similar model (Table S15). For 
respiratory and coughing observations, the presence or absence of the sign any time during 
the 28-day period was determined and analyzed. The GLIMMIX procedure with binomial 
distribution and logit link was utilized for analysis. The model included the fixed effect of 
group and random effects of litter and pen within litter. Back transformed least squares 
means, standard errors, and 95% confidence intervals were determined as well as 
comparisons for group 1 versus 2 (Table S16). In addition, lameness scores ≥ 1 for any two 
consecutive days was also analyzed using the same approach (Table S16). 
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Results 
Clinical observations 
 In Study 1, no abnormal respirations or coughing were noted in any pig in any group. 
Lameness was noted in animals as early as five days post-challenge. One animal (10%) in 
each group 2, 3, and 4 was scored as lame. Of the single lame animals in each group 2 and 3, 
both animals received a score of “1” on two consecutive days:  Days 20-21 for the pig in 
group 2 and Days 18-19 for the pig in group 3. The single lame animal in group 4 received 
scores of “2”, “3”, “1” and “1” on Days 8, 9, 17, and 18, respectively. Group 1 and group 5 
had the highest incidences of lameness with 40% and 70% affected, respectively. The four 
lame animals in group 1 were scored as lame on multiple days, with scores ranging from “1” 
to “3”:  one animal receiving a score of “1” or “2” on Days 14-21; one with scores of “1 or 
“2” on Days 6-7 and Days 12-14; one with scores of “1” or “2” on Days 15-21; and the last 
with scores of “1” to “3” on Days 16-21. The seven lame animals in group 5 all received 
scores on multiple days, with scores ranging from “1” to “4”:  one animal receiving a score 
of “1” or “2” on Days 12-21; one with scores of “1” on each of Days 17-21; one with a score 
of “3” on Day 9 and then scores of “1” on each of Days 10-13 and Days 15-19; one with 
scores of “1” or “2” on Days 16-21; one with a score of “1” on each of Days 19-21; one with 
a score of “4” on Day 7, “2” on Day 8, and “1” on each of Days 15-21; and one with a score 
of “1” on each Days 15-16 and a score of “2” on Day 20. All non-infected group 6 animals 
remained clinically normal throughout the duration of the study. See Figure 2.1A for a 
summary of the percentage of animals positive in the challenged groups. 
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 The average daily gain (ADG) for Study 1 was calculated for all groups as shown in 
Figure 2.2. With the exception of group 3, all challenged groups had a similar average daily 
gain with group 5 showing the lowest average of 0.4 kg/day. Group 1, 2 and 4 each had an 
average of 0.5 kg/day. Group 3 and the non-infected group 6 each had an average of 0.7 
kg/day. 
 Figure 2.3A shows the distribution of clinical observations from Study 2. Abnormal 
respirations were noted in 64.3% of the pigs in group 1 and 71.4% of the pigs in group 2. 
Animals began showing signs of abnormal respirations on Day 10 and Day 11 for group 1 
and 2, respectively, and continued intermittently for both groups through study termination. 
Coughing was minimal with 14.3% of the pigs in group 1 and 10.7% of the pigs in group 2 
affected. Coughing scores were noted in both groups on four sporadic days each. Lameness 
was observed in 82.1% of the pigs in group 1 and 75.0% of the pigs in group 2 and was noted 
  
Fig. 2.1. Study 1 Clinical evaluations by group. A. Assessment for lameness and arthritis. 
B. Assessment for polyserositis. Groups:  1=IP (intraperitoneal), 2=IV (intravenous), 3=IN 
(intranasal), 4=IP, IV, IN (high dose), 5=IP, IV, IN (low dose). All group 6 non-infected 
controls remained free from clinical findings and are not represented. Data represents the 
percent (%) positive animals ± standard error. 
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in both groups as early as the second study day and continued through study termination. 
Lameness scores ranged from “1” to “3” throughout the observation phase. All non-infected 
group 3 animals remained clinically normal throughout the duration of the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Fig. 2.2. Study 1 average daily weight gain by group. Groups:  1=IP (intraperitoneal), 
2=IV (intravenous), 3=IN (intranasal), 4=IP, IV, IN (high dose), 5=IP, IV, IN (low dose), 
6=no treatment. Data represents the mean kg/day ± standard error.
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Fig. 2.3. Study 2 clinical evaluations by group. A. Assessment for abnormal respiration, 
coughing, and lameness. B. Assessment for polyserositis. Groups:  1=IP, IV, IN, 2=IP, IV. 
IP=intraperitoneal; IV=intravenous; IN=intranasal. All group 3 non-infected controls 
remained free from clinical findings and are not represented. No peritonitis was observed. 
Data represents the percent (%) positive animals ± standard error. There were no significant 
differences between groups for any category. 
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 The average daily gains for Study 2 were calculated to be 0.56 kg/day and 0.51 
kg/day for group 1 and group 2, respectively, as shown in Figure 2.4. Non-infected group 3 
animals were housed separately from the challenged animals and statistical comparisons 
were performed for the challenged groups only. 
 
 
 
 
 
 
 
 
Gross pathology 
 In Study 1, pericarditis was noted in all challenged groups with the exception of 
group 3.  As seen in Figure 2.1B, group 2 had the highest incidence with 90% affected. 
Groups 4 and 5 each had 50%, while group 1 had 20% affected. Pleuritis was noted in three 
challenged groups with 30% of the pigs in group 2, 40% of the pigs in group 4, and 20% of 
the pigs in group 5 affected. Peritonitis was only noted in one animal (10%) from group 2. 
All of the animals in the non-challenged group 6 remained free from polyserositis. 
 Signs of arthritis were present in at least one animal in each challenged group. As 
shown in Figure 2.1A, the number of animals with at least one joint positive for arthritis were 
 
Fig. 2.4. Study 2 average daily weight gain by group. Groups:  1=IP, IV, IN, 2=IP, IV. 
IP=intraperitoneal; IV=intravenous; IN=intranasal. Comparisons were made between group 
1 and 2 and therefore the non-infected group 3 data is not shown. Data represents the least 
squares mean kg/day ± standard error. There was no significant difference between groups.
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higher in group 1 (30%), group 4 (50%) and group 5 (50%) than in group 2 (10%) and group 
3 (10%). None of the group 6 non-challenged animals showed signs of arthritis in any joint. 
 A single mortality occurred during this study. One animal in group 2 was found dead 
on Day 19 and upon gross examination, was found to have pleuritis and severe pericarditis 
consistent with MHR infection. 
 The distribution of polyserositis for Study 2 can be seen in Figure 2.3B. The 
incidence of pericarditis was high with over half of the animals in group 1 (57.1%) and group 
2 (75.0%) affected. Pleuritis was noted in 17.9% of the animals in group 1 and 10.7% of the 
animals in group 2. No peritonitis was observed in either group in Study 2. Non-infected 
group 3 animals remained free from gross lesions. 
 A single mortality occurred in Study 2. One animal in group 1 was found dead on 
Day 14. Upon necropsy, this pig was noted to have severe pericarditis and focal areas of 
pleuritis with areas of consolidation consistent with MHR infection. 
 The number of animals with at least one joint positive for signs of arthritis in Study 2 
was 35.7% for group 1 and 50.0% for group 2. Figure 2.5 shows the distribution of arthritis 
among the eight joints examined. The tarsi were most often affected with 21.4% of the left 
tarsi and 28.6% of the right tarsi affected in group 1 and 35.7% of both the right and the left 
tarsi affected in group 2. The left elbow (14.3%), right elbow (10.7%), left stifle (10.7%), and 
right stifle (10.7%) of group 1 also exhibited signs of arthritis. Similarly, the left elbow 
(28.6%), right elbow (25%), left stifle (21.4%) and right stifle (14.3%) of group 2 were 
affected. The carpi for both groups showed no signs of arthritis. No signs of arthritis were 
noted in any joint for any of the non-infected group 3 animals. 
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Histopathology  
 Histopathology was only performed for Study 1. Samples from group 3 were free of 
any significant findings, while groups 2, 4 and 5 had the highest degree of microscopic 
lesions as shown in Table 2.2. Epicardial/pericardial adhesions, fibrosis and lymphocytic 
inflammation were noted in affected heart samples. All samples from non-infected group 6 
showed no significant findings. Figure 2.6A shows the percentage of animals in each group 
receiving a score > 0 for each category. These results paralleled the gross pathological 
observations shown in Figure 1B.   
 
 
 
 
Fig. 2.5. Study 2 assessment of arthritis by joint and group. Groups:  1=IP, IV, IN, 2=IP, 
IV. IP=intraperitoneal; IV=intravenous; IN=intranasal; LE, RE = left and right elbow; LC, 
RC = left and right carpal; LS, RS = left and right stifle; LT, RT = left and right tarsal. Data 
represents the percent (%) animals positive for arthritis at that joint ± standard error. There 
were no significant differences between groups for any joint 
0
5
10
15
20
25
30
35
40
45
50
LE RE LC RC LS RS LT RT
%
 P
os
iti
ve
 P
ig
s 
1
2
 43  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2.  Histopathology scores for Study 1. 
Group 
Lung Tissue Heart Tissue 
PleuritisA InfiltratesA InflammationB FibrosisC 
1 Affected pigs/total pigs 
0/10 3/10 1/10 3/10 
Total Group Score 0 4 3 6 
2 Affected pigs/total pigs 
2/9 5/9 6/9 8/9 
Total Group Score 4 8 13 19 
3 Affected pigs/total pigs 
0/10 0/10 0/10 0/10 
Total Group Score 0 0 0 0 
4 Affected pigs/total pigs 
2/10 4/10 3/10 4/10 
Total Group Score 2 4 6 8 
5 Affected pigs/total pigs 
3/10 4/10 5/10 5/10 
Total Group Score 4 5 9 11 
6 Affected pigs/total pigs 
0/6 0/6 0/6 0/6 
Total Group Score 0 0 0 0 
Groups: 1—IP, 2—IV, 3—IN, 4—IP, IV, IN (high dose), 5—IP, IV, IN (low dose), 6—no 
treatment. 
A = pleuritis and peribronchiolar/septal infiltrates scored as none (0), mild (1), moderate (2), 
or severe (3). B = lymphocytic inflammation scored as no inflammation (0), mild 
accumulation of lymphocytes (1), moderate accumulation of lymphocytes (2), or severe 
accumulation of lymphocytes (3). C = fibrosis of the epicardium scored as no fibrosis (0), 
mild fibrosis (1), moderate fibrosis (2), or severe fibrosis (3). 
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PCR 
 For Study 1, all nasal swabs collected on D0 were negative for MHR and MHS by 
PCR, demonstrating a lack of colonization by either organism prior to study initiation. 
Study 1 joint swabs resulted in few positive results for MHR. For the elbow-stifle swabs, 
20% were positive in group 1 and 10% in both group 2 and 3; none of the group 4 or 5 
samples were positive for MHR. For the carpi-tarsi swabs, 20% of the samples in group 2 
were positive for MHR by PCR; all samples in group 1, 3, 4, and 5 were negative. Joint 
 
Fig. 2.6. Study 1 in vitro testing. A. Histological evaluations for lung (pleuritis and 
peribronchiolar/septal infiltrates) and heart (lymphocytic inflammation and fibrosis of the 
epicardium). B. M. hyorhinis PCR for heart tissue, lung tissue and joint swabs. Groups:  
1=IP (intraperitoneal), 2=IV (intravenous), 3=IN (intranasal), 4=IP, IV, IN (high dose), 
5=IP, IV, IN (low dose). All group 6 non-infected controls received no histological scores 
and were all PCR negative and are therefore not represented. Histological data represents 
the percent (%) animals with a score of > 0 ± standard error. PCR data represents the 
percent (%) animals PCR positive for the respective samples ± standard error. 
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swabs collected from non-infected group 6 were negative for MHR by PCR. All joint swabs 
were negative for MHS by PCR. 
 Fresh lung tissue from Study 1 was homogenized prior to total nucleic acid extraction 
and PCR testing. For groups 1-5, 10%, 20%, 0%, 40% and 10% of lung samples, 
respectively, were positive for MHR by PCR. Lung samples collected from non-infected 
group 6 were negative for MHR by PCR. All lung samples were negative for MHS by PCR. 
 Fresh heart tissue from Study 1 was homogenized prior to total nucleic acid 
extraction and PCR testing. Results for MHR PCR closely match results for the lung tissue. 
For groups 1-5, 10%, 20%, 0%, 30% and 10% of heart samples, respectively, were positive 
for MHR by PCR. Heart tissue samples collected from non-infected group 6 were negative 
for MHR by PCR. All heart samples were negative for MHS by PCR. See Fig. 2.6B for a 
summary of Study 1 MHR PCR results by group. 
 For Study 2, all nasal swabs collected on Day 0 were negative for MHR, MHS, and 
MHP by PCR, demonstrating a lack of colonization by any of these Mycoplasma species 
prior to study initiation. 
 Greater than half of the joint swabs collected in from both groups in Study 2 were 
positive for MHR by PCR as shown in Figure 2.7. For the elbow-stifle swabs, 53.4% of 
group 1 samples and 64.0% of the group 2 samples were MHR positive by PCR. For the 
carpi-tarsi swabs, 60.8% of group 1 samples and 75.4% of the group 2 samples were MHR 
positive by PCR. All joint swabs collected from non-infected group 3 animals were negative 
for MHR by PCR. All joint swabs were negative for MHS and MHP by PCR. 
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 In lieu of fresh tissue collection, swabs of the pericardium and pleura were collected 
from animals in Study 2. As shown in Figure 2.7, 22.5% of group 1 and 22.0% of group 2 
pericardial swabs were positive for MHR by PCR. For the pleural swabs, 14.3% of group 1 
samples and 21.4% of group 2 samples were positive for MHR by PCR. All pericardial and 
pleural swabs from non-infected group 3 animals were negative for MHR by PCR. All 
pericardial and pleural swabs were negative for MHS and MHP by PCR. 
Bacteriology 
 Aerobic and anaerobic culture of all necropsy samples on blood agar showed no 
growth of any significant bacterial pathogens (i.e. Streptococcus suis and Haemophilus 
parasuis). 
 
 
Fig. 2.7. Study 2 M. hyorhinis PCR for heart, lung, and joint swabs. Groups:  1=IP, IV, 
IN, 2=IP, IV. IP=intraperitoneal; IV=intravenous; IN=intranasal. All group 3 non-infected 
controls were PCR negative and are therefore not represented. Data represents the percent 
(%) animals PCR positive for the respective sample ± standard error. There were no 
significant differences between groups for any sample. 
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Discussion 
 The challenge isolate used in our studies was found to grow to higher titers in tissue 
culture as compared to standard in vitro broth techniques. This is not uncommon for some 
strains of MHR (11). Our initial animal experiments proved this material was indeed virulent 
and suitable for animal challenge (data not shown).  
 Previous studies (6, 12, 13) have reported that a single IP administration of MHR, or 
combination of IP and IN on a single day, can result in polyserositis and/or lameness using 
traditional, broth-derived cultures of MHR. However, these studies either used extremely low 
group numbers (n=2) or infected piglets at ages (e.g. three weeks; three months) outside of 
which current literature suggests animals are most susceptible (six to seven weeks) (1). Our 
initial efforts in reproducing these results were mixed (data not shown). In development of 
this challenge model, our goal was to achieve greater than 50 % of both polyserositis and 
lameness in inoculated animals in order to suitably evaluate potential vaccine candidates for 
these clinical manifestations of MHR infection. 
 Treatment groups for Study 1 were confounded by housing and, therefore, a direct 
statistical comparison across all five groups cannot be made. However, results indicate that 
clinical manifestation of disease was dependent more on the route of administration than the 
given dose when utilizing cell-associated MHR challenge material. This is evidenced by 
comparing results from group 2 (IV administration) and group 3 (IN administration) which 
both received single inoculations at the same dose of MHR (7.96 × 108 CCU/pig). 
Differences in clinical outcomes differ greatly:  IV administration resulted in substantial 
polyserositis, both grossly and microscopically, while IN administration showed no signs of 
 48  
polyserositis. Additionally, a single IP administration (group 1) at twice the dose (1.59 × 109 
CCU/pig) of that listed above did not induce the same level of polyserositis as the IV 
administration (group 2), but did result in an increased incidence of lameness compared to 
the other single-dose administrations (Fig. 2.1A and B). Further, pigs administered the three 
consecutive-day IP, IV, and IN challenge (group 4 and 5) showed a more robust disease 
manifestation, resulting in both polyserositis and lameness. It is unclear why the lower dose 
administered to group 5 (1.43 × 109 CCU/pig) resulted in greater lameness than group 4 (2.86 
× 109 CCU/pig) when other results (pericarditis, arthritis, and weight gain) for these two 
groups were similar. We have attempted to reduce the subjectivity in lameness observations 
and account for incidental or transient lameness by defining a “lame” animal as one observed 
with lameness scores on at least two consecutive days. 
 It should also be noted that group 5 received a similar total dose as the single IP 
administration (group 1), yet group 5 had higher numbers of affected pigs for polyserositis, 
lameness, and arthritis as well as reduced ADG. Perhaps the additional handling time and 
manipulations that groups 4 and 5 incurred stressed these animals more than the others, 
increasing anxiety as well as the susceptibility to infection. We did not control for the 
possibility of this effect in either study. 
 Study 1 provided sufficient proof of concept data to further optimize the multiple 
route, consecutive-day approach for the MHR challenge model. Mock infections were 
performed using antigen-free cultures and showed that clinical manifestations were 
Mycoplasma-dependent (data not shown). Study 2 was designed to evaluate the necessity of 
the third-day, IN challenge in the model as Study 1 indicated minimal success with IN 
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administration alone. Study 2 also terminated at 28 days post-challenge (dpc), seven days 
later than Study 1. This extension was included to determine if mortalities would increase 
given the severity of pericarditis observed in the model. No increase in mortality was 
observed, however, two additional group 2 animals were scored as lame due to the seven day 
extension. Treatment groups were co-mingled in this study and, therefore, direct comparisons 
between groups were possible. Results from Study 2 are clear:  there were no significant 
differences noted between animals administered three-consecutive-day inoculation (IP, IV, 
and IN) and animals administered two-consecutive-day inoculation (IP and IV only) for any 
parameter measured. The IN administration can, consequently, be omitted from the challenge 
model protocol without negatively affecting clinical outcomes of MHR infection. This 
omission will reduce time and resources in both the laboratory, for producing sufficient 
quantity of challenge material, and in the animal facilities, for time allotted to animal 
manipulations. 
 The differences in outcomes between the multiple route, consecutive-day challenge 
and the single route, single-day challenges may be due to a weaker overall inflammatory 
response in the later and therefore resulting in less joint involvement; whereas the former 
may allow for sufficient and chronic inflammatory response, leading to polyarthritis (14). 
Further, it is possible that the consecutive-day approach allows for antigen over-abundance 
and accumulation of small immune complexes leading to a Type III hypersensitivity reaction 
(15) or autoimmunity (16). 
 The natural route of infection and the pathogenesis for MHR are currently unknown 
(1, 2).  Our results indicate that systemic infection via the circulatory and/or lymphatic 
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system is highly likely. Although the route of initial entry into the host still remains unclear, 
MHR colonizes the upper respiratory tract (2), and it is very likely the organism enters the 
host via this route. Our results for IN inoculation, though, provide little data to support this 
hypothesis. Perhaps given sufficient time (> 21 days post challenge) animals administered 
MHR by IN inoculation might indeed succumb. It is also possible that environmental MHR 
is simply more efficient with colonization and infection than in vitro cultures which make 
feasible the upper respiratory route as a means of entry.  Alternatively, fighting is common 
among wean-to-finish pigs and perhaps biting provides the mechanism of entry, creating an 
opening for which MHR can be transmitted from a colonized animal directly to the 
bloodstream of another. 
Conclusion 
 We have shown that the optimized, consecutive-day inoculation using cell-associated 
MHR material was successful in achieving > 50 % affected animals for both lameness and 
pericarditis. The model can therefore be defined as administration of cell-associated MHR to 
seven week old CDCD pigs at 20 mL/IP and 10 mL/IV on the first and second day of 
challenge, respectively, for a total recommended dose of 1.5 × 109 ± 0.5 CCU per pig. 
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Abstract 
 Mycoplasma hyorhinis (MHR) is a major cause of lameness, arthritis, and 
polyserositis among grower pigs. Reduced performance and culling due to MHR infection 
result in economic losses in swine production. 
 We have developed an MHR challenge model in seven week old CDCD pigs using 
cell-associated MHR which results in both severe pericarditis and lameness. In this study we 
sequentially challenged CDCD pigs at seven, ten, thirteen, and sixteen weeks of age with our 
cell-associated challenge material. Lameness was observed in over 60 % of the animals in the 
first three age groups but fell to 33 % in the oldest age group. The number of animals with 
arthritis fell from 100 % at seven weeks, to 56 % at ten weeks and approximately 25 % at 
both thirteen and sixteen weeks of age. Pericarditis was observed in 87 % of the seven week 
challenge group, 28 % in the ten week challenge group, 8 % in the thirteen week challenge 
group and 4 % in the sixteen week challenge group. All challenged groups showed an 
average daily gain (ADG) of at least 0.6 lbs/day less than the age-matched non-challenged 
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control groups, with the largest margin noted at thirteen weeks of age at a 1.2 lbs/day 
difference. 
 Results of this study show that animals were susceptible to MHR-associated lameness 
through sixteen weeks of age while susceptibility to MHR-associated polyserositis appeared 
to peak at seven weeks of age.  
Introduction 
 Mycoplasma hyorhinis (MHR) causes disease in three- to ten-week old animals but 
most commonly causes polyserositis and polyarthritis in pigs around seven weeks of age (1, 
2). Economic losses due to MHR can be attributed to reduced performance (weight gain and 
feed conversion) and culling due to lameness (3). There are currently no licensed, 
commercially available vaccines for MHR.  
 We have previously established a robust experimental infection protocol for MHR in 
seven-week old caesarian derived-colostrum deprived (CDCD) pigs which results in severe 
pericarditis and lameness (submitted). Some literature has suggested an age limitation to the 
susceptibility of MHR (4) although eight-weeks of age was the limit of testing. In this study, 
we evaluated our MHR challenge model using cell associated challenge material in the same 
litters of animals at seven, ten, thirteen, and sixteen weeks of age. The results demonstrate 
the age of greatest susceptibility and thus, can define the preferred duration of immunity for 
any potential vaccine as well as provide guidance for prophylactic antibiotics to minimize 
their use. 
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Materials and Methods 
Challenge material 
 The MHR challenge isolate originated from the joint fluid of a pig displaying clinical 
signs of mycoplasma infection. After initial culturing in modified Friis media (5), the 
infection dose of MHR was cultured on confluent monolayers of MDCK (Madin-Darby 
canine kidney) cells. Cell maintenance media was minimum essential media (MEM; 
Gibco/Thermo Fisher Scientific Inc., Waltham, MA) supplemented with 10 % fetal bovine 
serum (FBS; SAFC, St. Louis, MO). Growth media was removed prior to infection and 
Mycoplasmas were then added to the tissue culture at approximately 10 % (v/v) of the total 
final volume. Cells with mycoplasma were allowed to incubate at  37° C for approximately 
two hours before adding pre-warmed media consisting of MEM supplemented with 2 % FBS. 
After the presence of cytopathic effect (CPE) was noted, generally occurring around 4-7 days 
post-infection, the culture was harvested by briefly shaking the flasks and collecting the 
supernatant. The MHR culture was then combined with 10 % (v/v) sterile glycerol, dispensed 
into working volumes and stored at < -60° C until challenge. Quantification of the challenge 
doses was performed by color changing units (CCU). 
 No freezing step was used prior to harvest as described previously (submitted). This 
preparation greatly reduced the amount of cellular debris in the challenge material which, in 
turn, reduced incidences of anaphylaxis post-intravenous challenge. 
Animal information 
 Commercial cross breed CDCD piglets, both gilts and in-tact barrows, were acquired 
from a Class A dealer. Nasal swabs (eSwab™, Copan; Murrieta, CA) were collected prior to 
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challenge and were negative for MHR, M. hyopneumoniae (MHP) and M. hyosynoviae 
(MHS) as determined by real-time PCR analysis. Sera were also collected prior to challenge 
and were free from MHP antibodies by ELISA (IDEXX, Westbrook, ME). Animals were 
seven weeks ± five days of age at the time of study initiation and were deemed to be in good 
health and nutritional status. After arrival to the study site, no biologicals or pharmaceuticals 
other than the challenge material were administered to the test animals. Non-medicated feed 
was used at rations appropriate for the age, condition, and species of test animal. Water was 
provided ad libitum. Housing was a BSL-2 USDA inspected facility and the study was 
conducted following the Guide for the Care and Use of Agricultural Animals in Agricultural 
Research and Teaching (6). 
 Pigs were blocked by litter and randomly divided into four groups of 25 animals each 
for experimental challenge, labeled groups 1-4. Four groups of five pigs each were used for 
non-challenged control animals, labeled groups 5-8. Animals were housed in four rooms with 
two pens per room. Pens were a raised deck with metal slatted flooring and metal gating for 
sides. Pigs in Group 1 and 4 were housed in separate rooms. Pigs in Group 2 and 3 were 
housed together until challenge for Group 2, at which time animals in Group 2 were 
segregated into their own room. Pigs in Group 4 were housed in two rooms at the time of 
challenge due to size and space requirements. Non-challenged animals in Group 5-8 were 
housed independently of the challenged animals and co-mingled together in one room in two 
pens. 
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Experimental inoculation 
 Pigs in Group 1 were inoculated with MHR at 20 mL/intraperitoneal injection (IP) on 
Day 0, 10 mL/intravenous injection (IV) on Day 1, and 10 mL/intranasal application (IN; 5 
mL/nostril) on Day 2, for a total dose of 5.73 × 109 CCU/pig. Pigs in Group 2, 3 and 4 were 
inoculated with MHR in identical fashion beginning on Day 21 (2.55 × 109 CCU/pig), Day 
42 (3.72 × 109 CCU/pig), and Day 63 (4.26 × 109 CCU/pig), respectively (see Table S17 in 
Appendix B). The MHR inoculum was titrated by CCU using five replicates per assay, in 
triplicate, on each challenge day. The dose for any given day was recorded as the mean of the 
triplicate assays and the total applied dose was the summation of the three mean titers. All 
titers for the first, second and third day of challenge for any given group, as well as across 
groups on any given day, resulted in a coefficient of variation (CV) of less than 5%. The CV 
for all 36 titrations was less than 5%. 
Clinical observations 
 Pigs were observed daily for lameness during their respective challenge periods, from 
the first challenge day (0 dpc) through 21 days post challenge (21 dpc). Lameness was scored 
0-5 according to the system outlined in Table 3.1. A pig was considered lame if it received a 
score of  
≥ 1 on any two (or more) consecutive days. Weight measurements were taken just prior to 
challenge on 0 dpc and just prior to euthanasia on 21 dpc. At study termination, all pigs were 
anesthetized and then euthanized by electrocution. The experimental schedules of events are 
summarized in Table S18 in Appendix B. 
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Table 3.1. Scoring system for lameness. 
Score Description  
0 = Normal—no visible lameness. 
1 = Mild—not constantly lame when walking, walks at a normal speed, is weight 
bearing while walking and standing, lameness is indicated by intermittent reduced 
weight bearing on one limb or shortening of the stride. 
2 = Moderate—constant and observed throughout every step at a walking pace, 
bearing some weight on the leg at a walk and standing, but short-striding one or 
more legs while walking, walks at a normal speed. 
3 = Moderately Severe—puts no weight on the leg the first few steps after standing, 
constant, obvious lameness while at a walking pace, putting very little weight on 
the leg at a walk or while standing, requires the pig to slow its speed of walking. 
4 = Severe—will stand (may require assistance) for at least 3 minutes, non-weight 
bearing on one or more legs at walk or standing, still able to three-legged walk. 
5 = Recumbent—will not stand even with assistance. 
 
Gross pathological examination and sample collection 
 Following euthanasia, a gross pathological examination was performed. The thoracic 
and abdominal cavities were opened and examined for evidence of polyserositis. Pericardial 
swabs (eSwab™, Copan; Murrieta, CA) were taken from all pigs. Pleural swabs were taken 
from only those animals exhibiting pleuritis. Serosal swabs were taken from only those 
animals exhibiting peritonitis. All swabs were tested for MHR, MHS and MHP by real-time 
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PCR. The elbows, stifles, carpi and tarsi were opened and examined for signs of arthritis 
including, but not limited to, abnormal and/or excessive synovial fluid, abnormal synovial 
membranes, and abnormal articular surfaces. For each pig, a single swab (eSwab™, Copan; 
Murrieta, CA) was used to sample the articular surfaces of both elbows and both stifles. This 
process was repeated using a new, single swab for all four carpi and tarsi.  All joint swabs 
were tested for MHR, MHS, and MHP by real-time PCR. 
Real-time PCR 
 Total nucleic acid extractions and real-time PCR were performed as described 
previously (Chapter 2, page 25). The method of detection by real-time PCR for MHP has 
been previously described (7). 
Statistical analyses 
 Statistical summaries were conducted using SAS Version 9.4. Treatment was 
confounded by housing and results were therefore summarized by treatment group. 
Individual average daily gain during the 21 day challenged period was calculated by 
subtracting the 0 dpc weight from the 21 dpc weight and dividing by 21. Average daily gain 
for each treatment group was summarized using the MEANS procedure of SAS. Means, 
standard errors, and 95% confidence intervals (CI’s) for each treatment were determined 
(Table S19). The presence of pericarditis, pleuritis, and peritonitis, as well as PCR swab 
results were each summarized by treatment group using the FREQ procedure of SAS. The 
proportion positive, standard error, and Clopper-Pearson Exact 95% CI’s were determined 
for each treatment group (Table S20 and S21). The percent of joints with arthritis for each 
animal was summarized by group using the MEANS procedure of SAS. Means, standard 
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errors, and 95% CI’s for each treatment were determined (Table S22). In addition, the 
percent of animals with at least one affected joint was summarized using the FREQ 
procedure of SAS. The proportion positive, standard error, and Clopper-Pearson Exact 95% 
CI’s were determined for each treatment group (Table S22). The presence or absence of 
lameness during the 21 day challenge period was determined and summarized. The 
proportion of lame animals within each treatment group was reported with the standard error 
and Clopper-Pearson Exact 95% CI’s using the FREQ procedure of SAS (Table S23). 
Results 
Clinical observations 
 Lameness was observed in all challenged groups 1-4 (Fig. 3.1). Group 1, 2, and 3 all 
resulted in over half of the animals lame in each group with 65.2 %, 68.0 %, and 68.0 % 
affected animals, respectively. Fewer pigs were affected in group 4 with 33.3 % scored as 
lame. 
 None of the animals in each of the non-challenged groups 5 and 7 were scored as 
lame. One animal in the non-challenged group 6 received a lameness score of “1” from 5 dpc 
(Day 26) through 10 dpc (Day 31). Two animals in the non-challenged group 8 received 
lameness scores. One pig received a score of “1” on the last three observation days, 19 dpc 
(Day 82) through 21 dpc (Day 84). The other pig was noted with lameness very early in the 
observation period receiving a score of “2” on 1 dpc (Day 64), scores of “1” on 4 and 5 dpc 
(Day 67 and 68), scores of “2” on 6 and 7 dpc (Day 69 and 70), and scores of “1” on each of 
the remaining observation days, 8 dpc (Day 71) through 21 dpc (Day 84). 
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Fig. 3.1. Assessment of lameness. Groups:   1 = 7 weeks of age; 2 = 10 weeks of age; 3 = 13 
weeks of age; 4 = 16 weeks of age. Data are for the MHR challenged groups only and 
represent the proportion positive animals per group ± standard error. 
  
 There was little difference between the mean weight for challenged and non-
challenged animals on 0 dpc as seen in Table 3.2. At necropsy (21 dpc), however, there was a 
large discrepancy between the mean weight of animals challenged with MHR and those not 
receiving challenge. For the seven-week age groups, non-challenged group 5 animals 
weighed an average of 18.0 lbs. more than group 1. For the ten-week age groups, non-
challenged group 6 animals weighed an average of 17.7 lbs. more than group 2. For the 
thirteen-week age groups, non-challenged group 7 weighed an average of 30.2 lbs. more than 
group 3. For the sixteen-week age groups, non-challenged group 8 weighed an average of 
20.7 lbs. more than group 4. 
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Table 3.2. Mean weight (lbs) on first and last day of challenge. 
 Treatment 
Group* n 
0 dpc 
 Mean Weight 
(lbs) ± 
Standard Error 
0 dpc 
Difference, 
Challenge –  
Non-challenge 
(lbs) 
21 dpc 
 Mean Weight 
(lbs) ± 
Standard Error 
21 dpc 
Difference, 
Challenge –  
Non-challenge 
(lbs) 
1 23 22.0 ± 0.67 
-0.8 
32.0 ± 1.36 
-18.0 
5 5 22.8 ± 0.80 50.0 ± 1.65 
 
 
 
 
 
 
2 25 50.8 ± 1.02 
-0.2 
69.6 ± 1.76 
-17.7 
6 5 51.0 ± 4.21 87.3 ± 5.64 
 
 
 
 
 
 
3 25 93.5 ± 1.87 
-5.2 
114.9 ± 2.44 
-30.2 
7 5 98.7 ± 2.98 145.1 ± 5.79 
 
 
 
 
 
 
4 24 125.7 ± 2.24 
-7.0 
160.3 ± 2.88 
-20.7 
8 5 132.7 ± 5.45 181.0 ± 6.65 
*1 (Challenge) and 5 (Non-challenge) = 7 weeks of age (0 dpc = Day 0);  
2 (Challenge) and 6 (Non-challenge) = 10 weeks of age (0 dpc = Day 21);  
3 (Challenge) and 7 (Non-challenge) = 13 weeks of age (0 dpc = Day 42);  
4 (Challenge) and 8 (Non-challenge) = 16 weeks of age (0 dpc = Day 63).  
dpc = days post challenge 
 
  The average daily gain (ADG) was also calculated for all groups (Fig 3.2). All 
non-challenged animals (groups 5-8) gained an average of ≥ 1.3 lbs. per day with group 7 
and 8 averaging a gain of ≥ 2.2 lbs. per day. In contrast, three of the four challenged groups 
(groups 1-3) gained on average ≤ 1.0 lb. per day with group 4 having an average gain of 1.7 
lbs. per day. 
 63  
 
Fig. 3.2. Average daily weight gain. Groups:  7 wk = seven week old animals, group 1 
(challenge) and group 5 (non-challenge); 10 wk = ten week old animals, group 2 (challenge) 
and group 6 (non-challenge); 13 wk = thirteen week old animals, group 3 (challenge) and 
group 7 (non-challenge); 16 wk = sixteen week old animals, group 4 (challenge) and group 8 
(non-challenge). Data represent the mean lbs/day ± standard error. ADG = average daily 
gain. 
 
 One animal in group 1 was excluded (euthanized) from the study. This animal was 
observed to be lame at the time of study initiation on 0 dpc. No data from this animal was 
included in the analyses. 
 Mortalities, although few, were noted in all challenged groups. Results from all of the 
following animals were included in the analyses. One pig in group 1 was found dead on 9 
dpc, and upon necropsy was noted to have an active gastric ulcer at the pars esophagea. This 
animal was also noted to have mild pericarditis, peritonitis, and excess synovial fluid in both 
rear tarsi. With the exception of the ulcer, these clinical signs are consistent with MHR 
infection; however, death was most likely attributable to ulceration of the pars esophagea 
(UPE). 
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 One animal in group 2 was found dead on 13 dpc and upon necropsy was noted to 
have a pale carcass and a large, active gastric ulcer at the pars esophagea. This animal was 
also noted to have excess synovial fluid in the left elbow. Death was most likely attributable 
to UPE. 
 Two animals in group 3 did not make it to the end of the challenge period. One 
animal was euthanized for humane reasons on 11 dpc due to severe lameness (recumbent). 
Both stifles had excess synovial fluid. The clinical signs of disease were consistent with 
MHR and mortality was most likely due to virulent challenge. Another animal in group 3 was 
found dead on 19 dpc; however, no gross lesions were observed at necropsy and the cause of 
death could not be determined. 
 One animal in group 4 was found dead on 18 dpc. No gross lesions were noted, 
although excess synovial fluid was noted in the tarsi and both stifles. Lung tissue was 
submitted to Iowa State University Veterinary Diagnostic Laboratory (ISU-VDL) for further 
examination. Hematoxylin and eosin (H/E) staining of fixed lung showed moderate 
interlobular and perivascular edema. Multifocal alveoli contained edema fluid with scant 
fibrin. Routine culture of fresh lung tissue showed no significant bacterial growth. The cause 
of death could not be determined. 
Gross pathology 
 The incidence of polyserositis can be seen in Figure 3.3. Pericarditis was observed in 
87.0 % of the animals in group 1. The number of affected pigs declined in subsequent 
challenges with 28.0 % in group 2, 8.0 % in group 3, and 4.2 % in group 4. All non-
challenged animals in groups 5-8 remained free from pericarditis. 
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Fig. 3.3. Gross assessment for polyserositis. Groups:   1 = 7 weeks of age; 2 = 10 weeks of 
age; 3 = 13 weeks of age; 4 = 16 weeks of age. Data are for the MHR challenged groups only 
and represents the proportion positive animals ± standard error. 
 
 Pleuritis was observed in 26.1 % of the animals in group 1, 4.0 % of the animals in 
group 2, and 16.0 % of the animals in group 3. None of the animals in group 4 were affected 
with pleuritis. All non-challenged animals in groups 5-8 remained free from pleuritis. 
 Peritonitis was noted in 21.7 % of the animals in group 1, 16.0 % of the animals in 
group 2, and 8.0 % of the animals in group 3. None of the animals in group 4 were affected 
with peritonitis. All non-challenged animals in groups 5-8 remained free from peritonitis. 
 The number of pigs per group with at least one joint exhibiting signs of arthritis 
decreased as the age of the animals increased (Fig. 3.4A). All of the animals (100 %) in 
group 1 showed at least one arthritic joint. The incidence of arthritis fell in subsequent 
challenges with 56.0 % of the animals affected in group 2, 24.0 % of the animals affected in 
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group 3, and 25.0 % of the animals affected in group 4. All non-challenged animals in groups 
5-8 showed no signs of arthritis in any joints examined.  
 Further, the number of affected joints per pig was analyzed in the challenged groups 
(Fig. 3.4B). The total number of joints affected per animal decreased with the increase of age 
at challenge. Of the eight joints examined, the average proportion of positive joints was 
46.2 % for group 1, 17.5 % for group 2, 4.0 % for group 3, and 8.9 % for group 4. 
 
  
Fig. 3.4. Assessment for arthritis. A. Proportion of animals per group with at least one joint 
showing signs of arthritis. Data are for MHR challenged groups only and represent the 
proportion of positive animals ± standard error. B. Proportion of affected joints per animal in 
each group. Data are for MHR challenged groups only and represent the proportion positive 
joints ± standard error. Groups:   1 = 7 weeks of age; 2 = 10 weeks of age; 3 = 13 weeks of 
age; 4 = 16 weeks of age. 
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Real-time PCR 
 Nasal swabs collected one day prior to each challenge were all negative for MHR, 
MHS, and MHP by PCR, demonstrating a lack of colonization by any of these Mycoplasma 
species prior to study initiation. 
 Fewer than 50 % of all the serosal swabs (Fig. 3.5A) were positive for MHR by PCR. 
For pericardial swabs, 26.1 % of the samples from group 1, 4.0 % of the samples from group 
2, and 8.3 % of the samples from group 4 were positive for MHR by PCR. All pericardial 
swabs from group 3 were negative for MHR by PCR. All pericardial swabs from non-
challenged animals in groups 5-8 were negative for MHR by PCR. All pericardial swabs 
collected were negative for MHP and MHS by PCR. 
 Pleural swabs were only taken from those animals exhibiting gross pleuritis. Of the 
six pleural swabs collected from group 1, two were positive for MHR by PCR. Pleural swabs 
collected from group 2 and group 3 were all negative for MHR by PCR. No pleural swabs 
were collected from group 4. No pleural swabs were collected from the non-challenged 
animals in groups 5-8. All pleural swabs collected were negative for MHP and MHS by PCR. 
 Peritoneal swabs were only collected from those animals exhibiting gross peritonitis. 
Of the five samples collected from group 1, one was positive for MHR by PCR. Peritoneal 
swabs collected from group 2 and group 3 were all negative for MHR by PCR. No peritoneal 
swabs were collected from group 4. No peritoneal swabs were collected from non-challenged 
animals in groups 5-8. All peritoneal swabs collected were negative for MHP and MHS by 
PCR. 
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 A greater number of MHR PCR positive results were detected from the joint swabs 
(Fig. 3.5B) than with serosal swabs. Elbow-stifle swabs collected from group 1 resulted in 
82.6 % samples positive for MHR by PCR. There were fewer MHR positive results in the 
subsequent challenges, with 36.0 % in group 2, 32.0 % in group 3, and 16.7 % in group 4 
positive by PCR. All elbow-stifle swabs from non-challenged animals in groups 5-8 were 
negative for MHR by PCR. All elbow-stifle swabs collected were negative for MHP and 
MHS by PCR. 
 
  
Fig. 3.5. M. hyorhinis PCR for necropsy swabs. A. Serosal swabs. Pericardial swabs were 
collected from all animals. Pleural and peritoneal swabs were collected only from those 
animals exhibiting gross lesions. Data are for MHR challenged groups and represent the 
proportion of positive samples ± standard error. B. Joint swabs. A single swab was used to 
sample surfaces of both the elbows and stifles.  A single swab was used to sample surfaces of 
both carpi and tarsi. Data are for MHR challenged groups and represents the proportion of 
positive samples ± standard error. Groups:   1 = 7 weeks of age; 2 = 10 weeks of age; 3 = 13 
weeks of age; 4 = 16 weeks of age. 
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 Carpal-tarsal swabs followed a similar trend to the elbow-stifle swab PCR results. 
Group 1 had 87.0 % samples positive for MHR. There were fewer positive results in the 
subsequent challenges, with 36.0 % in group 2, 12.0 % in group 3, and 4.2 % in group 4 
positive for MHR by PCR. All carpal-tarsal swabs from non-challenged animals in group 5-8 
were negative for MHR by PCR. All carpal-tarsal swabs collected were negative for MHP 
and MHS by PCR. 
Discussion 
 Prior research suggests piglets of six to seven weeks of age are most susceptible to 
natural infection by MHR (2, 8, 9). Our previous studies using cell associated challenge 
material support these findings (submitted). The goal of this study was to evaluate the 
effectiveness of our MHR challenge model and cell associated challenge material to cause 
disease in animals older than seven weeks of age. 
 The use of CDCD animals in this model makes it extremely difficult to procure the 
appropriate number of animals at the correct ages to challenge all groups simultaneously. 
Even if such requirements could be fulfilled, the size differences between the age groups 
tested would make it impossible to co-mingle all challenge groups as the larger animals 
would simply out-compete the smaller ones. With housing confounding treatment, a direct 
statistical comparison between groups 1-4 is not possible. However, we attempted to 
minimize any differences in the protocol between these groups to allow for a better 
understanding of how MHR affects the same litters within a herd following infection at 
sequential ages. This included utilization of the same stock of MHR challenge material and 
the same sample collection, husbandry and housing protocols. 
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 Group 1 animals were seven weeks of age at the time of inoculation and represented 
the “positive control” group based on previous reports mentioned above. This group of 
animals confirmed the susceptibility of these litters to MHR infection as well as the 
effectiveness of the challenge material used throughout the study. Results for group 1 were 
similar to those observed in our previous challenge model evaluations with high incidences 
of pericarditis, lameness, and arthritis. No animals in the seven-week non-challenged group 5 
showed any signs of MHR-associated disease (e.g. pericarditis, lameness, and arthritis). 
Further, the ADG for group 1 was approximately half of that observed for group 5. Non-
challenged animals were housed separately from their age-matched, challenged counterparts 
to maintain biosecurity. With housing confounding treatment, a direct statistical comparison 
between these groups is not possible. However, results from group 1 confirm effectiveness of 
the challenge model in these litters of animals. 
 Group 2, 3, and 4 were challenged in three-week intervals at ten, thirteen, and sixteen 
weeks of age, respectively. The incidence of pericarditis was greatly reduced from group 1 
(87 %) to group 2 (28 %) and continued to decrease in group 3 (8 %) and group 4 (4 %). 
Thus, protection from polyserositis by any potential vaccine candidate should extend through 
seven weeks at a minimum to limit the most severe pericarditis noted. Discriminate antibiotic 
use can also be recommended as mycoplasma-effective drugs (i.e. lincomycin) may not be 
necessary in older animals still exhibiting severe polyserositis if the prescriber suspected 
MHR as the root cause.   
 Lameness in group 2 and 3 (68 %) was similar to group 1 (65 %), while group 4 had a 
reduced incidence of lameness (33 %). Arthritis also decreased with age, from 100 % 
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affected animals in group 1 to 25 % in group 4. Although 1/3 of the animals at 16 weeks of 
age still exhibited lameness, the downward trend of lameness observations, arthritis and PCR 
detection indicate that vaccine protection need only carry through 10 to 13 weeks of age to 
limit the most severe lameness and arthritis. 
 It should be noted that lameness was observed in three non-challenged animals. One 
animal in group 6 (ten week age group) was scored as lame on six consecutive days (5 dpc 
through 10 dpc). Two animals in group 8 (sixteen week age group) were scored as lame. One 
animal was scored lame on the second day of observations and then intermittently throughout 
the remainder of the observation period, while the other animal was scored lame on the last 
three days of the observation period. The lack of any gross lesions (polyserositis and 
arthritis), as observed in the challenged groups, as well as the lack of any MHR PCR positive 
samples for these animals supports the cause of the observed lameness as non-mycoplasma 
related. These results do not invalidate results obtained from the challenged animals during 
this time period. It does, however, demonstrate that lameness alone is not necessarily an 
indicator of MHR infection. 
 The low number of MHR PCR positive pericardial swabs is similar to findings in our 
previous studies (data not shown). It is possible this is due to assay sensitivity; however, the 
recovery of MHR positive samples in the joint swabs suggest otherwise. Likely, these results 
could be attributable to the timing of the sample collection. Swabs are not collected until 21 
days post-challenge in an effort to allow sufficient time for clinical observations of lameness 
to manifest. Therefore, it is likely that MHR had been cleared form the heart (and lungs) by 
the time of necropsy. The high number of MHR positive joint swabs may also be due to the 
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progression of MHR infection, indicating that the heart is affected earlier and the joints later 
in the course of disease. The pathogenesis of MHR has not been definitively defined and a 
time-course sample collection study design would be required to confirm this hypothesis. 
 The clinical observations of pericarditis, lameness, arthritis, and weight gain show 
that the severity of MHR infection lessened at each subsequent challenge from the seven 
week of age time-point. We have not tested our challenge model in animals younger than six 
weeks of age, but it may be inferred that younger animals are equally susceptible. It is 
possible that the older animals may be able to provide a more substantial immune response, 
lessening the systemic effects (polyserositis), but still resulting in chronic inflammatory 
arthritis as described by Cole and Cassell (10). Talker et al. (11) demonstrated an increase in 
numbers of various T cell subsets from birth through six months of age, and in particular a 
strong increase in γδ T cells from weaning through approximately 19 weeks of age. Perhaps 
the numbers of effector cells are insufficient to combat MHR until after two months of age. 
Although MHR was still able to cause disease in some animals, by sixteen weeks of age, 
signs of infection were modest. 
Conclusion 
 To the best of our knowledge, this is the first study to evaluate the progression of 
MHR infection in animals of the same litters, inoculated sequentially at seven, ten, thirteen 
and sixteen weeks of age. Rates of polyserositis were greatly reduced in the later three 
groups. Lameness was equivalent among the first three age groups and lessened at sixteen 
weeks of age, while incidence of arthritis was reduced in the three oldest groups of animals. 
For all age groups, the ADG was ≥ 0.6 lbs./day below that of non-challenged animals. 
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 MHR greatly affects animals at seven weeks of age with severity lessening through at 
least sixteen weeks of age.  
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Abstract 
 Lameness and polyserositis in pigs caused by Mycoplasma hyorhinis (MHR) are 
generally treated with antibiotics and may require multiple doses. The costs of these 
antibiotics combined with economic losses from culling and reduced feed conversion due to 
lameness are hardships to the swine producer. In this study we have demonstrated efficacy of 
an inactivated MHR vaccine administered to three-week old caesarian-derived colostrum-
deprived (CDCD) piglets. Three doses of vaccine (high, medium, and low) were evaluated 
and compared to a placebo control. MHR challenge occurred three weeks after vaccination. 
Pigs were observed for lameness and respiratory distress for three weeks following 
challenge. Pigs were then euthanized and a gross pathological evaluation for polyserositis 
and arthritis was performed. A minimum immunizing dose of vaccine was defined as 
containing at least 7.41 × 107 CCU of MHR per 2.0 mL dose as represented by the medium 
dose vaccine. This vaccine provided significant reductions of lameness and pericarditis with 
preventive fractions of 0.76 (95% CI [0.26, 0.92]) and 0.58 (95% CI [0.31, 0.74]), 
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respectively, compared to the placebo control group. A significant increase in post-challenge 
weight gain (p < 0.0001) was also achieved with this vaccine, with an average daily gain 
(ADG) of 0.92 lbs/day compared to 0.57 lbs/day in the placebo group. 
Introduction 
 Among the species of mycoplasma which are pathogenic in swine, Mycoplasma 
hyorhinis (MHR) has the most diverse range of clinical effects. As with Mycoplasma 
hyopneumoniae (MHP) and Mycoplasma hyosynoviae (MHS), MHR colonizes the upper 
respiratory tract and can easily be recovered from the nasal cavity and tonsils of infected pigs 
(1, 2). MHR-associated disease occurs in the lungs and joints where the bacteria cause 
pneumonia and polyarthritis, respectively (3-6). It is also a common cause of polyserositis (3, 
5, 6). In particular, we have noted severe pericarditis in experimentally infected animals (B. 
T. Martinson, F. C. Minion, D. M. Jordan, submitted for publication). MHR has also been 
implicated in cases of eustachitis and otitis (3, 7). 
 The most severe MHR infections, in particular polyserositis and lameness, lead to 
reductions in weight gain and feed conversion as well as culling of lame animals which result 
in economic losses to producers (8). As no licensed commercial vaccine is currently 
available, treatment of MHR has typically been with prophylactic and therapeutic antibiotics. 
 In this study, we evaluated three different doses of an inactivated MHR vaccine in 
caesarian-derived colostrum-deprived (CDCD) piglets at three weeks of age for protection 
against MHR-associated pericarditis and lameness. We determined the minimum immunizing 
dose of this vaccine, demonstrated significant reductions for both of the primary parameters 
measured, and achieved significant increases in weight gain compared to a placebo control 
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group. Results indicate the use of such a vaccine would decrease production losses and the 
need of antibiotics for treatment of MHR-associated disease. 
Materials and Methods 
Experimental design 
 In this randomized complete block design, 120 piglets were blocked by litter and 
enrolled into one of four treatment groups (28 animals per group). Animals received either a 
placebo control product (CTRL) or one of three doses of our experimental MHR vaccine 
(HIGH, MED, and LOW). A fifth group of eight animals received no treatment (NTX) 
throughout the study, acting as environmental negative controls. Twenty-two days after 
vaccination, all animals except NTX were challenged with MHR. Animals were observed 
daily post-challenge for signs of respiratory distress, coughing, lameness and well-being. 
Twenty-one days after challenge, all animals were euthanized and a gross pathological 
examination was performed. The study was performed following the Guide for the Care and 
Use of Agricultural Animals in Agricultural Research and Teaching (9) in BSL-2 USDA 
inspected facilities. 
Animals 
 CDCD piglets were purchased from Struve Labs International (SLI; Manning, IA) 
and were 20 days of age at the time of vaccination (Day 0). Both females and intact males 
were used. Animals were identified by uniquely numbered ear tags and acclimated with pen-
mates prior to vaccination. Piglets were determined to be free from colonization by MHR as 
determined by MHR-specific PCR of nasal swabs collected on Day -6. Piglets were also 
determined to be free from antibodies to MHP and porcine reproductive and respiratory 
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syndrome virus (PRRSV) by ELISA (IDEXX Laboratories, Inc.; Westbrook, MA) from 
blood collected on Day -1. Pigs were given a prophylactic treatment of Excede® (Zoetis; 
Florham Park, NJ) six days prior to vaccination (Day -6) per label instructions. No other 
biologicals or pharmaceuticals were administered during the study other than vaccine and 
challenge. All animals were deemed to be healthy prior to vaccination. A diet of milk 
replacer was given until pigs were able to wean to non-medicated, dry food at which time 
water was provided ad libitum. Pigs were observed daily to ensure sufficient feed, water, and 
well-being. 
 The vaccination phase of the study was conducted at SLI. Pigs were initially housed 
in individual isolators until approximately two weeks of age at which time they were moved 
into brooders of two to three litter-mates each. Five days prior to challenge (Day 17), animals 
were transported to Veterinary Resources, Inc. (VRI; Cambridge, IA) for the challenge phase 
of the study. Pigs were again blocked by litter and housed for equal representation of 
treatment groups within pens where possible. During the challenge phase, NTX animals were 
housed separately from the challenged animals to prevent exposure to MHR. Pens were a 
raised deck with metal slatted flooring. Personnel involved in collecting data or performing 
laboratory assays were blinded to the allocation of pigs to treatment group. 
Vaccine 
 Boehringer Ingelheim Vetmedica, Inc.’s (BIVI) MHR vaccine isolate originated from 
a pig with clinical signs of Mycoplasma hyorhinis infection. Initial isolation and speciation 
was performed in modified Friis media using standard techniques (10). For experimental 
vaccine production, McCoy cells (murine fibroblasts) in suspension were infected with MHR 
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and then subsequently inactivated with binary ethylenimine (BEI) per BIVI’s proprietary 
outline of production. 
 A high, medium, and low dose vaccine were generated. The high dose vaccine 
contained the complete culture described above blended with Seppic Montanide™ ISA207 
VG at 50% (w/w). For the medium and low dose vaccines, the MHR culture was first diluted 
1:2 or 1:10, respectively, in phosphate buffered saline (PBS) before blending with adjuvant at 
50% (w/w). The respective dose of MHR in the HIGH, MED, and LOW vaccine preparations 
was calculated to be 1.48 × 108, 7.41 × 107, and 1.48 × 107 CCU per 2.0 mL dose as 
determined by color changing units (CCU) from the pre-inactivation MHR harvest material. 
 A mycoplasma-free, adjuvanted placebo was generated which contained the exact 
composition as the high dose experimental vaccine, without MHR. 
 Pigs were administered a single 2.0 mL dose of vaccine or placebo intramuscularly 
(IM) in the right side of the neck on Day 0. 
Challenge 
 A heterologous isolate of MHR was used for virulent challenge. The preparation of 
the infection dose has been previously described (see Chapter 2). The challenge dose was 
quantified by CCU. 
Animals were administered MHR challenge as follows:  20 mL/intraperitoneal (IP) on Day 
22, 10 mL/intravenous (IV) on Day 23, and 10 mL/intranasal (IN) on Day 24 for a total dose 
of 5.39 × 108 CCU per animal. 
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Observations 
 Animals were observed for general health daily prior to challenge. From four days 
prior to challenge (D18) through study termination (Day 43), all pigs were observed daily for 
clinical signs of MHR infection including respiratory distress, coughing, and lameness as 
described in Table 4.1. A pig was considered lame if it received a lameness score of ≥ 1 on 
any two (or more) consecutive days. 
Table 4.1. Clinical observation scoring description. 
Score Respiration Cough Lameness 
0 Normal—no 
respiratory discomfort 
Normal—no cough Normal—no visible lameness at a 
walk 
1 Mild—mild increase in 
respiratory rate 
Mild—slight cough that 
does not seem to disturb 
normal activities 
Mild—difficult to observe lameness 
as the animal walks around the pen, 
not constantly lame when walking, 
walks at a normal speed, is weight 
bearing while walking and standing; 
lameness is indicated by intermittent 
reduced weight bearing on one limb 
or shortening of the stride. 
2 Moderate—notable 
increase in respiratory 
rate 
Moderate—loud, 
pronounced cough that 
disrupts normal 
activities 
Moderate—constant and observed 
throughout every step at a walking 
pace, bearing some weight on the leg 
at a walk and standing, but short-
striding one or more legs while 
walking, walks at a normal speed. 
3 Severe—thumping Severe—dry, hacking 
cough that appears 
painful 
Moderately Severe—puts no weight 
on the leg the first few steps after 
standing, constant, obvious lameness 
while at a walking pace, putting very 
little weight on the leg at a walk or 
while standing; lameness requires 
the pig to slow its speed of walking. 
4 N/A N/A Severe—will stand, may require 
assistance, for at least 3 minutes, 
non-weight bearing on one or more 
legs at walk or standing, still able to 
three-legged walk. 
5 N/A N/A Recumbent—will not stand even 
with assistance. 
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Sample collection 
 Nasal swabs (eSwab™, Copan; Murrieta, CA) were collected on Day -6 (prior to 
antibiotic treatment and vaccination) and were tested for MHR by real-time PCR as 
previously described (see Chapter 2, pg. 25). Blood was collected on Day -1 (prior to 
vaccination) for MHP and PRRSV ELISA. Weights were collected on Day -1 (one day prior 
to vaccination), Day 21 (one day prior to challenge), and Day 42 (one day prior to necropsy). 
On Day 43, all pigs were anesthetized and euthanized via electrocution. A gross pathological 
evaluation was then performed. The carpi, tarsi, elbows and stifles from all animals were 
opened and examined for indications of mycoplasma-associated arthritis (e.g. excess or 
abnormal synovial fluid, abnormal synovial membranes, abnormal articular surfaces). A 
single, common swab (eSwab™, Copan; Murrieta, CA) was used to sample all articular and 
synovial surfaces of the carpi and tarsi for each pig. This procedure was repeated using a new 
swab for the four elbow and stifle joints for each pig. 
 The thoracic and abdominal cavities were examined for polyserositis (pleuritis, 
pericarditis, and peritonitis). Pericarditis was further scored on the following scale:  No 
pericarditis (0)—smooth pericardial and epicardial membranes; Mild (1)—subtle 
roughening of the epicardium and noticeable thickening of the pericardial membrane, no 
adhesions present; Moderate (2)—obvious exudate and/or fluid in the pericardial sac and 
thickening of the epicardium and pericardium, adhesions present; Severe (3)—obliteration of 
the pericardial space due to exudates. After scoring, a swab (eSwab™, Copan; Murrieta, CA) 
of the pericardial surface (visceral) was collected from all pigs. Joint swabs and pericardial 
swabs were tested by MHR-specific real-time PCR. 
81 
 
Statistical analysis 
 All analyses were conducted by a BIVI statistician using SAS version 9.4 (SAS 
Institute Inc.; Cary, North Carolina). Analysis of abnormal respirations and coughing (ever 
present), lameness (two or more consecutive days post-challenge) and pericarditis 
(presence/absence) are reported (see Appendix C Table S24, S25, and S26, respectively). For 
each analysis, the preventive fraction (PF) and 95% confidence interval (CI) versus CTRL 
were estimated for each vaccine group. The GLIMMIX procedure of SAS was utilized to 
obtain parameter and variance/covariance estimates for the proportion affected for each 
treatment group. The model included the fixed effect of treatment group and random effect of 
pen. The analysis utilized a binomial distribution and logit link function. CI’s were calculated 
using the delta method via the IML procedure of SAS. Weight measurements during the 
vaccination phase and challenge phase were analyzed separately. For the challenge phase, a 
repeated measures mixed model was utilized for the analysis of body weights using the 
MIXED procedure of SAS. The model included the fixed effect of treatment, day, and 
treatment by day interaction. Pen and litter within pen were included as random effects. An 
unstructured covariance structure was utilized. Least squares means (LSM) by treatment and 
day (see Appendix C Table 27) and the average daily gain (ADG) by treatment (see 
Appendix C Table 28), along with 95% CI’s, are reported. Comparisons to the CTRL group 
are reported within day using alpha=0.05. Comparisons to the CTRL group for ADG are also 
reported using alpha=0.05. For the vaccination phase, data were analyzed using the MIXED 
procedure in SAS and the model included the fixed effect of treatment litter as a random 
effect. LSM by treatment, along with 95% CI’s, are reported. Comparisons to the CTRL 
group are reported using alpha=0.05. 
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Results 
Animals 
 Of the 120 pigs enrolled in this study, 110 of 112 animals in the vaccine/placebo 
groups and seven of eight NTX animals survived to the challenge phase of the study. One pig 
each in the NTX and LOW group were euthanized for humane reasons due to systemic 
bacterial infection (non-mycoplasma). A second pig in the LOW group died following 
complications with blood collection on Day 21. 
 Of the 117 pigs which survived to the challenge phase, three did not complete the 
study. Immediately following IV challenge on Day 23, a pig in the MED vaccine group 
exhibited anaphylaxis. Despite administration of epinephrine, the pig died shortly thereafter. 
A single pig in the placebo CTRL group was found dead eleven days post-challenge (Day 
33). This pig had been observed with diarrhea on Days 31, 32, and 33. Upon necropsy, the 
elbow and stifle joints were noted with excessive fluid; focal areas of pleuritis, severe 
peritonitis and moderate pericarditis were observed. Diagnostic samples (including fresh and 
fixed colon, intestine, lung, and heart as well as a pericardial swab) were collected and sent 
to Iowa State University Veterinary Diagnostic Laboratory (ISU-VDL) for further testing. A 
diagnosis of fibrinopurulent polyserositis was given with MHR as the causative agent. A pig 
in the HIGH vaccine group was found dead on Day 42. Upon necropsy, this pig exhibited 
pleuritis, peritonitis and severe pericarditis, as well as multiple joints with excess synovial 
fluid. Swabs from carpal, tarsal and stifle joints as well as a pericardial swab were collected 
and sent to ISU-VDL for further testing. Samples were positive for MHR and negative for 
Haemophilus parasuis by PCR. Death was attributed to virulent MHR challenge. 
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Clinical observations 
 Lameness was observed in a total of 30 animals. As seen in Figure 4.1, over half of 
the pigs were affected in the CTRL group with greater than 50% reductions in all vaccine 
groups. The HIGH and MED vaccine groups showed a significant reduction in lameness 
compared to the CTRL group with PF’s of 0.64 (95% CI [0.10, 0.86]) and 0.76 (95% CI 
[0.26, 0.92]), respectively. The LOW group had a PF of 0.59 (95% CI [-0.01, 0.84]); 
however, with a lower CI < 0, this result was not significant. Lameness was noted as early as 
Day 24 and continued through study termination on Day 43. Two pigs in the CTRL group 
showed signs of lameness prior to challenge and were excluded from all analyses. As shown 
in Figure 4.2, the average duration of lameness for the CTRL group was 5.5 days while the 
HIGH, MED and LOW vaccine groups averaged 1.6, 1.0, and 2.7 days of lameness, 
respectively. Duration of lameness was considered a secondary measurement and therefore 
pairwise comparisons between groups were not performed. 
 Abnormal respirations were noted in twelve animals with at least one animal in each 
challenged group affected. These observations occurred as early as three days post-challenge 
(Day 25) and continued intermittently through to necropsy on Day 43. Only one pig (MED 
group) exhibited coughing post-challenge, and on only one day (Day 34). Abnormal 
respirations and coughing were combined for analysis and are shown in Figure 4.1. There 
were no significant differences between any vaccine group and the placebo CTRL group for 
abnormal respirations and coughing. 
 None of the NTX pigs exhibited any clinical signs in the post-challenge observation 
period. 
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Fig.4.1. Clinical observations post-challenge. Observations of abnormal respirations and 
coughing were combined. A pig was deemed lame if it received a score of ≥ 1 on two or 
more consecutive days. CTRL = placebo control, HIGH = high dose vaccine, MED = 
medium dose vaccine, LOW = low dose vaccine; NTX group showed no clinical signs and 
are not represented. Data represents the least squares means for the proportion positive ± 
standard error. Significant reductions for lameness: *PF = 0.64 (95% CI [0.10, 0.86]), **PF 
= 0.76 (95% CI [0.26, 0.92]). 
 
 
 
Fig. 4.2. Duration of lameness. Average number of post-challenge days with lameness score 
≥ 1. CTRL = placebo control, HIGH = high dose vaccine, MED = medium dose vaccine, 
LOW = low dose vaccine; NTX group did not exhibit lameness and are not represented. Data 
represents the mean number of days with abnormal lameness score ± standard deviation. 
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Gross pathology 
 Pericarditis was observed in all challenged groups as shown in Figure 4.3. The CTRL 
group was most severely affected with all but one animal having pericarditis. All of the three 
vaccine groups showed a significant reduction of pericarditis with PF’s of 0.52 (95% CI 
[0.26, 0.69]), 0.58 (95% CI [0.31, 0.74]), and 0.32 (95% CI [0.07, 0.50]) for the HIGH, 
MED, and LOW dose groups, respectively. Of all the animals with pericarditis, only one 
animal was noted with “mild” lesions while all remaining pigs fell into the “moderate” or 
“severe” categories. 
 
Fig. 4.3. Pericarditis. Pigs were observed for pericarditis at necropsy. CTRL = placebo 
control, HIGH = high dose vaccine, MED = medium dose vaccine, LOW = low dose 
vaccine; NTX group did not exhibit pericarditis at necropsy and are not represented. Data 
represents the least squares means for the proportion positive ± standard error. Significant 
reductions: *PF = 0.52 (95% CI [0.26, 0.69]), **PF = 0.58 (95% CI [0.31, 0.74]), ***PF = 
0.32 (95% CI [0.07, 0.50]). 
 
 Pleuritis was present in 42% of the CTRL pigs and 7%, 30%, and 35% of the HIGH, 
MED and LOW dose vaccine group pigs, respectively. Peritonitis was observed in 54% of 
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pigs, respectively. The carpi, tarsi, elbows and stifles were examined for signs of arthritis. A 
pig was considered positive for arthritis if any joint was positive for arthritis. For the CTRL 
group, 96% of the pigs were affected; whereas for the HIGH, MED, and LOW dose vaccine 
groups, 21%, 19%, and 23% of the pigs were affected, respectively. 
 Pleuritis, peritonitis, and arthritis were considered secondary parameters and therefore 
pairwise comparisons between groups were not performed. 
 None of the NTX pigs exhibited polyserositis or arthritis. 
Body weight 
 Figure 4.4A shows the average body weights for all challenged groups just prior to 
vaccination, just prior to challenge and just prior to necropsy. No significant differences were 
noted between vaccinates and placebo animals on Day -1 or Day 21. Following challenge, 
the HIGH, MED and LOW vaccine groups weighed an average of 7.83 lbs., 6.50 lbs., and 
3.94 lbs. more than the CTRL group, respectively, on Day 42. The mean weights for HIGH, 
MED (p < 0.0001, each) and LOW (p = 0.027) vaccine groups were significantly greater than 
the placebo CTRL group at Day 42. NTX animals were not included in this analysis; 
however, measurements were collected and the mean weights and standard deviations were 
calculated to be 4.95 ± 0.50 lbs., 15.30 ± 2.97 lbs., and 42.21 ± 6.90 lbs. on Day -1, 21 and 
42, respectively. 
 The average daily gain (ADG) was calculated during the challenge phase (Day 21 to 
42) and is shown in Figure 4.4B. Similar to the Day 42 mean weight comparison, ADG’s for 
the HIGH, MED (p < 0.0001, each) and LOW (p = 0.0012) vaccine groups were significantly 
higher than the placebo CTRL group. 
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Fig. 4.4. Analysis of body weight. A. Mean weight one day prior to vaccination (Day -1), 
one day prior to challenge (Day 21), and one day prior to necropsy (Day 42). Data represents 
the least squares mean ± standard error. B. Average daily gain (ADG) for the challenge phase 
(Day 21 to 42). Data represents lbs/day ± standard error. CTRL—placebo control, HIGH—
high dose vaccine, MED—medium dose vaccine, LOW—low dose vaccine; NTX group not 
included in analysis.* p<0.0001, **p=0.027, ***p=0.001. 
PCR 
 Pericardial and joint swabs were evaluated by MHR PCR. The CTRL group had the 
highest number of positive pericardial samples with 42% of the swabs testing positive for 
MHR. The number of positive pericardial swabs was fewer in the vaccine groups with 4% in 
the HIGH group and 15% in both the MED and LOW groups. 
 A pig was considered PCR positive for joint swabs if at least one of the two joint 
swabs collected was positive for MHR. The CTRL group had the highest number of positive 
pigs with 81% having one or more positive joint swabs. There were fewer numbers of 
positive animals in the vaccine groups with 29% of HIGH, 22% of MED, and 31% of LOW 
group pigs positive for one or more joint swab. PCR was considered supportive data and 
therefore pairwise comparisons between groups were not performed. 
 All pericardial and joint swabs from the NTX group were PCR negative for MHR. 
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Discussion 
 The objective of this study was to evaluate three different doses of BIVI’s inactivated 
MHR vaccine for efficacy against virulent challenge in CDCD piglets at three weeks of age. 
All non-challenged NTX pigs remained free from clinical signs of MHR infection and all 
samples from this group were negative for MHR by PCR thus confirming biosecurity and a 
lack of exposure to environmental MHR. All but one pig in the placebo CTRL group had 
pericarditis and over half of the pigs in this group were lame, indicating an effective MHR 
challenge.   
 The HIGH, MED and LOW doses of the vaccine all showed significant reductions of 
pericarditis compared to the CTRL group. For lameness, only the HIGH and MED doses of 
vaccine had positive PF values with lower CI’s > 0, showing significant reductions compared 
to the CTRL group. When looking at the results for clinical observations (Fig. 4.1) and 
pericarditis (Fig. 4.3), a titration effect of the vaccine is apparent. In some instances such as 
lameness and pericarditis, the MED dose vaccine slightly out-performed the HIGH dose 
vaccine; whereas, in the case of weight gain, the reverse is true. In all instances, the HIGH 
and MED doses of vaccine performed better than the LOW dose vaccine. Still, the LOW 
dose vaccine was efficacious and did provide a significant reduction of pericarditis and 
significant increase in weight gain. 
 Manifestations of respiratory symptoms were minimal (Fig. 4.1.) despite the fact that 
IN inoculation was included as part of the challenge protocol. Previous reports indicate that 
MHR can be frequently isolated from pneumonic lungs (5, 11, 12); however, our respiratory 
findings are in agreement with the clinical signs and lesions described by Rovira et al (2010). 
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It should be noted we have since refined our challenge model to omit the third day IN 
challenge (see Chapter 2). 
 The incidence of polyserositis was higher in this study than observed in our previous 
experiments (see Chapter 2 and 3). The severity and frequency of pericarditis (25 of 26 
CTRL pigs affected) supports a highly virulent challenge. It is possible that the age of the 
animals played a role in this observed increase. A large portion of our previous challenge 
model work was evaluated in seven-week old pigs; whereas, in this study pigs were six-
weeks of age at challenge. We have already demonstrated susceptibility to MHR-associated 
pericarditis is greatly reduced after seven weeks of age (see Chapter 3). Perhaps pigs younger 
than seven-weeks of age are even more at risk. 
 The MHR PCR results are similar to past findings (see Chapter 2 and 3) where a 
lower number of MHR PCR positive results are obtained from pericardial swabs than joint 
swabs. We attribute this phenomenon to the progression of disease for MHR.  Although the 
pathogenesis of MHR is as yet poorly defined, our results suggest that systemic infection 
initially and drastically affects the heart. The bacteria then disseminate to the rest of the body 
(liver, brain, kidneys, etc.) including a prolonged and chronic infection of the joints. Our 
post-challenge phase is three weeks in length to allow for sufficient time for lameness to 
manifest, and we propose that MHR is in the process of being cleared from the pericardial 
cavity by the time of necropsy. Direct pairwise comparisons of the number of MHR PCR 
positive samples were not performed, but vaccinated animals did show reductions of MHR 
PCR positive samples compared to the placebo group for both pericardial swabs (vaccinates 
≤ 15 %, CTRL = 42%) and joint swabs (vaccinates ≤ 31 %, CTRL = 81 %). It may be 
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possible that our vaccine reduces the numbers of MHR which reach the target tissues; 
however, our PCR is qualitative and total bacterial load was not measured. Quantitative 
assays have since been developed (2) and may be utilized in future studies to evaluate such 
parameters. 
 To conclude, this study has proven our inactivated Mycoplasma hyorhinis vaccine 
administered to three-week old CDCD piglets to be efficacious. We demonstrated a 
minimum immunizing dose of MHR (7.41 × 107 CCU per 2.0 mL dose) provided significant 
reductions of both lameness and pericarditis and a significant increase in weight gain 
compared to non-vaccinated pigs. 
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Abstract 
Background 
 Mycoplasma hyorhinis (MHR) is a pathogen of swine causing polyserositis and arthritis. 
It is also a common contaminant of tissue culture in the laboratory setting. We sought to exploit 
the later by evaluating protein expression of a single isolate of MHR cultured in two ex vivo 
systems and comparing to a standard broth culture. 
Results 
 Of the 658 predicted proteins in the MHR reference proteome HUB-1, 291 were 
identified in this study. The average protein coverage was 30% with a false discovery rate of ≤ 
1.3%. We confirmed the existence of 35 hypothetical proteins and identified several putative 
membrane-associated and transporter proteins which were up-regulated in the two ex vivo 
cultures compared to broth culture of the same isolate. 
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Conclusion 
 Our results demonstrate differential expression of particular MHR proteins in two ex vivo 
systems. Proteins up-regulated in tissue culture may provide insight into the mechanisms 
necessary for in vivo infection and are potential candidates for vaccine targets. 
Background  
 Mycoplasma hyorhinis (MHR) is a pathogen of swine causing polyserositis, lameness and 
arthritis in young pigs (1-3). As no commercial vaccines are currently available, treatment 
consists of antibiotic therapy. The pathogenesis and virulence factors of MHR are not well 
understood, making it difficult to identify potential vaccine targets. We have defined an in vivo 
model to establish virulence of MHR isolates (see Chapter 2), thus allowing for evaluation of 
vaccine candidates.  
 MHR is a common contaminant of tissue culture and some strains can be adapted to 
growth on certain cell lineages (4-9). In this study we sought to evaluate the proteome of two ex 
vivo cultures of a single isolate of MHR for differential expression as compared to standard broth 
culture. Madin-Darby canine kidney (MDCK) adherent epithelial cells and McCoy mouse 
fibroblast cells in suspension (non-adherent) were utilized for the tissue culture systems. A 
modified Friis media (10) was used for the broth culture. One dimensional liquid 
chromatography nanospray ionization tandem mass spectrometry (1D-LC NSI MS/MS) was 
utilized to evaluate the cultures in a manner similar to a previous study performed with 
Mycoplasma hyopneumoniae (11). The genome of M. hyorhinis HUB-1 was sequenced by Liu et 
al in 2010 (12), has 658 protein-encoding genes, and was used as a reference for our cultures. 
Results from this study will help to further our understanding of the mechanisms MHR employ 
to cause infection in biological systems. 
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Results 
Identified proteins 
 Protein coverage averaged 23.4%, with 29.3 mass spectrum matches and 6.5 unique 
peptide sequences per protein. False discovery rates ranged from 1% to 1.3% across all samples. 
Overall, 291 of 658 known and predicted MHR HUB-1 proteins were identified, representing 
44% of the proteome. Tables S34, S35, and S36 contain the proteins identified in each culture 
type, along with coverage calculations and the number of unique spectra and peptides for each 
protein. Thirty-five proteins designated as hypothetical were identified in this analysis, 
confirming their existence. The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE 
partner repository (13) with the data set identifier PXD004533 and 10.6019/PXD004533. 
Included in the submission are detailed peptide identifications from this study using the filter 
criteria presented in the methods section. 
 Isolating MHR from host cells and obtaining proteome coverage comparable to broth 
grown cells presented a challenge due to host cell contamination. Similar proteome coverage is 
essential in performing a valid differential expression analysis. Table 5.1 shows the number of 
MHR proteins identified in the broth, MDCK, and McCoy cultures, along with the average 
coverage, unique spectra, and unique peptides per protein. Histograms (Figure 5.1) were 
generated to further illustrate the consistency of the proteomics for the three culture types. These 
histograms largely overlap, indicating that a similar depth of proteome coverage was achieved 
for each. 
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Table 5.1. Protein identification metrics. Total number of proteins. Averages for protein 
coverage, number of unique spectra, and number of unique peptides. 
Culture Type 
Number of 
Proteins 
Average  
% Coverage 
Average Number 
of Unique Spectra 
Average Number 
of Unique 
Peptides 
Broth 234 23.2 32.5 6.6 
MDCK 252 23.8 34.9 6.6 
McCoy 201 23.2 20.4 6.3 
Combined 229 23.4 29.3 6.5 
 
 
Figure 5.1. Histograms of protein coverage. Broth = modified Friis media; MDCK = Madin-
Darby canine kidney adherent epithelial cells; McCoy = mouse fibroblast cells in suspension 
(non-adherent). 
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Differential expression 
 Comparisons of the identified proteins were made between broth vs. MDCK cultures, 
broth vs. McCoy cultures, and MDCK vs. McCoy cultures. For the broth vs. McCoy comparison, 
99 proteins showed a significant difference (p < 0.05) in expression. For the broth vs. MDCK 
comparison, 76 proteins showed a significant difference (p < 0.05) in expression. The 
comparison for MDCK vs. McCoy identified 76 proteins with a significant difference (p < 0.05) 
in expression levels. 
 Figure 5.2 is a Venn diagram which illustrates the overlap of the proteins identified as 
significant (p < 0.05) for differential expression in each of the three comparisons. Appendix D: 
Table S29 lists the 34 proteins uniquely identified to the broth vs. McCoy cell comparison. Of 
these proteins, eight were up-regulated and 26 were down-regulated in McCoy cultures. All up-
regulated proteins showed a ≥ 2.7 fold increase, with six of the eight proteins at a ≥ 5.7 fold 
increase in expression (note that all fold changes are expressed as log2). The 26 down-regulated 
proteins varied from a 1.2 to 10.5 fold decrease in expression in McCoy cells, with sixteen 
proteins showing a ≥ 6.4 fold decrease in expression. 
 Appendix D: Table S30 lists the 20 proteins uniquely identified to the broth vs. MDCK 
comparison. Of these proteins, 16 were up-regulated and four down-regulated in MDCK 
cultures. The up-regulated proteins ranged from a 0.8 to 9.9 fold increase, with six proteins 
showing a ≥ 8.5 fold increase. The down-regulated proteins ranged from a 0.9 to 9.9 fold 
decrease in expression in MDCK cells. 
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Figure 5.2. Venn diagram for intersection of comparisons for differential expression. Broth 
= modified Friis media; MDCK = Madin-Darby canine kidney adherent epithelial cells; McCoy 
= mouse fibroblast cells in suspension (non-adherent). Comparisons were made using the first 
term as the control and the second term as the experimental treatment with the numbers 
representing the number of proteins significant (p < 0.05) for differential expression (over or 
under) in the treatment group. 
  
 Appendix D: Table S31 lists the 22 proteins uniquely identified to the MDCK cell vs. 
McCoy cell comparison. Only two of these proteins were up-regulated, showing a 2.5 and a 7.4 
fold increase in expression in McCoy cells. The 20 down-regulated proteins ranged from a 0.6 to 
9.2 fold decrease in McCoy cells, with 5 proteins showing a ≥ 5.6 fold decrease in expression. 
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 The center of the Venn diagram (Fig. 5.2) lists nine proteins common to all three 
comparisons (see Appendix D: Table S32). Twenty-nine proteins were identified in the overlap 
of the comparisons of broth culture to each of the ex vivo systems and all showed identical 
direction of expression (over/under) in both MDCK and McCoy cell cultures as listed in 
Appendix D: Table S33. Six of the 29 proteins were up-regulated in both cell types with similar 
levels of expression, ranging from a 2.1 to an 8.5 fold increase in McCoy cells and a 1.8 to a 9.2 
fold increase in MDCK cells. The 23 down-regulated proteins also showed similar levels of 
expression, ranging from a 1.3 to 10.4 fold decrease in McCoy cultures; whereas, under 
expression in MDCK cells ranged from a 0.8 to 10.8 fold decrease. 
Discussion 
 Our hypothesis was that ex vivo cultures more closely resemble in vivo infection by MHR 
and that potential vaccine targets could be identified in this study for further evaluation in the 
host animal. As such, most of our interests lie in the up-regulated proteins from the ex vivo 
cultures. However, the down-regulated proteins also help to expand the understanding of MHR 
biology. 
 As shown in Figure 5.1 and Table 5.1, proteome coverage was similar for each culture 
type. One of the challenges with multiple species proteomics is contamination leading to 
decreased proteome coverage of one or more species involved. Based on quality and consistency 
of the proteomics across all three culture types, the isolation of MHR from MDCK and McCoy 
cells was very effective. Broth and MDCK cultures were similar in all aspects listed in Table 5.1 
(number of proteins, protein coverage, unique spectra and peptide). McCoy cultures resulted in a 
40 % reduction in the average number of spectra per protein, 17 % fewer proteins, but only a 5 % 
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reduction in peptides per protein and no difference in protein coverage. The reduction in number 
of spectra per protein likely results from competition with non-MHR proteins for mass 
spectrometry analysis time. It could also be that fewer MHR proteins are expressed when McCoy 
cells are used as a host. Figure 5.3 is a heat map of differentially expressed proteins only. 
Hierarchical clustering of replicates indicates good reproducibility within each culture type. 
 Among the up-regulated proteins in the comparisons are several predicted transporter and 
membrane-associated proteins. These proteins would likely be surface exposed with antigenic 
regions accessible by host antibodies making them viable candidates for vaccine evaluations.  
 For the broth vs. McCoy comparison (Appendix D: Table S29), an ABC transporter 
permease (gene MHR_0064), a hypothetical protein (gene MHR_0453) with predicted hydrolase 
activity, and a hypothetical protein (gene MHR_0655) with predicted transmembrane regions 
(14) all showed ≥ 8.4 log increase in expression. The cargo for the 74 kDa transporter permease 
is unknown, as is the substrate for the 33 kDa predicted hydrolase. The P59-like protein encoded 
by gene MHR_0073 showed a 5.7 fold increase in expression in McCoy cell cultures. This 57 
kDa protein contains two ABC transporter domains (14); however, this transport function is 
currently hypothetical and the potential cargo unknown. There were five hypothetical proteins 
down-regulated in McCoy cell cultures:  three with predicted transmembrane regions (genes 
MHR_0628, MHR_0285, and MHR_0630), one (gene MHR_0293) with putative hydrolase 
activity, and the last (gene MHR_0508) a probable transcriptional regulator (14). All five of 
these proteins were down-regulated from 2.0 to 9.2 fold. The probable transcriptional regulator is 
predicted to have a cytoplasmic locale (14). Transcriptional regulation in MHR has not been 
thoroughly evaluated (15). It is unclear whether this probable regulator induces or represses 
transcription, but given that the proteins encoded by dnaX (MHR_0101) were up-regulated 7.8  
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Figure 5.3. Heat map for distribution of proteins among the culture types which were significant 
(p<0.05) for differential expression.  Red indicates up-regulated and blue indicates down-regulated. 
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fold, DNA syntheses was likely occurring, offering numerous potential binding sites. If it is a 
repressor, it’s reduced expression would lead to up-regulation of the target gene and could point 
to regulation of any one of the eight up-regulated proteins, including DNA polymerase III. 
Regardless, the signal to turn this putative regulator on or off is unknown. The Trka-C domain 
protein encoded by trkA (MHR_0649), a predicted transmembrane transporter for potassium ions 
(14), and the oligopeptide transport permease encoded by oppF (MHR_0359) were each down-
regulated in McCoy cultures 8.3 fold and 8.9 fold, respectively. It is difficult to interpret the 
reduced need for these two transporters in the McCoy cultures as this may simply be due to the 
levels of potassium and availability of amino acids in the culture medium. Lastly, the lipoprotein 
encoded by MHR_0357 was down-regulated 10.5 fold. Such a large drop in expression in 
McCoy cell cultures may indicate that this lipoprotein does not play a vital role in the infection 
process, possibly acting as a decoy antigen in the host as has been shown for some of the 
variable lipoproteins (Vlp’s) for MHR (16). 
 The broth vs. MDCK comparison (Appendix D: Table S30) identified a glycerol-3-
phosphate dehydrogenase encoded by gpsA (MHR_0350), which was up-regulated 9.9 fold in 
MDCK cultures. This enzyme plays a major role in carbohydrate metabolism and lipid 
biosynthesis (17, 18) and has been shown to be associated with the inner cytoplasmic membrane 
for E. coli (18). The protein encoded by gene MHR_0074 is a putative amino acid or sugar ABC 
transporter with several predicted transmembrane regions (14). This 66 kDa permease had a 9.1 
fold increase in expression in MDCK cultures. A LemA-family protein (gene MHR_0589) and 
oligoendopeptidase F (gene MHR_0363, pepF) were also up-regulated, 2.9 and 2.6 fold, 
respectively. The LemA protein has predicted transmembrane regions with homology to a two-
component regulatory system in a single protein (14, 19). Hrabak and Willis (1992) 
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demonstrated the requirement of this protein for Pseudomaonas syringae pv. syringae to cause 
disease in bean plants. The function of LemA in MHR has not been evaluated. 
Oligoendopeptidase F is a metalloendopeptidase requiring metal ions for the hydrolysis of 
peptide bonds (20). An ortholog of this protease has been identified in M. hyopneumoniae and 
has been found to cleave bradykinin which may assist with survival in the host (21). The role of 
this protein has not been investigated in MHR. The down-regulated proteins in the MDCK 
cultures include a 96 kDa lipoprotein (gene MHR_0659) and a xylose ABC transporter permease 
(xylH) which were down-regulated 2.7 and 9.9 fold, respectively. 
 There were only two up-regulated proteins identified in the MDCK vs. McCoy 
comparison (Appendix D: Table S31). One of these was a ribosomal protein. The other was an 
oligopeptide transport permease encoded by oppC and up-regulated 2.5 fold in McCoy cultures 
compared to MDCK cultures. This ABC transporter has several predicted transmembrane 
regions (14). Conversely, the oligopeptide transporter encoded by oppD showed a 2.1 fold 
decrease in McCoy cultures compared to MDCK cultures. Several transmembrane proteins and 
transporters, as well as one hypothetical protein with predicted transmembrane regions, were also 
down-regulated in McCoy cell cultures compared to MDCK cell cultures. It is unknown why 
these proteins might be unnecessary, or less necessary, in McCoy cultures as compared to 
MDCK cultures. While both represent mammalian cells, differences between the tissue culturing 
protocols may be possible explanations. The growth medium was modified essential media 
(MEM) for the MDCK cells and Dulbecco’s modified essential media (DMEM) for the McCoy 
cells. Both were supplemented with fetal bovine sera. Although all of the components of MEM 
are present, DMEM is enriched with additional amino acids (including asparagine, aspartic acid, 
glutamic acid, proline and serine), vitamins, and inorganic salts (www.sigmaaldrich.com). It is 
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also likely that the difference between anchored cells versus those in suspension require 
distinctive means for infection by the mycoplasmas. Cell type (epithelial vs. fibroblast) and 
species host (canine vs. murine) may also influence outcomes. 
 There were 29 proteins which overlapped the two broth vs. ex vivo comparisons 
(Appendix D: Table S33). These proteins showed identical direction of regulation (up/down) in 
both MDCK and McCoy cultures. Six of these proteins were up-regulated in both ex vivo 
cultures, with arginyl-tRNA synthetase showing the greatest fold increase in both cell types 
compared to broth. Although MHR does not utilize arginine for an energy source, the increased 
expression for this particular tRNA ligase would indicate a greater need by MHR for arginine in 
ex vivo systems. Adenine phosphoribosyltransferase (apt) was similarly up-regulated in both 
systems at a 2.8 to 3.3 fold increase. This enzyme plays a role in the salvage pathway, important 
in bacteria such as MHR which lack de novo synthesis pathways for nucleic acid precursors. An 
uncharacterized lipoprotein of 88 kDa (gene MHR-0061) showed similar over expression in 
MDCK cultures (2.0 fold increase) and McCoy cultures (2.6 fold increase). The function of this 
lipoprotein is not yet defined. Contrary to the enzyme identified in the broth vs. MDCK 
comparison, a second oligoendopeptidase F (gene MHR_0356, pepF) was identified as being 
slightly down-regulated (1.3 to 1.8 fold) in both tissue culture systems. Additionally, a zinc 
metalloproteinase C (gene MHR_0553) was down-regulated in both systems but to a greater 
extent (8.6 to 8.9 fold) than the second pepF protein. The DnaK heat-shock chaperone protein 
was mildly down-regulated in both cell cultures (1.7 to 2.4 fold). Seven hypothetical proteins 
were also down-regulated in both ex vivo cultures, varying from 3.3 fold to 10.8 fold under 
expression. Lastly, the outer membrane protein P95 (gene MHR_0440) was down-regulated 8.5 
fold in MDCK cultures and 8.1 fold in McCoy cultures. This protein has been identified as an 
 104 
 
ortholog to the M. hyopneumoniae P97-like adhesin (22). The M. hyopneumoniae P97 protein 
has been shown to bind to ciliated epithelial cells (23). As a functional ortholog, it may be likely 
that P95 is not needed for attachment to the non-ciliated MDCK and McCoy cells. 
 Besides the proteins identified above, previous MHR research offers additional proteins 
of interest. The MHR lipoprotein P37 has been thoroughly investigated with implications in 
human carcinoma and cancer invasiveness (24-28). In our study, this high affinity transport 
system protein encoded by gene MHR_0625 was identified in the Broth vs. McCoy and MDCK 
vs. McCoy comparisons and falls into the 27-protein overlap in the Venn diagram (Fig. 1). The 
P37 protein was significantly (p < 0.05) down-regulated 2.8 fold in the broth vs. McCoy 
comparison and 2.7 fold in the MDCK vs. McCoy comparison. Given the plethora of research 
for P37, perhaps this protein has a tropism for cancer cells and simply was unnecessary for 
infection of murine fibroblasts. 
 Mycoplasma hyorhinis possess a set of variable lipoproteins (Vlp’s) which undergo 
antigenic variation, may be important for host evasion, and have been shown to vary in repertoire 
number by isolate (12, 16, 29-33). Our reference strain, HUB-1, possesses all seven known vlp 
genes in the order 5’-vlpD-vlpE-vlpF-*-IS-*-vlpG-vlpA-*-IS-*-vlpB-vlpC-3’ (12, 34) where ‘IS’ 
are insertion sequences and ‘*’ are genes for uncharacterized or hypothetical proteins (in 5’ to 3’ 
order: MHR_0340, MHR_0342, MHR_0345, and MHR_0347). The MHR isolate used in this 
study has not been fully characterized to determine which vlp genes are present. No Vlp’s were 
noted in our analyses, likely an artefact of our methodology. It is not possible to determine from 
our data whether Vlp expression changes in these two specific tissue culture systems. 
Transcriptional profiling may assist in identifying the presence or absence of mRNA in future 
studies.  
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Conclusions  
 To the best of our knowledge, this is the only differential proteomic analysis comparing 
in vitro and ex vivo cultures of Mycoplasma hyorhinis. Thirty-five hypothetical M. hyorhinis 
proteins have been confirmed. We identified several putative membrane-associated and 
transporter proteins which were up-regulated in two ex vivo cultures compared to a broth culture 
of the same isolate. These proteins provide candidates for further investigation in future in vitro 
and in vivo studies. 
Materials and Methods 
Sample preparation 
 The M. hyorhinis (MHR) isolate used in this study originated from the joint fluid of a 
clinically affected pig. Isolation occurred in a modified Friis media (10) supplemented with 10 % 
(v/v) porcine serum (Life Technologies, Grand Island, NY) and 5% (v/v) yeast extract (Life 
Technologies, Grand Island, NY). Purity was confirmed by aerobic and anaerobic culture on 
sheep blood agar and identity was confirmed by real-time PCR, amplifying the 16S rRNA gene. 
A low passage (pass 7) stock was titrated by color changing units (CCU) assay and had a 
resulting titer of 7.63 log10 CCU/mL. This stock was used to inoculate the broth and tissue 
cultures for LC-MS/MS analysis. 
 For broth cultures, six 50 mL conical tubes (BD Biosciences, Bedford, MA) each 
containing 28.0 mL of modified Friis media were inoculated with 2.0 mL per tube of MHR. Caps 
were sealed tightly and all six tubes were incubated at 37 °C while shaking at 100 rpm. Cultures 
were allowed to incubate for five days (~120 hours) to reach peak CCU at late log phase, as 
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indicated by pH shift (acidification) of the growth media. All six samples were harvested by 
freezing at < -60 °C without cryo-preservative. 
 Two sets of ex vivo cultures were produced, one composed of adherent monolayers of 
Madin-Darby canine kidney (MDCK) cells and one as a suspensions of McCoy cells (murine 
fibroblasts). For MDCK cultures, cells were inoculated in six 75 cm2 vented culture flasks (BD 
Biosciences, Bedford, MA) in minimum essential media (MEM; Life Technologies, Grand 
Island, NY) supplemented with 5 % FBS (fetal bovine serum; SAFC, Lenexa, KS). Flasks were 
incubated at 37 °C + 5 % CO2 to ≥ 98 % confluency. Prior to infection, media was removed and 
cells were rinsed with 0.1 M phosphate buffered saline (PBS; Life Technologies, Grand Island, 
NY). Mycoplasmas were then added at 2.0 mL per flask and allowed to incubate at 37 °C for at 
least two hours prior to adding 28.0 mL per flask of pre-warmed media consisting of MEM 
supplemented with 2 % FBS. Cultures were allowed to incubate as previous for five days (~120 
hours) to reach peak CCU, as indicated by ≥ 90 % cytopathic effect (CPE) of the cell 
monolayers. All six samples were harvested by freezing the flasks at ≤ -60 °C for two hours and 
thawing in a 37 °C incubator. Cell lysate from each flask was then transferred to individual 50 
mL conical tubes and frozen at ≤ -60 °C without cryo-preservative.  
 For McCoy cultures, cells were inoculated into six 125 mL disposable spinner flasks 
(Corning Inc. Life Sciences, Lowell, MA) in Dulbeco’s minimum essential media (DMEM; 
SAFC, Lenexa, KS) supplemented with 5 % FBS and 2.5 % HEPES (Life Technologies, Grand 
Island, NY) for a total volume of 28.0 mL per flask. Cells were allowed to incubate for three 
days at 37 °C while stirring at 100 rpm before inoculating each flask with 2.0 mL of MHR 
directly into the cell suspension. Cultures were allowed to incubate as previous for four days 
(~96 hours) to reach peak CCU, as indicated by a drop in McCoy cell viability to below 80 % as 
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measured by a Vi-CELL® cell analyser (Beckman Coulter, Jersey City, NJ), indicating the 
presence of CPE. For harvest, the contents of the six flasks were transferred to individual 50 mL 
conical tubes and frozen at ≤-60 °C without cryo-preservative. 
 Representative samples of each culture type were confirmed to be MHR by real-time 
PCR and by western blotting using MHR specific, anti-P70 monoclonal antibody purchased from 
Dr. Kim Wise, University of Missouri (35). Titers of each culture type at the time of freezing 
were 7.6 log10 CCU/mL, 6.8 log10 CCU/mL, and 8.5 log10 CCU/mL for the broth, MDCK and 
McCoy cultures, respectively. Protein concentrations were 6.11 mg/mL, 3.45 mg/mL, and 3.07 
mg/mL for broth, MDCK and McCoy cultures, respectively, as measured using Quant-IT protein 
assay kit and Qubit fluorometer (Life Technologies, Grand Island, NY). Representative samples 
of Mycoplasma-free control cultures were MHR PCR and P70 negative. 
 MHR culture preparations involved no vertebrates for this study and required no ethical 
committee approvals. The research was performed according to the guidelines and standards of 
Boehringer Ingelheim Vetmedica, Inc. (BIVI), the University of Arizona, and Iowa State 
University. 
Mass spectrometry 
 Infected MDCK and McCoy cultures were gently rinsed with PBS and centrifuged at 
3000 RCF, 4 ºC for 5 minutes. The supernatant was removed and an additional 5 ml of PBS was 
added. Cultures were vortexed vigorously to suspend free MHR cells and then centrifuged at 
3000 RCF, 4 ºC for 5 minutes. The supernatant containing suspended MHR cells was transferred 
to high speed centrifuge tubes and centrifuged at 20,000 RCF, 4 ºC for 1 hour. Pelleted cells 
were rinsed with PBS and centrifuged at high speed once again to re-pellet. The supernatant was 
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removed and pelleted MHR cells were resuspended in 500 μl hexafluoroisopropanol (HFIP) for 
cell lysis. Tubes were bath sonicated for 30 seconds and vortexed to completely resuspend and 
lyse the cells. The lysate was transferred to 2 ml screw top tubes for further processing.   
 Broth cultured MHR were centrifuged at 20,000 RCF, 4 ºC for 1 hour and the supernatant 
discarded. Cells were washed using 5 ml PBS, centrifuged again and the supernatant discarded. 
Pelleted cells were resuspended in 500 μl HFIP. Tubes were vortexed to completely resuspend 
and lyse the cells and the lysate was then transferred to 2 ml screw top tubes for further 
processing. 
 HFIP was subsequently removed using vacuum centrifugation. Dried cell lysate was 
rehydrated with the addition of 5 μl of 100 mM ammonium bicarbonate (ABC). Five μl of 100 
mM dithiothreitol in 100 mM ABC was added and samples were placed at 85 ºC for 5 minutes to 
reduce disulfide bonds. Once returned to room temperature, 5 μl of 100 mM iodoacetamide was 
added to alkylate the reduced disulfide bonds and samples were placed in the dark for 30 
minutes. Two μg proteomics grade trypsin (T6567, Sigma, St. Louis, MO) was added to each 
sample and the total volume was raised to 100 μl using 100 mM ABC. Samples were incubated 
at 37 ºC overnight. Following digestion, samples were desalted using a reverse phase peptide 
trap (TR1/25108/52, Michrom Bioresources, Auburn, CA) according to the manufacturer’s 
instructions. Purified peptides were dried using vacuum centrifugation, resuspended in 3 μl of 2 
% acetonitile (ACN), 0.1 % formic acid (FA) in water and transferred to HPLC vials for further 
analysis. 
 Separation of peptides was performed using a Dionex U3000 splitless nanoflow HPLC 
system operated at 333 nl minute using a gradient from 2 –50 % acetonitrile over 60 minutes, 
 109 
 
followed by a 15 minute wash with 95 % acetonitrile and a 15 minute equilibration with 2 % 
acetonitrile. The C18 column, an in-house prepared 75 μm × 15 cm reverse phase column packed 
with Halo 2.7 μm, 90 Å C18 material (MAC-MOD Analytical, Chadds Ford, PA) was located in 
the ion source just before a silica emitter. A potential of 2100 volts was applied using a liquid 
junction between the column and emitter. A Thermo LTQ Velos Pro mass spectrometer using a 
nanospray Flex ion source was used to analyze the eluate from the U3000. Scan parameters for 
the LTQ Velos Pro were one MS scan followed by 10 MS/MS scans of the 5 most intense peaks. 
MS/MS scans were performed in pairs, a CID fragmentation scan followed a HCD fragmentation 
scan of the same precursor m/z. Dynamic exclusion was enabled with a mass exclusion time of 3 
min and a repeat count of 1 within 30 sec of initial m/z measurement. Spectra were collected 
over the entirety of each 90 minute chromatography run. 
Identification of peptides 
 Raw mass spectra were converted to MGF format using MSConvert, part of the 
ProteoWizard software library (36), in preparation for spectrum-database matching. The mass 
spectra for each culture type were searched against the reference proteome of M. hyorhinis HUB-
1 (12) using X!tandem 2015.12.15.2 (37) and OMSSA 2.1.8 (38) algorithms. Because MDCK 
and McCoy cell line proteins are impossible to completely remove from isolated Mycoplasma 
cells using the techniques described above, NCBI reference protein sets for Canis familiaris and 
Mus musculus were also included in the analysis. A fasta database was constructed by 
concatenating the HUB-1, MDCK, and McCoy protein fasta files into a single file. A 
randomized version of this database was then concatenated to create a combined database which 
could be used to identify peptides and evaluate dataset quality simultaneously. X!tandem and 
OMSSA algorithms were employed via the University of Arizona High Performance Computing 
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Center to perform spectrum matching. Precursor and fragment mass tolerance were set to 0.3 
Daltons for both OMSSA and X!tandem. Trypsin cleavage rules were used for both algorithms 
with up to 2 missed cleavages. Amino acid modifications searched consisted of single and 
double oxidation of Methionine, oxidation of Proline, N-terminal acetylation, 
carbamidomethylation of Cysteine, deamidation of Asparagine and Glutamine and 
phosphorylation of Serine, Threonine, and Tyrosine. X!tandem xml and OMSSA xml results 
were filtered using the Perl programming language to remove any peptide matches with an E-
value > 0.05 as well as proteins identified by a single peptide sequence. To address the problem 
of contaminating host proteins, only peptides uniquely identifying each protein were retained for 
further analysis. This ensured neither Canis nor Mus peptides affect the calculated expression 
levels for HUB-1 proteins. 
Comparative protein analysis 
 Differential expression of proteins between broth cultured MHR and that grown in 
MDCK and McCoy cultures was evaluated using peptide elution profiles. Analyses were 
performed separately for broth vs. MDCK, broth vs. McCoy, and MDCK vs. McCoy 
comparisons. Precursor mass spectra were extracted from the raw data in MS1 format using the 
MSConvert GUI software from the ProteoWizard tool set (36). Peptide precursor m/z values 
were extracted from the previously compiled protein identifications using Perl. Elution profiles 
for peptide-spectrum matches were calculated by parsing each corresponding MS1 file and 
summing the ion current for that match's m/z value within a 0.3 Da tolerance, effectively 
integrating the elution profiles. Each trace started at the scan number of the peptide-spectrum 
match and preceded both forward and backward until the chromatogram noise level, or a 
distance of 250 scans, was reached. Multiple peptide-spectrum matches with the same precursor 
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m/z were only counted once, ensuring the same integral was not included multiple times. Once 
all peptide-spectrum matches were processed, intensities were summed for each protein on a per-
replicate basis. Proteins not identified in a replicate were represented with the average noise level 
of the replicate's chromatogram for further calculations. The reasoning behind this is two-fold: 1) 
peptides not identified in a replicate could be present at levels at or below the noise level of the 
chromatogram causing the mass spectrometer to ignore them, and 2) for calculating expression 
ratios between lines, zero cannot be in the denominator. Data were normalized using a mode 
based technique. First, the mode of the protein intensities for each replicate was calculated, 
representing the most commonly occurring protein intensity. Next, for each identified protein, 
the intensity per replicate was divided by the mode of the same replicate. This ensures that 
normalization is not affected by the minimum and maximum intensities, which can vary 
tremendously between replicates. A resampling analysis was performed for each protein by 
evaluating the difference in means of the replicates of both conditions. From this resampling 
analysis, a p-value was calculated indicating the significance of the difference in means. Two 
additional resampling analyses were performed for each protein, comparing both conditions to 
their own baselines. These baseline analyses provide a mechanism to further reduce false 
positives introduced by differences in chromatogram ion current as electron multiplier 
performance decreases. Proteins were considered to be differentially expressed if the difference 
in means between conditions resulted in a p-value ≤ 0.05 and the difference in means between 
one of the conditions and its baseline was ≤ 0.05. Results of the differential expression analysis 
were saved as a tab-delimited text file. 
 NCBI gene identifiers for M. hyorhinis HUB-1 were used to retrieve other database 
information using the “Retrieve/ID mapping” tool of UniProt (14). Associated information for 
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these proteins, including KEGG identifiers, GO terms, gene names, and cross-reference 
identifiers, were retrieved from various databases. A candidate list of proteins significant for 
differential expression as described above was prepared for each comparison. Proteins from each 
list were used to draw an intersecting Venn diagram using BioVenn (39) in order to identify 
proteins that were overlapping between comparisons. 
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CHAPTER 6. CONCLUSION 
 
General Discussion 
 A challenge model for Mycoplasma hyorhinis (MHR) was developed for use in 6-7 
week old caesarian-derived, colostrum-deprived (CDCD) pigs. The challenge material used 
in this model is derived from infected tissue culture. This is not the first mycoplasma model 
to utilize such material (1), nor is it the first MHR model to cause polyserositis and/or 
lameness (2-11). It is, however, the first model to use a) cell-associated MHR, b) in CDCD 
pigs, c) utilizing a consecutive-day administration, and d) resulting in severe and consistently 
reproducible outcomes of pericarditis, arthritis and lameness. The consecutive-day challenge 
administration was found to result in pericarditis and lameness in ≥ 50% of the challenged 
animals; whereas, administration by a single route (e.g. intraperitoneal, intravenous) on a 
single day resulted in only one of these outcomes within our observation period. Intravenous 
administration tended to result in a high incidence of polyserositis but low lameness. While 
intraperitoneal administration tended to result in more lameness but less polyserositis. A 
single intranasal application resulted in little-to-no disease. The consecutive three-day 
challenge model initially developed was refined to a two-day model, omitting the intranasal 
challenge while retaining similar disease outcomes. 
 The intranasal findings are a bit surprising. As MHR colonizes the upper respiratory 
tract, lateral and/or vertical transmission via the respiratory route was suspected (12-14). It is 
entirely possible that using our virulent, cell-associated material via the intranasal route may 
still cause disease; however, this administration may require more time for clinical signs to 
manifest. The 21-day post-challenge period in this model is both clinically efficient and 
economical with drastic clinical results. These are desired outcomes in models to be utilized 
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for vaccination-challenge studies as the length of these studies adds to increased overall costs 
for the investigator. 
 An experimental vaccine was developed for evaluation in the challenge model. This 
proprietary vaccine (Boehringer Ingelheim Vetmedica, Inc.) is a whole-cell bacterin 
consisting of MHR-infected murine fibroblasts and an oil-based adjuvant. Three doses of this 
vaccine (high, medium, and low) were evaluated for efficacy in three-week old CDCD 
piglets with primary parameters being pericarditis and lameness. Animals were vaccinated at 
three-weeks of age, challenged three weeks- post vaccination, and necropsied 21-days post 
challenge. All three vaccine doses provided for a significant reduction in pericarditis as 
compared to a placebo control group. The high and medium doses of vaccine also provided 
for significant reductions of lameness compared to the placebo control group. All vaccinated 
animals weighed significantly more than the placebo control group at the time of necropsy. 
Such a vaccine will provide benefit in reducing clinical signs of disease associated with 
MHR in the production setting and will further help to reduce antibiotic usage currently 
utilized for such. 
 An experiment was also conducted to evaluate the susceptibility to the challenge 
model in increasingly older animals. Groups of the same litters of CDCD pig were 
challenged with MHR at seven, ten, thirteen and sixteen weeks of age. Animals were 
necropsied 21-days post challenge. Animals showed an age-related decrease in outcomes of 
pericarditis, with nearly 90 % affected when challenged at seven weeks but slightly less than 
30 % affected when challenged at ten weeks of age. This declining trend continued, 
ultimately resulting in just 4 % of the animals with pericarditis when challenged at sixteen 
weeks of age. Lameness, however, was similar in the seven, ten, and thirteen week of age 
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challenged groups with 65-68 % of the animals affected. It was not until the challenge at 
sixteen weeks of age that lameness dropped, with only 33 % of the animals being affected. 
These results will help define the desired duration of immunity for experimental MHR 
vaccines. This should also aid in the diagnostic setting; whereas the likelihood of MHR 
contributing to polyserositis declines rapidly from seven weeks of age and would therefore 
be an unlikely, or at most, a rare cause of polyserositis in animals three months of age and 
older. 
 Lastly, we performed a proteomic analysis between two ex vivo cultures of MHR and 
a conventionally derived broth culture and confirmed differential expression in the tissue 
culture-associated samples. While our data cannot confirm that the expression noted ex vivo 
more closely resembles that of MHR in vivo expression, several membrane-associated 
proteins of interest were identified and will be candidates for future research for associations 
with virulence and/or potential vaccine evaluations. Some of the identified proteins are very 
likely the reason both our cell-associated challenge and vaccine culture have shown greater 
success than our broth culture counterparts (data not shown). 
 These studies culminate in the design and successful generation of a safe and 
efficacious vaccine which will aid in the reduction of MHR-associated polyserositis, arthritis 
and lameness in pigs. 
Recommendations for Future Research 
 To truly determine whether ex vivo cultures better approximate the proteome 
expressions of in vivo cultures of MHR, affected tissues from infected pigs need to be 
collected and analyzed in a manner similar to that described in Chapter 5. In fact, we have 
collected pericardial scrapings from MHR challenged and non-challenged animals for such 
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an experiment. Unfortunately, the sheer quantities of host protein present in the samples 
severely hindered peptide identification and the associated differential analysis (data not 
shown). Better sample collection methods or sample preparation techniques should be 
evaluated to achieve distinguishable MHR peptide sequences to allow for differential 
analysis to the ex vivo samples. Perhaps synovial fluid may be a “cleaner” sample with fewer 
host proteins to sort through. Further, accompanying transcriptomics (i.e. RNA-seq) would 
provide supportive data for confirmation of the quantity of mRNA present for translation in 
the samples. Haider and Pal have provided examples of combining the two approaches (15).  
 Similarly, as we have examined the effect an association with tissue culture has on 
the protein expression of MHR, one could conversely examine what effect the MHR is 
having on the genomic and/or proteomic expression in the tissue culture cells. Studies such 
as these may provide further insight into the mechanisms MHR employ to cause infection in 
a living cell. 
 The membrane proteins identified in our proteomic analysis provide a narrow list of 
candidates one could evaluate as subunit vaccines or in a vector-delivery system. These 
approaches have been evaluated for M. hyopneumoniae, although results were in either in 
non-target species or were met with varying results in the swine host (16-24). The “cocktail” 
approach suggested by Galli et al (17) may provide the best chance for positive results given 
the number and variability of MHR surface proteins. Regardless of approach, our research 
has provided for a model to evaluate them in and a whole-cell vaccine to use as a positive 
control to compare efficacy. 
 Alternatively, recent genetic advances may allow for evaluations of deletion mutants 
of MHR in the host animal utilizing the disease model described herein. Such evaluations 
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targeting proteins identified in our proteomic analysis could help to define virulence factors 
for this organism. A method for site-directed mutagenesis has been described for M. 
hyopneumoniae (25). The breakthrough with CRISPR (26, 27) has yet to be fully exploited 
for Mycoplasma species. It is hopeful such tools can adapted for use with Mycoplasma 
hyorhinis. 
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APPENDIX A. SUPPLEMENTAL INFORMATION FOR CHAPTER 2 
 
 
 
Table S1. Study 1 dose and route of administration on day of study. 
Group Day 0 Day 1 Day 2 
1 
(n=10) 
40 mL IP* (1.59 x 109 CCU) — — 
2 
(n=10) 
20 mL IV* (7.96 x 108 CCU) — — 
3 
(n=10) 
20 mL IN* (7.96 x 108 CCU) — — 
4 
(n=10) 
40 mL IP (1.59 x 109 CCU) 20 mL IV (8.53 x 108 CCU) 20 mL IN (4.18 x 108 CCU) 
5 
(n=10) 
20 mL IP (7.96 x 108 CCU) 10 mL IV (4.27 x 108 CCU) 10 mL IN (2.09 x 108 CCU) 
6 (n=6) — — — 
*IP = intraperitoneal, IV = intravenous, IN = intranasal. 
 
 
 
 
 
 
 
 
 
Table S2. Study 2 dose and route of administration on day of study. 
Group Day 0 Day 1 Day 2 
1 
(n=28) 
20 mL IP (1.12 x 109 
CCU) 
10 mL IV (6.76 x 108 
CCU) 10 mL IN (1.0 x 10
8 CCU) 
2 
(n=28) 
20 mL IP (1.12 x 109 
CCU) 
10 mL IV (6.76 x 108 
CCU) — 
3 (n=8) — — — 
*IP = intraperitoneal, IV = intravenous, IN = intranasal. 
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Table S3. Scoring system for respiration, coughing and lameness 
Observation Score 0 Score 1 Score 2 Score 3 Score 4 Score 5 
Respiration Normal Abnormal — — — — 
Coughing Normal Abnormal — — — — 
Lameness Normal  
(no visible 
lameness) 
Mild  
(not 
constantly 
lame when 
walking, 
walks at a 
normal 
speed, is 
weight 
bearing 
while 
walking and 
standing, 
lameness is 
indicated by 
intermittent 
reduced 
weight 
bearing on 
one limb or 
shortening 
of the stride) 
Moderate 
(constant 
and 
observed 
throughout 
every step at 
a walking 
pace, 
bearing 
some weight 
on the leg at 
a walk and 
standing, but 
short-
striding one 
or more legs 
while 
walking, 
walks at a 
normal 
speed) 
Moderately 
Severe  
(non-weight 
bearing on 
the leg the 
first few 
steps after 
standing, 
constant, 
obvious 
lameness 
while at a 
walking 
pace, putting 
very little 
weight on 
the leg at a 
walk or 
while 
standing, 
requires the 
pig to slow 
its speed of 
walking) 
Severe 
(will stand 
(may require 
assistance) 
for at least 3 
minutes, 
non-weight 
bearing on 
one or more 
legs at walk 
or standing, 
still able to 
three-legged 
walk) 
Recumbent 
(will not 
stand even 
with 
assistance) 
 
Table S4.  Schedule of Events for Study 1. 
Time Event (group) Samples 
Day 0 Challenge by IP (1, 4, 5) 
Challenge by IV (2) 
Challenge by IN (3) 
Nasal swabs collected for PCR 
Blood collected for ELISA 
Weight measurement 
Day 1 Challenge by IV (4, 5) None 
Day 2 Challenge by IN (4, 5) None  
Days 0-21 (all) Clinical observations and Respiratory, Coughing, and Lameness 
Scores 
Day 21 Euthanasia (all) Gross examination for polyserositis 
Lung tissue collection (fresh for PCR, fixed for histopathology) 
Heart tissue collection (fresh for PCR, fixed for histopathology) 
Elbow/stifle joint swab for PCR 
Carpi/tarsi joint swab for PCR 
Weight measurement 
*IP = intraperitoneal, IV = intravenous, IN = intranasal. 
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Table S5.  Schedule of Events for Study 2. 
Time Event (group) Samples 
Day 0 Challenge by IP (1, 2) 
 
Nasal swabs collected for PCR 
Blood collected for ELISA 
Weight measurement 
Day 1 Challenge by IV (1, 2) None 
Day 2 Challenge by IN (1) None 
Days 0-28 (all) Clinical observations and Respiratory, Coughing, and Lameness 
Scores 
Day 28 Euthanasia (all) Gross examination for polyserositis 
Pericardial swab for PCR 
Pleural swab for PCR 
Elbow/stifle joint swab for PCR 
Carpi/tarsi joint swab for PCR 
Weight measurement 
*IP = intraperitoneal, IV = intravenous, IN = intranasal. 
 
 
 
 
 
 
 
 
Table S6.  Study 1 average daily gain (ADG) statistical summary. 
Treatment 
Group Number 
Mean 
(kg/day) 
Standard 
Error 
Lower 
95% CI 
Upper 
95% CI 
1 10 0.5 0.05 0.4 0.7 
2 9 0.5 0.05 0.4 0.6 
3 10 0.7 0.03 0.6 0.7 
4 10 0.5 0.05 0.3 0.6 
5 10 0.4 0.05 0.3 0.5 
6 6 0.7 0.04 0.6 0.8 
Groups:  1=IP (intraperitoneal), 2=IV (intravenous), 3=IN (intranasal), 
4=IP,IV,IN (high dose), 5=IP,IV,IN (low dose). One animal in Group 2 
died prior to D21. CI=confidence interval. 
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Table S7.  Study 1 polyserositis statistical summary. 
Treatment 
Group 
Ratio 
Postive/Total 
Positive 
(%) 
Standard 
Error 
Lower 
95% 
CI 
Upper 
95% 
CI 
Pleuritis 
1 0/10 0 0 0 30.8 
2 3/10 30 14.5 6.7 65.2 
3 0/10 0 0 0 30.8 
4 4/10 40 15.5 12.2 73.8 
5 2/10 20 12.6 2.5 55.6 
6 0/6 0 0 0 45.9 
Peritonitis 
1 0/10 0 0 0 30.8 
2 1/10 10 9.5 0.3 44.5 
3 0/10 0 0 0 30.8 
4 0/10 0 0 0 30.8 
5 0/10 0 0 0 30.8 
6 0/6 0 0 0 45.9 
Pericarditis 
1 2/10 20 12.6 2.5 55.6 
2 9/10 90 9.5 55.5 99.7 
3 0/10 0 0 0 30.8 
4 5/10 50 15.8 18.7 81.3 
5 5/10 50 15.8 18.7 81.3 
6 0/6 0 0 0 45.9 
Pleuritis or Peritonitis or Pericarditis Positive 
1 2/10 20 12.6 2.5 55.6 
2 9/10 90 9.5 55.5 99.7 
3 0/10 0 0 0 30.8 
4 6/10 60 15.5 26.2 87.8 
5 5/10 50 15.8 18.7 81.3 
6 0/6 0 0 0 45.9 
Groups:  1=IP (intraperitoneal), 2=IV (intravenous), 3=IN (intranasal), 
4=IP,IV,IN (high dose), 5=IP,IV,IN (low dose). CI=confidence interval 
(Clopper-Pearson exact confidence limits). 
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Table S8.  Study 1 arthritis statistical summary. 
Treatment 
Group 
Ratio 
Postive/Total 
Positive 
(%) 
Standard 
Error 
Lower 
95% CI 
Upper 
95% CI 
1 3/10 30 14.5 6.7 65.2 
2 1/10 10 9.5 0.3 44.5 
3 1/10 10 9.5 0.3 44.5 
4 5/10 50 15.8 18.7 81.3 
5 5/10 50 15.8 18.7 81.3 
6 0/6 0 0 0 45.9 
Groups:  1=IP (intraperitoneal), 2=IV (intravenous), 3=IN (intranasal), 4=IP,IV,IN 
(high dose), 5=IP,IV,IN (low dose). CI=confidence interval (Clopper-Pearson exact 
confidence limits). A positive animal showed at least one joint with signs of 
arthritis. 
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Table S9.  Study 1 PCR results statistical summary. 
Treatment 
Group 
Ratio 
Postive/Total 
Positive 
(%) 
Standard 
Error 
Lower 
95% CI 
Upper 
95% CI 
Heart Tissue 
1 1/10 10 9.5 0.3 44.5 
2 3/10 30 14.5 6.7 65.2 
3 0/10 0 0 0 30.8 
4 3/10 30 14.5 6.7 65.2 
5 1/10 10 9.5 0.3 44.5 
6 0/6 0 0 0 45.9 
Lung Tissue 
1 1/10 10 9.5 0.3 44.5 
2 3/10 30 14.5 6.7 65.2 
3 0/10 0 0 0 30.8 
4 4/10 40 15.5 12.2 73.8 
5 1/10 10 9.5 0.3 44.5 
6 0/6 0 0 0 45.9 
Carpal/Tarsal Swab 
1 2/10 20 12.6 2.5 55.6 
2 1/10 10 9.5 0.3 44.5 
3 1/10 10 9.5 0.3 44.5 
4 0/10 0 0 0 30.8 
5 0/10 0 0 0 30.8 
6 0/6 0 0 0 45.9 
Elbow/Stifle Swab 
1 0/10 0 0 0 30.8 
2 2/10 20 12.6 2.5 55.6 
3 0/10 0 0 0 30.8 
4 0/10 0 0 0 30.8 
5 0/10 0 0 0 30.8 
6 0/6 0 0 0 45.9 
Groups:  1=IP (intraperitoneal), 2=IV (intravenous), 3=IN (intranasal), 
4=IP,IV,IN (high dose), 5=IP,IV,IN (low dose). CI=confidence interval 
(Clopper-Pearson exact confidence limits). 
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Table S10.  Study 1 lameness statistical summary. 
Treatment 
Group 
Ratio 
Postive/Total 
Positive 
(%) 
Standard 
Error 
Lower 
95% CI 
Upper 
95% CI 
1 4/10 40 15.5 12.2 73.8 
2 1/10 10 9.5 0.3 44.5 
3 1/10 10 9.5 0.3 44.5 
4 1/10 10 9.5 0.3 44.5 
5 7/10 70 14.5 34.8 93.3 
6 0/6 0 0 0 45.9 
Groups:  1=IP (intraperitoneal), 2=IV (intravenous), 3=IN (intranasal), 4=IP,IV,IN 
(high dose), 5=IP,IV,IN (low dose). CI=confidence interval (Clopper-Pearson exact 
confidence limits). A pig was considered positive if it received a score ≥ 1 for any 
two consecutive days. 
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Table S11.  Study 1 Histology statistical summary. 
Treatment 
Group 
Ratio 
Postive/Total 
Positive 
(%) 
Standard 
Error 
Lower 
95% CI 
Upper 95% 
CI 
Pleuritis of the Lungs 
1 0/10 0 0 0 30.8 
2 2/9 22.2 13.9 2.8 60 
3 0/10 0 0 0 30.8 
4 2/10 20 12.6 2.5 55.6 
5 3/10 30 14.5 6.7 65.2 
6 0/6 0 0 0 45.9 
Peribronchiolar/Septal Infiltrates of the Lungs 
1 3/10 30 14.5 6.7 65.2 
2 5/9 55.6 16.6 21.2 86.3 
3 0/10 0 0 0 30.8 
4 4/10 40 15.5 12.2 73.8 
5 4/10 40 15.5 12.2 73.8 
6 0/6 0 0 0 45.9 
Lymphocytic Inflammation of the Heart 
1 1/10 10 9.5 0.3 44.5 
2 6/9 66.7 15.7 29.9 92.5 
3 0/10 0 0 0 30.8 
4 3/10 30 14.5 6.7 65.2 
5 5/10 50 15.8 18.7 81.3 
6 0/6 0 0 0 45.9 
Fibrosis of the Heart 
1 3/10 30 14.5 6.7 65.2 
2 8/9 88.9 10.5 51.8 99.7 
3 0/10 0 0 0 30.8 
4 4/10 40 15.5 12.2 73.8 
5 5/10 50 15.8 18.7 81.3 
6 0/6 0 0 0 45.9 
Groups:  1=IP (intraperitoneal), 2=IV (intravenous), 3=IN (intranasal), 4=IP,IV,IN 
(high dose), 5=IP,IV,IN (low dose). CI=confidence interval (Clopper-Pearson exact 
confidence limits). A pig was considered positive if it received a score >0 for each 
respective category. One animal in Group 2 died prior to D21 and fixed tissue was not 
collected. 
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Table S12.  Study 2 average daily gain (ADG) statistical summary. 
Treatment 
group Number 
Least 
Squares 
Means 
Standard 
Error 
Lower 
95% CI 
Upper 
95% CI p-value 
1 27 0.56 0.031 0.43 0.69 
0.2991 
2 28 0.51 0.031 0.38 0.64 
Groups:  1=IP,IV,IN, 2=IP,IV. IP=intraperitoneal; IV=intravenous; IN=intranasal. 
One animal in Group 1 died prior to D28. Analyses performed between challenged 
groups; non-infected group 3 was housed separately and not included. 
 
 
Table S13.  Study 2 polyserositis statistical summary. 
Treatment 
group Number Mean 
Standard 
Error of 
Mean 
Lower 
95% CI 
Upper 
95% CI p-value 
Pleuritis 
1 28 0.178 0.1063 0.000 1.000 
0.6471 
2 28 0.098 0.0737 0.000 1.000 
Pericarditis 
1 28 0.571 0.0979 0.008 0.995 
0.4072 
2 28 0.75 0.0848 0.010 0.999 
Groups:  1=IP,IV,IN, 2=IP,IV. IP=intraperitoneal; IV=intravenous; IN=intranasal. 
Mean=back transformed least squares means (proportion positive). No peritonitis 
was observed. Analyses performed between challenged groups; non-infected group 3 
was housed separately and not included. 
 
 
Table S14.  Study 2 PCR results statistical summary. 
Treatment 
group Number Mean 
Standard 
Error of 
Mean 
Lower 
95% CI 
Upper 
95% CI p-value 
Pericardial Swab 
1 28 0.225 0.0976 0.000 0.997 
0.9720 
2 28 0.220 0.0970 0.000 0.997 
Pleural Swab 
1 28 0.143 0.0664 0.000 0.994 
0.6142 
2 28 0.214 0.0780 0.001 0.990 
Carpal/Tarsal Swab 
1 28 0.608 0.0975 0.009 0.996 
0.4523 
2 28 0.754 0.0848 0.009 0.999 
Elbow/Stifle Swab 
1 28 0.534 0.1295 0.002 0.999 
0.6553 
2 28 0.640 0.1217 0.002 0.999 
Groups:  1=IP,IV,IN, 2=IP,IV.. Mean=back transformed least squares means 
(proportion positive). Analyses performed between challenged groups; non-infected 
group 3 was housed separately and not included. 
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Table S15.  Study 2 arthritis statistical summary. 
Treatment 
group Number Mean 
Standard 
Error of 
Mean 
Lower 
95% CI 
Upper 
95% 
CI 
p-value 
Left Elbow 
1 28 0.143 0.0661 0.000 0.994 
0.4218 
2 28 0.286 0.0854 0.002 0.988 
Left Stifle 
1 28 0.107 0.0584 0.000 0.996 
0.4774 
2 28 0.214 0.0776 0.001 0.990 
Left Tarsal 
1 28 0.182 0.0860 0.000 0.997 
0.4089 
2 28 0.343 0.1172 0.001 0.997 
Right Elbow 
1 28 0.088 0.0777 0.000 1.000 
0.5192 
2 228 0.239 0.1506 0.000 1.000 
Right Stifle 
1 28 0.105 0.0584 0.000 0.997 
0.7519 
2 28 0.140 0.0669 0.000 0.995 
Right Tarsal 
1 28 0.262 0.1039 0.000 0.997 
0.6058 
2 28 0.354 0.1183 0.001 0.997 
Any Joint Positive for Arthritis 
1 28 0.346 0.1063 0.001 0.995 
0.4608 
2 28 0.500 0.1141 0.003 0.997 
Groups:  1=IP,IV,IN, 2=IP,IV. IP=intraperitoneal; IV=intravenous; IN=intranasal. 
Mean=back transformed least squares means (proportion positive). Carpi from both 
groups remained free from arthritis. Analyses performed between challenged 
groups; non-infected group 3 was housed separately and not included. 
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Table S16.  Study 2 clinical observations statistical summary. 
Treatment 
group Number Mean 
Standard 
Error of 
Mean 
Lower 
95% CI 
Upper 
95% 
CI 
p-value 
Respiration 
1 28 0.644 0.1036 0.006 0.998 0.7057 
  2 28 0.714 0.0963 0.006 0.999 
Coughing 
1 28 0.077 0.1253 0.000 1.000 0.9308 
  2 28 0.059 0.1007 0.000 1.000 
Lameness 
1 28 0.670 0.1096 0.004 0.999 0.7683 
  2 28 0.620 0.1151 0.003 0.999 
Groups:  1=IP,IV,IN, 2=IP,IV. IP=intraperitoneal; IV=intravenous; IN=intranasal. 
Mean=back transformed least squares means (proportion positive). A pig was 
positive for respiration or coughing if ever not normal. A pig was positive for 
lameness if it received a score of ≥ 1 on any two consecutive days. Analyses 
performed between challenged groups; non-infected group 3 was housed separately 
and not included. 
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APPENDIX B. SUPPLEMENTAL INFORMATION FOR CHAPTER 3 
Table S17. Challenge dose and route of administration on day of study. 
Group 0 dpc* 1 dpc 2 dpc Total Applied Dose 
1 (n=24) Day 0:  20 mL/IP** 
Day 1:  
10 mL/IV** 
Day 2:  
10 mL/IN** 5.73 × 10
9 CCU***/pig 
2 (n=25) Day 21:  20 mL/IP 
Day 22:  
10 mL/IV 
Day 23:  
10 mL/IN 2.55 × 10
9 CCU/pig 
3 (n=25) Day 42:  20 mL/IP 
Day 43:  
10 mL/IV 
Day 44:  
10 mL/IN 3.72 × 10
9 CCU/pig 
4 (n=25) Day 63:  20 mL/IP 
Day 64:  
10 mL/IV 
Day 65:  
10 mL/IN 4.26 × 10
9 CCU/pig 
5-8 (n=5, 
each) — — — — 
*dpc = days post-challenge; **IP = intraperitoneal, IV = intravenous, IN = intranasal; ***CCU = color changing 
units. 
 
 
Table S18.  Schedule of Events. 
Time Event Group Samples 
-1 dpc* Sample collection All Blood collection for ELISA 
Nasal swab collection for PCR 
0 dpc Challenge by IP** 1, 2, 3, 4 Weight measurement 
1 dpc Challenge by IV** 1, 2, 3, 4 None 
2 dpc Challenge by IN** 1, 2, 3, 4 None 
0 dpc -  
21 dpc 
Observations All Clinical observations and lameness scoring 
21 dpc Euthanasia All Gross examination for polyserositis 
Pericardial swab for PCR 
Pleural swab for PCR (if pleuritis present) 
Peritoneal swab for PCR (if peritonitis present) 
Elbow/stifle joint swab for PCR 
Carpal/tarsal joint swab for PCR 
Weight measurement 
*dpc = days post challenge; **IP = intraperitoneal, IV = intravenous, IN = intranasal. Group:  1 = 7 weeks of age (0 
dpc = Day 0); 2 = 10 weeks of age (0 dpc = Day 21); 3 = 13 weeks of age (0 dpc = Day 42); 4 = 16 weeks of age (0 
dpc = Day 63). 
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Table S19.  Statistical summaries for weight measurements. 
Treatment 
Group* Number 
Mean 
(lbs) 
Standard 
Error 
Lower 
95% CI 
Upper 
95% CI 
0 dpc 
1 23 22.0 0.67 20.6 23.4 
2 25 50.8 1.02 48.7 52.9 
3 25 93.5 1.87 89.7 97.4 
4 24 125.7 2.24 121.0 130.3 
5 5 22.8 0.80 20.5 25.0 
6 5 51.0 4.21 39.3 62.7 
7 5 98.7 2.98 90.4 107.0 
8 5 132.7 5.45 117.6 147.9 
21 dpc 
1 22 32.0 1.36 29.2 34.8 
2 24 69.6 1.76 66.0 73.3 
3 23 114.9 2.44 109.9 120.0 
4 23 160.3 2.88 154.3 166.3 
5 5 50.0 1.65 45.4 54.5 
6 5 87.3 5.64 71.6 102.9 
7 5 145.1 5.79 129.0 161.1 
8 5 181.0 6.65 162.6 199.5 
Average Daily Gain (ADG) 
1 22 0.5 0.06 0.4 0.6 
2 24 0.9 0.08 0.7 1.1 
3 23 1.0 0.06 0.9 1.1 
4 23 1.7 0.12 1.4 1.9 
5 5 1.3 0.08 1.1 1.5 
6 5 1.7 0.08 1.5 1.9 
7 5 2.2 0.17 1.7 2.7 
8 5 2.3 0.13 1.9 2.7 
*1 and 5 = 7 weeks of age (0 dpc = Day 0); 2 and 6 = 10 weeks of age (0 
dpc = Day 21); 3 and 7 = 13 weeks of age (0 dpc = Day 42); 4 and 8 = 16 
weeks of age (0 dpc = Day 63). CI=confidence interval, dpc = days post 
challenge. 
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Table S20.  Statistical summaries for polyserositis. 
Treatment 
Group* Number 
Proportion 
Positive 
Standard 
Error 
Lower 
95% CI 
Upper 
95% CI 
Pericarditis 
1 23 0.870 0.070 0.664 0.972 
2 25 0.280 0.090 0.121 0.494 
3 25 0.080 0.054 0.010 0.260 
4 24 0.042 0.041 0.001 0.211 
5 5 0.000 0.000 0.000 0.522 
6 5 0.000 0.000 0.000 0.522 
7 5 0.000 0.000 0.000 0.522 
8 5 0.000 0.000 0.000 0.522 
Pleuritis 
1 23 0.261 0.092 0.102 0.484 
2 25 0.040 0.039 0.001 0.204 
3 25 0.160 0.073 0.045 0.361 
4 24 0.000 0.000 0.000 0.142 
5 5 0.000 0.000 0.000 0.522 
6 5 0.000 0.000 0.000 0.522 
7 5 0.000 0.000 0.000 0.522 
8 5 0.000 0.000 0.000 0.522 
Peritonitis 
1 23 0.217 0.086 0.075 0.437 
2 25 0.160 0.073 0.045 0.361 
3 25 0.080 0.054 0.010 0.260 
4 24 0.000 0.000 0.000 0.142 
5 5 0.000 0.000 0.000 0.522 
6 5 0.000 0.000 0.000 0.522 
7 5 0.000 0.000 0.000 0.522 
8 5 0.000 0.000 0.000 0.522 
*1 and 5 = 7 weeks of age (0 dpc = Day 0); 2 and 6 = 10 weeks of age 
(0 dpc = Day 21); 3 and 7 = 13 weeks of age (0 dpc = Day 42); 4 and 8 
= 16 weeks of age (0 dpc = Day 63). CI=confidence interval. 
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Table S21.  Statistical summaries for M. hyorhinis PCR. 
Treatment 
Group* Number 
Proportion 
Positive 
Standard 
Error 
Lower 
95% CI 
Upper 
95% CI 
Pericardial Swabs 
1 23 0.261 0.092 0.102 0.484 
2 25 0.040 0.039 0.001 0.204 
3 25 0.000 0.000 0.000 0.137 
4 24 0.083 0.056 0.010 0.270 
5 5 0.000 0.000 0.000 0.522 
6 5 0.000 0.000 0.000 0.522 
7 5 0.000 0.000 0.000 0.522 
8 5 0.000 0.000 0.000 0.522 
Pleural Swabs 
1 6 0.333 0.192 0.043 0.777 
2 1 0.000 0.000 0.000 0.975 
3 4 0.000 0.000 0.000 0.602 
Peritoneal Swabs 
1 5 0.200 0.179 0.005 0.716 
2 4 0.000 0.000 0.000 0.602 
3 2 0.000 0.000 0.000 0.842 
Elbow/Stifle Swabs 
1 23 0.826 0.079 0.612 0.950 
2 25 0.360 0.096 0.180 0.575 
3 25 0.320 0.093 0.149 0.535 
4 24 0.167 0.076 0.047 0.374 
5 5 0.000 0.000 0.000 0.522 
6 5 0.000 0.000 0.000 0.522 
7 5 0.000 0.000 0.000 0.522 
8 5 0.000 0.000 0.000 0.522 
Carpal/Tarsal Swabs 
1 23 0.870 0.070 0.664 0.972 
2 25 0.360 0.096 0.180 0.575 
3 25 0.120 0.065 0.025 0.312 
4 24 0.042 0.041 0.001 0.211 
5 5 0.000 0.000 0.000 0.522 
6 5 0.000 0.000 0.000 0.522 
7 5 0.000 0.000 0.000 0.522 
8 5 0.000 0.000 0.000 0.522 
*1 and 5 = 7 weeks of age (0 dpc = Day 0); 2 and 6 = 10 weeks of age (0 
dpc = Day 21); 3 and 7 = 13 weeks of age (0 dpc = Day 42); 4 and 8 = 16 
weeks of age (0 dpc = Day 63). CI=confidence interval. 
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Table S22.  Statistical summaries for arthritis. 
Group Number Proportion Positive 
Standard 
Error 
Lower 
95% CI 
Upper 
95% CI 
At least one joint positive 
1 23 1.000 0.000 0.852 1.000 
2 25 0.560 0.099 0.349 0.756 
3 25 0.240 0.085 0.094 0.451 
4 24 0.250 0.088 0.098 0.467 
5 5 0.000 0.000 0.000 0.522 
6 5 0.000 0.000 0.000 0.522 
7 5 0.000 0.000 0.000 0.522 
8 5 0.000 0.000 0.000 0.522 
Proportion joints positive per animal 
1 23 0.462 0.047 0.365 0.559 
2 25 0.175 0.041 0.091 0.259 
3 25 0.040 0.016 0.008 0.072 
4 24 0.089 0.036 0.015 0.162 
5 5 0.000 0.000 . . 
6 5 0.000 0.000 . . 
7 5 0.000 0.000 . . 
8 5 0.000 0.000 . . 
*1 and 5 = 7 weeks of age (0 dpc = Day 0); 2 and 6 = 10 weeks of age 
(0 dpc = Day 21); 3 and 7 = 13 weeks of age (0 dpc = Day 42); 4 and 8 
= 16 weeks of age (0 dpc = Day 63). CI=confidence interval. 
 
 
 
Table S23.  Statistical summary for lameness. 
Treatment 
Group* Number 
Proportion 
Positive 
Standard 
Error 
Lower 
95% CI 
Upper 
95% CI 
1 23 0.652 0.099 0.427 0.836 
2 25 0.680 0.093 0.465 0.851 
3 25 0.680 0.093 0.465 0.851 
4 24 0.333 0.096 0.156 0.553 
5 5 0.000 0.000 0.000 0.522 
6 5 0.200 0.179 0.005 0.716 
7 5 0.000 0.000 0.000 0.522 
8 5 0.400 0.219 0.053 0.853 
*1 and 5 = 7 weeks of age (0 dpc = Day 0); 2 and 6 = 10 weeks of age 
(0 dpc = Day 21); 3 and 7 = 13 weeks of age (0 dpc = Day 42); 4 and 8 
= 16 weeks of age (0 dpc = Day 63). CI=confidence interval. A pig was 
considered positive if it received a score ≥ 1 for any two consecutive 
days. 
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Table S24. Summary of observations for abnormal respirations and coughing. 
Treatment1 
Affected 
animals/total 
animals 
Mean2 Standard Error 
PF3 vs 
CTRL 
Lower 
 95% CI4 
Upper  
95% CI 
CTRL 5/26 0.1947 0.0821 — — — 
HIGH 1/28 0.0346 0.0345 0.82 -0.63 0.98 
MED 3/27 0.1085 0.0614 0.44 -1.30 0.86 
LOW 4/26 0.1510 0.0729 0.22 -1.78 0.78 
1 = CTRL—placebo control, HIGH—high dose vaccine, MED—medium dose vaccine, LOW—low dose vaccine; 
NTX group not included in analysis. Two CTRL pigs were excluded from analysis due to lameness at the time of 
challenge. 
2 = least squares mean 
3 = preventive fraction 
4 = confidence interval 
 
 
Table S25. Summary of observations for lameness. 
Treatment1 
Affected 
animals/total 
animals 
Mean2 Standard Error 
PF3 vs 
CTRL 
Lower 
 95% CI4 
Upper  
95% CI 
CTRL 14/26 0.5402 0.1302 — — — 
HIGH 6/28 0.1922 0.0897 0.64 0.10 0.86 
MED 4/27 0.1287 0.0727 0.76 0.26 0.92 
LOW 6/26 0.2200 0.0993 0.59 -0.01 0.84 
1 = CTRL—placebo control, HIGH—high dose vaccine, MED—medium dose vaccine, LOW—low dose vaccine; 
NTX group not included in analysis. Two CTRL pigs were excluded from analysis due to lameness at the time of 
challenge. 
2 = least squares mean 
2 = preventive fraction 
3 = confidence interval 
 
 
Table S26. Summary of incidence of pericarditis. 
Treatment1 
Affected 
animals/total 
animals 
Mean2 Standard Error 
PF3 vs 
CTRL 
Lower 
 95% CI4 
Upper  
95% CI 
CTRL 25/26 0.9615 0.03771 — — — 
HIGH 13/28 0.4643 0.09425 0.52 0.26 0.69 
MED 11/27 0.4074 0.09456 0.58 0.31 0.74 
LOW 17/26 0.6538 0.0933 0.32 0.07 0.5 
1 = CTRL—placebo control, HIGH—high dose vaccine, MED—medium dose vaccine, LOW—low dose vaccine; 
NTX group not included in analysis. Two CTRL pigs were excluded from analysis due to lameness at the time of 
challenge. 
2 = least squares mean 
2 = preventive fraction 
3 = confidence interval 
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Table S27. Summary of weight gain in the vaccination phase and challenge phase. 
Treatment1 Number of Animals 
Mean2 
(lbs) 
Standard 
Error p-value 
Lower 
 95% CI4 
Upper  
95% CI 
Day 21 (Vaccination Phase) 
CTRL 26 14.58 0.61 — — — 
HIGH 28 14.21 0.59 0.5490 -0.86 1.60 
MED 27 13.90 0.60 0.2820 -0.57 1.93 
LOW 28 13.67 0.60 0.1440 -0.32 2.14 
Day 42 (Challenge Phase) 
CTRL 25 26.62 1.32 — — — 
HIGH 28 34.45 1.27 < 0.0001 -11.30 -4.38 
MED 27 33.12 1.29 < 0.0001 -9.99 -3.03 
LOW 26 30.56 1.29 0.0270 -7.43 -0.46 
1 = CTRL—placebo control, HIGH—high dose vaccine, MED—medium dose vaccine, LOW—low dose vaccine; 
NTX group not included in analysis. Two CTRL pigs were excluded from analysis due to lameness at the time of 
challenge. 
2 = least squares mean 
2 = preventive fraction 
3 = confidence interval 
 
 
 
Table S28. Summary of average daily weight gain (ADG). 
Treatment1 Number of Animals Mean
2 Standard Error p-value 
Lower 
 95% CI4 
Upper  
95% CI 
CTRL 25 0.57 0.05 — — — 
HIGH 28 0.96 0.05 < 0.0001 -0.53 -0.25 
MED 27 0.92 0.05 < 0.0001 -0.48 -0.21 
LOW 26 0.80 0.05 0.0012 -0.37 -0.09 
1 = CTRL—placebo control, HIGH—high dose vaccine, MED—medium dose vaccine, LOW—low dose vaccine; 
NTX group not included in analysis. Two CTRL pigs were excluded from analysis due to lameness at the time of 
challenge. 
2 = least squares mean 
2 = preventive fraction 
3 = confidence interval 
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Table S29. Identification of 34 proteins unique to the Broth vs. McCoy comparison and significant (p < 0.05) 
for differential expression. Protein identification by liquid chromatography, tandem mass spectrometry (LC-
MS/MS) using M. hyorhinis HUB-1 database. 
UniProtKB 
Entry1 Protein Description
2 Gene Name3 
Fold 
Change4  
Broth vs. 
McCoy 
E0TK92 ABC transporter permease protein MHR_0064 8.59 
E0TKG7 hypothetical protein MHR_0453 8.58 
E0TLN4 hypothetical protein MHR_0655 8.36 
E0TL22 Phosphotransferase enzyme family protein MHR_0211 8.03 
E0TKC7 DNA polymerase III gamma and tau subunit (dnaX) MHR_0101 7.83 
E0TKA1 P59-like protein MHR_0073 5.74 
E0TL86 Glutamyl-tRNA amidotransferase subunit B (gatB) MHR_0573 2.77 
E0TLE9 Fatty acid-binding protein DegV-like protein MHR_0265 2.68 
E0TL73 Elongation factor Tu (tuf) MHR_0560 -1.21 
E0TK65 NADH oxidase (nox) MHR_0035 -1.27 
E0TL32 ATP synthase subunit alpha (atpA) MHR_0221 -1.32 
E0TL34 Proton-translocating ATPase, beta subunit (atpD) MHR_0223 -1.78 
E0TLD6 hypothetical protein MHR_0628 -2.04 
E0TK50 Glycyl tRNA synthetase (glyS) MHR_0410 -2.24 
E0TLG9 hypothetical protein MHR_0285 -2.42 
E0TK39 50S ribosomal protein L2 (rplB) MHR_0399 -2.59 
E0TLA4 Ribosome recycling factor (frr) MHR_0595 -3.12 
E0TLJ6 Methyltransferase type 11 (cdd) MHR_0312 -3.28 
E0TKU9 NH(3)-dependent NAD(+) synthetase (nadE) MHR_0509 -6.39 
E0TKU8 hypothetical protein MHR_0508 -7.13 
E0TKW4 Predicted GTPase, probable translation factor (gtp1) MHR_0524 -7.31 
E0TK46 Probable endonuclease 4 (nfo) MHR_0406 -7.33 
E0TK34 50S ribosomal protein L29 (rmpC) MHR_0394 -7.58 
E0TL26 putative acyl carrier protein MHR_0215 -7.70 
E0TLM8 TrkA-C domain protein (trkA) MHR_0649 -8.25 
E0TL76 uracil phosphoribosyltransferase (upp) MHR_0563 -8.84 
E0TK04 Oligopeptide transport system permease protein (oppF) MHR_0359 -8.93 
E0TLH7 hypothetical protein MHR_0293 -9.06 
E0TK28 30S ribosomal protein S8 (rpsH) MHR_0388 -9.07 
E0TLD8 hypothetical protein MHR_0630 -9.18 
E0TK31 50S ribosomal protein L24 (rplX) MHR_0391 -9.20 
E0TLI1 COF family HAD hydrolase protein MHR_0297 -9.61 
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Table S29 (continued)   
 
E0TKJ1 Phosphotransferase system (PTS) enzyme I (ptsI) MHR_0477 -9.91 
E0TK02 Lipoprotein MHR_0357 -10.46 
1 unique entry identifier in the UniProtKB database (www.uniprot.org) 
2 names and synonyms of the protein in the UniProtKB database (www.uniprot.org) 
3 Mycoplasma hyorhinis HUB-1 gene name according to NCBI database (www.ncbi.nlm.nih.gov) 
4 Fold change of second term as compared to first term, expressed as log2 
 
 
Table S30. Identification of 20 proteins unique to the Broth vs. MDCK comparison and significant (p < 0.05) 
for differential expression. Protein identification by liquid chromatography, tandem mass spectrometry (LC-
MS/MS) using M. hyorhinis HUB-1 database. 
UniProtKB 
Entry1 Protein Description
2 Gene Name3 
Fold 
Change4  
Broth vs. 
MDCK 
E0TJZ5 Glycerol-3-phosphate dehydrogenase [NAD(P)+] (gpsA) MHR_0350 9.88 
E0TLF5 50S ribosomal protein L11 (rplK) MHR_0271 9.25 
E0TKA2 Amino acid or sugar ABC transport system, permease protein MHR_0074 9.05 
E0TL87 Putative transcriptional regulator MHR_0574 8.70 
E0TJW1 Putative MgpA-like protein MHR_0006 8.66 
E0TLP1 Ribonucleoside-diphosphate reductase beta chain (nrdF) MHR_0662 8.54 
E0TL98 LemA-family protein MHR_0589 2.85 
E0TLB9 hypothetical 33 kDa chaperonin MHR_0610 2.81 
E0TK08 Oligoendopeptidase F (pepF) MHR_0363 2.64 
E0TLN2 ATP synthase subunit B (atpD) MHR_0653 2.52 
E0TKG9 Probable L-ribulose-5-phosphate 3-epimerase, UlaE (sgaU) MHR_0455 2.50 
E0TKL0 Ribose-phosphate pyrophosphokinase (prsA) MHR_0117 1.69 
E0TLF7 CTP synthase (pyrG) MHR_0273 1.61 
E0TLM3 hypothetical protein MHR_0644 1.60 
E0TLJ3 Phosphopentomutase (deoB) MHR_0309 1.35 
E0TKI3 Enolase (eno) MHR_0469 0.84 
E0TKE5 L-lactate dehydrogenase (ldh) MHR_0431 -0.90 
E0TK36 30S ribosomal protein S3 (rpsC) MHR_0396 -1.66 
E0TLN8 Lipoprotein MHR_0659 -2.66 
E0TKQ7 Xylose ABC transporter permease protein (xylH) MHR_0164 -9.85 
1 unique entry identifier in the UniProtKB database (www.uniprot.org) 
2 names and synonyms of the protein in the UniProtKB database (www.uniprot.org) 
3 Mycoplasma hyorhinis HUB-1 gene name according to NCBI database (www.ncbi.nlm.nih.gov) 
4 Fold change of second term as compared to first term, expressed as log2 
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Table S31. Identification of 22 proteins unique to the MDCK vs. McCoy comparison and significant (p < 0.05) 
for differential expression. Protein identification by liquid chromatography, tandem mass spectrometry (LC-
MS/MS) using M. hyorhinis HUB-1 database. 
UniProtKB 
Entry1 Protein Description
2 Gene Name3 
Fold 
Change4  
MDCK vs. 
McCoy 
E0TKW7 30S ribosomal protein S6 (rpsF) MHR_0527 7.36 
E0TLE4 Oligopeptide transport system permease protein (oppC) MHR_0637 2.53 
E0TKV4 
pyruvate dehydrogenase E3 component dihydrolipoamide 
dehydrogenase (pdhD) MHR_0514 -0.63 
E0TLK0 FMN-dependent NADH-azoreductase (acpD) MHR_0316 -1.27 
E0TK51 Signal recognition particle protein (ffh) MHR_0411 -1.52 
E0TKV9 50S ribosomal protein L20 (rplT) MHR_0519 -1.53 
E0TKY6 6-phosphofructokinase (pfkA) MHR_0547 -1.62 
E0TKI6 Thiol-disulfide isomerase and thioredoxin (trxA) MHR_0472 -1.65 
E0TK52 Elongation factor Ts (tsf) MHR_0412 -1.69 
E0TKK1 ABC transporter xylose-binding lipoprotein MHR_0487 -2.04 
E0TLE3 Oligopeptide ABC transporter ATP binding protein (oppD) MHR_0636 -2.08 
E0TLK3 ABC transporter ATP-binding protein MHR_0319 -2.16 
E0TLQ8 Membrane protein, OxaA (oxaA) MHR_0679 -2.17 
E0TKT8 Protein P115 (smc) MHR_0498 -2.27 
E0TKT5 Predicted kinase, related to dihydroxyacetone kinase MHR_0495 -2.35 
E0TKH7 VACB-like ribonuclease II (rnr) MHR_0463 -2.39 
E0TK30 50S ribosomal protein L5 (rplE) MHR_0390 -2.79 
E0TKK2 ABC transporter, ATP-binding protein (ecfA) MHR_0109 -5.60 
E0TLL2 Expressed protein MHR_0328 -5.99 
E0TLF1 ATP-dependent helicase, PcrA (pcrA) MHR_0267 -7.70 
E0TLB0 Putative ATP-binding helicase protein MHR_0601 -7.70 
E0TLH8 hypothetical protein MHR_0294 -9.24 
1 unique entry identifier in the UniProtKB database (www.uniprot.org)  
2 names and synonyms of the protein in the UniProtKB database (www.uniprot.org) 
3 Mycoplasma hyorhinis HUB-1 gene name according to NCBI database (www.ncbi.nlm.nih.gov) 
4 Fold change of second term as compared to first term, expressed as log2
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Table S32. Identification of overlapping proteins common to all three comparisons (Broth vs. McCoy, Broth vs. MDCK, and MDCK vs. McCoy) and 
significant (p < 0.05) for differential expression. Protein identification by liquid chromatography, tandem mass spectrometry (LC-MS/MS) using M. hyorhinis 
HUB-1 database. 
UniProtKB 
Entry1 Protein Description
2 Gene Name3 
Fold 
Change4 
Broth vs. 
MDCK 
Fold 
Change4 
Broth vs. 
McCoy 
Fold 
Change4 
MDCK vs. 
McCoy 
E0TLD9 Chromosome replication initiation and membrane attachment protein MHR_0632 6.49 9.15 2.66 
E0TK90 uncharactized lipoprotein MHR_0062 2.59 1.66 -0.92 
E0TL96 Neutrophil activating factor (napA) MHR_0587 1.78 -7.41 -9.19 
E0TLB8 Trigger factor (tig) MHR_0609 0.71 -0.94 -1.65 
E0TL16 aminopeptidase MHR_0205 -1.29 -2.81 -1.51 
E0TL59 101 kDa protein MHR_0249 -1.80 -9.99 -8.20 
E0TK40 50S ribosomal protein L23 (rplW) MHR_0400 -2.11 -10.54 -8.43 
E0TK82 50S ribosomal protein L7/L12 (rplL) MHR_0054 -2.45 -11.46 -9.01 
E0TL36 101 kDa protein MHR_0225 -11.88 -2.99 8.89 
1 unique entry identifier in the UniProtKB database (www.uniprot.org) 
2 names and synonyms of the protein in the UniProtKB database (www.uniprot.org) 
3 Mycoplasma hyorhinis HUB-1 gene name according to NCBI database (www.ncbi.nlm.nih.gov) 
4 Fold change of second term as compared to first term, expressed as log2
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Table S33. Identification of 29 overlapping proteins common to both Broth vs. ex vivo comparisons (Broth vs. 
McCoy and Broth vs. MDCK) and significant (p < 0.05) for differential expression. Protein identification by 
liquid chromatography, tandem mass spectrometry (LC-MS/MS) using M. hyorhinis HUB-1 database. 
UniProtKB 
Entry1 Protein Description
2 (Enzyme class) Gene Name3 
Fold 
Change4  
Broth vs. 
MDCK 
Fold 
Change4  
Broth vs. 
McCoy 
E0TKB6 Arginyl-tRNA synthetase 1 (argS) MHR_0090 9.16 8.48 
E0TKM4 Topoisomerase IV subunit A (parC) MHR_0131 8.97 7.80 
E0TKZ3 putative intracellular protease/amidase MHR_0554 7.76 7.32 
E0TKW8  adenine phosphoribosyltransferase (apt) MHR_0528 3.26 2.78 
E0TK89 uncharactized lipoprotein MHR_0061 2.04 2.59 
E0TKQ1 Serine hydroxymethyltransferase 3 (glyA) MHR_0158 1.84 2.09 
E0TKQ6 xylose ABC transporter ATP-binding protein (xylG) MHR_0163 -2.36 -1.32 
E0TK18 DNA-directed RNA polymerase subunit alpha (rpoA) MHR_0377 -0.83 -1.62 
E0TL54 Transcription antitermination protein (nusG) MHR_0243 -1.63 -1.77 
E0TK01 Oligoendopeptidase F (pepF) MHR_0356 -1.29 -1.79 
E0TLC1 molecular chaperone DnaK (dnaK) MHR_0612 -1.73 -2.39 
E0TK27 50S ribosomal protein L6 (rplF) MHR_0387 -2.12 -3.06 
E0TK03 hypothetical protein MHR_0358 -3.91 -3.29 
E0TKY9 
ATP-dependent serine proteinase, heat shock 
protein (clpB) MHR_0550 -2.61 -3.84 
E0TK32 50S ribosomal protein L14 (rplN) MHR_0392 -8.08 -7.71 
E0TKF4 Outer membrane protein-P95 MHR_0440 -8.46 -8.09 
E0TKD7 Ribulose-phosphate 3-epimerase (rpe) MHR_0423 -8.49 -8.12 
E0TKF8 hypothetical protein MHR_0444 -8.51 -8.14 
E0TKR0 hypothetical protein MHR_0167 -8.69 -8.32 
E0TLH0 hypothetical protein MHR_0286 -8.71 -8.34 
E0TKZ2 Zinc metalloproteinase C MHR_0553 -8.94 -8.58 
E0TK17 50S ribosomal protein L17 (rplQ) MHR_0376 -9.17 -8.80 
E0TK35 50S ribosomal protein L16 (rplP) MHR_0395 -9.23 -8.86 
E0TLN9 hypothetical protein MHR_0660 -9.27 -8.90 
E0TK38 30S ribosomal protein S19 (rpsS) MHR_0398 -9.32 -8.95 
E0TKF3 hypothetical protein MHR_0439 -9.47 -9.10 
E0TKF7 Excinuclease ATPase subunit-like protein (uvrA) MHR_0443 -9.88 -9.51 
E0TKJ2 50S ribosomal protein L21 (rplU) MHR_0478 -9.91 -9.54 
E0TLJ8 hypothetical protein MHR_0314 -10.76 -10.39 
1 unique entry identifier in the UniProtKB database (www.uniprot.org) 
2 names and synonyms of the protein in the UniProtKB database (www.uniprot.org) 
3 Mycoplasma hyorhinis HUB-1 gene name according to NCBI database (www.ncbi.nlm.nih.gov) 
4 Fold change of second term as compared to first term, expressed as log2  
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Table S34. McCoy culture M. hyorhinis proteins 
   
NCBI GI NCBI Accession 
UniProt 
Accession Protein Description 
% 
Coverage 
Unique 
Spectra 
Unique 
Peptides 
304373392 YP_003856601.1 E0TLC0 Glyceraldehyde 3-phosphate dehydrogenase C 81.38 229 21 
304373258 YP_003856467.1 E0TKI6 Thiol-disulfide isomerase and thioredoxin 79.21 30 7 
304373351 YP_003856560.1 E0TL79 Probable purine nucleoside phosphorylase transmembrane protein 77.59 127 12 
304373302 YP_003856511.1 E0TKV6 Pyruvate dehydrogenase E1 component beta subunit 74.09 136 21 
304373345 YP_003856554.1 E0TL73 Elongation factor Tu 67.91 179 20 
304372893 YP_003856102.1 E0TKB8 Fructose-bisphosphate aldolase class II transmembrane protein 62.15 46 9 
304373314 YP_003856523.1 E0TKW8 adenine phosphoribosyltransferase 59.78 44 11 
304373300 YP_003856509.1 E0TKV4 pyruvate dehydrogenase E3 component dihydrolipoamide dehydrogenase 58.35 121 23 
304372963 YP_003856172.1 E0TKQ5 hypothetical protein MHR_0162 57.72 118 22 
304373217 YP_003856426.1 E0TKE5 L-lactate dehydrogenase 57.19 127 15 
304373112 YP_003856321.1 E0TLK0 FMN-dependent NADH-azoreductase 55.72 35 10 
304373349 YP_003856558.1 E0TL77 Deoxyribose-phosphate aldolase 1 55.61 32 8 
304372864 YP_003856073.1 E0TK89 uncharactized lipoprotein 54.99 90 31 
304372872 YP_003856081.1 E0TK97 Histone-like DNA-binding protein 54.44 9 3 
304373303 YP_003856512.1 E0TKV7 Pyruvate dehydrogenase E1-alpha subunit 53.55 111 16 
304373393 YP_003856602.1 E0TLC1 molecular chaperone DnaK 52.43 128 22 
304372959 YP_003856168.1 E0TKQ1 Serine hydroxymethyltransferase 3 52.39 43 12 
304373222 YP_003856431.1 E0TKF0 Phosphoglycerate kinase 51.00 47 14 
304373255 YP_003856464.1 E0TKI3 Enolase 50.89 152 18 
304373409 YP_003856618.1 E0TLD7 membrane protease subunits, stomatin/prohibitin-like protein, partial 50.00 13 6 
304373097 YP_003856306.1 E0TLI5 Acetate kinase AckA 49.5 30 14 
304373246 YP_003856455.1 E0TKH4 hypothetical protein MHR_0460 48.86 25 11 
304373096 YP_003856305.1 E0TLI4 Phosphate acetyltransferase 48.74 42 10 
304372835 YP_003856044.1 E0TK60 aminopeptidase 48.48 69 17 
304373432 YP_003856641.1 E0TLN2 ATP synthase subunit B 47.84 35 14 
304372957 YP_003856166.1 E0TKP9 Triosephosphate isomerase 47.33 38 9 
304373113 YP_003856322.1 E0TLK1 FMN-dependent NADH-azoreductase 1 46.39 73 6 
304373016 YP_003856225.1 E0TL29 ATP synthase C chain, sodium ion specific lipid-binding protein 45.87 20 3 
304373068 YP_003856277.1 E0TLF6 50S ribosomal protein L1 44.78 16 7 
304373200 YP_003856409.1 E0TK52 Elongation factor Ts 44.59 27 8 
304373370 YP_003856579.1 E0TL98 LemA-family protein 44.35 23 5 
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Table S34 (continued)      
304373201 YP_003856410.1 E0TK53 30S ribosomal protein S2 43.71 28 11 
304373166 YP_003856375.1 E0TK18 DNA-directed RNA polymerase subunit alpha 40.84 23 9 
304372890 YP_003856099.1 E0TKB5 Heat shock protein 40.38 22 8 
304373187 YP_003856396.1 E0TK39 50S ribosomal protein L2 39.86 24 7 
304372908 YP_003856117.1 E0TKD3 Hypoxanthine phosphoribosyltransferase 39.56 8 5 
304372840 YP_003856049.1 E0TK65 NADH oxidase 39.52 35 14 
304373021 YP_003856230.1 E0TL34 Proton-translocating ATPase, beta subunit 39.15 34 10 
304373350 YP_003856559.1 E0TL78 Thymidine phosphorylase 38.52 23 9 
304373308 YP_003856517.1 E0TKW2 Thiol peroxidase 35.47 28 4 
304373358 YP_003856567.1 E0TL86 Glutamyl-tRNA amidotransferase subunit B 35.02 25 11 
304373086 YP_003856295.1 E0TLH4 30S ribosomal protein S16 34.44 2 2 
304372813 YP_003856022.1 E0TJW3 dihydrolipoamide dehydrogenase 34.34 33 13 
304373332 YP_003856541.1 E0TKY6 6-phosphofructokinase 33.44 21 9 
304373190 YP_003856399.1 E0TK42 50S ribosomal protein L3 33.33 10 6 
304373156 YP_003856365.1 E0TK08 Oligoendopeptidase F 33.22 22 13 
304373241 YP_003856450.1 E0TKG9 Probable L-ribulose-5-phosphate 3-epimerase ulaE 32.66 25 7 
304373390 YP_003856599.1 E0TLB8 Trigger factor 32.44 60 14 
304372918 YP_003856127.1 E0TKL0 Ribose-phosphate pyrophosphokinase 32.21 14 7 
304372949 YP_003856158.1 E0TKP1 Xaa-pro aminopeptidase 32.01 16 8 
304373158 YP_003856367.1 E0TK10 Probable transketolase transmembrane protein 31.54 35 10 
304373243 YP_003856452.1 E0TKH1 Pentitol phosphotransferase enzyme II, A component 31.41 7 3 
304372865 YP_003856074.1 E0TK90 uncharactized lipoprotein 31.21 44 19 
304373339 YP_003856548.1 E0TKZ3 putative intracellular protease/amidase 30.94 5 3 
304373292 YP_003856501.1 E0TKU6 Pyruvate kinase 29.68 45 11 
304373129 YP_003856338.1 E0TLL7 Nicotinate phosphoribosyltransferase 28.96 17 6 
304372899 YP_003856108.1 E0TKC4 Lipoyltransferase and lipoate-protein ligase 28.88 14 8 
304372900 YP_003856109.1 E0TKC5 Expressed protein 28.85 3 2 
304372952 YP_003856161.1 E0TKP4 Seryl-trna synthetase protein 28.67 11 6 
304373175 YP_003856384.1 E0TK27 50S ribosomal protein L6 28.49 8 3 
304373433 YP_003856642.1 E0TLN3 ATP synthase subunit A 28.40 27 13 
304373184 YP_003856393.1 E0TK36 30S ribosomal protein S3 27.98 12 5 
304373275 YP_003856484.1 E0TKS9 Translation initiation factor IF-2 27.81 25 11 
304373312 YP_003856521.1 E0TKW6 Single-stranded DNA-binding protein 27.37 7 3 
304373380 YP_003856589.1 E0TLA8 2,3-bisphosphoglycerate-independent phosphoglycerate mutase 27.29 16 8 
304373146 YP_003856355.1 E0TJZ8 cell division protein FtsZ 27.27 16 7 
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Table S34 (continued)      
304373178 YP_003856387.1 E0TK30 50S ribosomal protein L5 27.07 8 3 
304373032 YP_003856241.1 E0TL45 50S ribosomal protein L9 26.90 7 4 
304373415 YP_003856624.1 E0TLE3 Oligopeptide ABC transporter ATP binding prote 26.55 9 5 
304373105 YP_003856314.1 E0TLJ3 Phosphopentomutase 26.01 14 7 
304373425 YP_003856634.1 E0TLM5 Pyrophosphatephospho hydrolase 25.54 6 4 
304373041 YP_003856250.1 E0TL54 Transcription antitermination protein 24.75 11 4 
304373301 YP_003856510.1 E0TKV5 
Dihydrolipoamide acetyltransferase component of pyruvate 
dehydrogenase complex 24.68 16 9 
304373144 YP_003856353.1 E0TJZ6 Protein mraZ 24.49 6 3 
304372903 YP_003856112.1 E0TKC8 hypothetical protein MHR_0102 24.21 2 2 
304373288 YP_003856497.1 E0TKU2 translation elongation factor G 23.64 19 10 
304373414 YP_003856623.1 E0TLE2 Oligopeptide transport system permease protein 23.6 20 13 
304372886 YP_003856095.1 E0TKB1 30S ribosomal protein S4 23.41 9 4 
304373240 YP_003856449.1 E0TKG8 Sugar isomerase SgaE 23.36 5 4 
304372898 YP_003856107.1 E0TKC3 Triacylglycerol lipase 22.85 11 5 
304373108 YP_003856317.1 E0TLJ6 Methyltransferase type 11 22.66 3 2 
304373019 YP_003856228.1 E0TL32 ATP synthase subunit alpha 22.44 19 10 
304373282 YP_003856491.1 E0TKT6 Phosphate acyltransferase 22.36 7 4 
304373066 YP_003856275.1 E0TLF4 Putative asparaginyl-trna synthetase protein 22.20 26 7 
304373084 YP_003856293.1 E0TLH2 50S ribosomal protein L19 21.67 4 2 
365897173 YP_004956719.1 E4PYV0 dihydrofolate reductase 21.38 4 3 
304372852 YP_003856061.1 E0TK77 5'-nucleotidase 21.07 26 9 
304373189 YP_003856398.1 E0TK41 50S ribosomal protein L4 21.02 10 5 
304373418 YP_003856627.1 E0TLE6 Lipoprotein 20.82 37 15 
304373167 YP_003856376.1 E0TK19 30S ribosomal protein S13 20.49 2 2 
304373431 YP_003856640.1 E0TLN1 hypothetical protein MHR_0652 20.00 7 5 
304373405 YP_003856614.1 E0TLD3 High affinity transport system protein p37 19.76 13 7 
304372933 YP_003856142.1 E0TKM5 Isoleucyl tRNA synthetase 19.73 17 12 
304372925 YP_003856134.1 E0TKL7 50S ribosomal protein L13 19.31 5 2 
304372964 YP_003856173.1 E0TKQ6 xylose ABC transporter ATP-binding protein 19.29 16 10 
304373020 YP_003856229.1 E0TL33 ATP synthase gamma chain 19.15 9 3 
304373227 YP_003856436.1 E0TKF5 Thioredoxin reductase 19.02 6 4 
304373331 YP_003856540.1 E0TKY5 hypothetical protein MHR_0546 18.84 14 6 
304373199 YP_003856408.1 E0TK51 Signal recognition particle protein 18.65 11 5 
304373242 YP_003856451.1 E0TKH0 hexulose 6 phosphate synthase 18.3 12 2 
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Table S34 (continued)      
304373317 YP_003856526.1 E0TKX1 Lysyl-tRNA synthetase 1 18.29 8 4 
304372915 YP_003856124.1 E0TKK7 DNA gyrase subunit A 18.24 21 10 
304372891 YP_003856100.1 E0TKB6 Arginyl-tRNA synthetase 1 18.01 11 6 
304372876 YP_003856085.1 E0TKA1 P59-like protein 17.58 19 7 
304373259 YP_003856468.1 E0TKI7 prolyl-tRNA synthetase 17.5 10 5 
304373058 YP_003856267.1 E0TL71 Glycerophosphodiester phosphodiesterase family protein 17.43 5 3 
304373006 YP_003856215.1 E0TL19 5'-nucleotidase 16.71 8 4 
304372859 YP_003856068.1 E0TK84 DNA-directed RNA polymerase subunit beta' 16.55 36 15 
304373073 YP_003856282.1 E0TLG1 Lipoprotein 16.47 15 7 
304373271 YP_003856480.1 E0TKJ9 DNA polymerase I 16.22 8 3 
304373067 YP_003856276.1 E0TLF5 50S ribosomal protein L11 16.00 2 2 
304373334 YP_003856543.1 E0TKY8 Membrane nuclease, lipoprotein 15.96 12 5 
304373149 YP_003856358.1 E0TK01 Oligoendopeptidase F 15.93 21 6 
304372807 YP_003856016.1 E0TJV7 DNA polymerase III beta subunit 15.78 9 4 
304373010 YP_003856219.1 E0TL23 GTPase obg 15.55 6 4 
304373174 YP_003856383.1 E0TK26 50S ribosomal protein L18 15.45 4 2 
304372836 YP_003856045.1 E0TK61 molecular chaperone DnaJ 15.32 3 2 
304372996 YP_003856205.1 E0TL09 Lipoprotein 15.28 17 10 
304373221 YP_003856430.1 E0TKE9 P3 15.27 10 5 
304373407 YP_003856616.1 E0TLD5 P60-like lipoprotein 14.65 12 6 
304373323 YP_003856532.1 E0TKX7 alanyl-tRNA synthetase 14.54 14 9 
304372879 YP_003856088.1 E0TKA4 Ag 243-5 protein 14.32 12 6 
304373305 YP_003856514.1 E0TKV9 50S ribosomal protein L20 14.29 3 2 
304373157 YP_003856366.1 E0TK09 Elongation factor P 13.98 2 2 
304373423 YP_003856632.1 E0TLM3 hypothetical protein MHR_0644 13.70 8 6 
304373143 YP_003856352.1 E0TJZ5 Glycerol-3-phosphate dehydrogenase [NAD(P)+] 13.51 4 3 
304373029 YP_003856238.1 E0TL42 Fructose permease IIC component 13.47 11 6 
304373376 YP_003856585.1 E0TLA4 Ribosome recycling factor 13.44 4 3 
304373416 YP_003856625.1 E0TLE4 Oligopeptide transport system permease protein 13.28 9 3 
304373061 YP_003856270.1 E0TLE9 Fatty acid-binding protein DegV-like protein 13.15 13 2 
304373318 YP_003856527.1 E0TKX2 cell division protease FtsH 13.09 20 9 
304373366 YP_003856575.1 E0TL94 ABC transporter ATP-binding protein 13.01 12 5 
304373009 YP_003856218.1 E0TL22 Phosphotransferase enzyme family protein 12.86 5 3 
304373270 YP_003856479.1 E0TKJ8 putative hydrolase 12.69 2 2 
304373313 YP_003856522.1 E0TKW7 30S ribosomal protein S6 12.09 5 2 
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Table S34 (continued)      
304373347 YP_003856556.1 E0TL75 hypothetical protein MHR_0562 11.74 2 2 
304373118 YP_003856327.1 E0TLK6 Glutamyl-tRNA synthetase 11.73 7 4 
304373436 YP_003856645.1 E0TLN6 hypothetical protein MHR_0657 11.73 4 2 
304373408 YP_003856617.1 E0TLD6 hypothetical protein MHR_0628 11.63 12 7 
304373359 YP_003856568.1 E0TL87 Putative transcriptional regulator 11.60 5 4 
304373411 YP_003856620.1 E0TLD9 Chromosome replication initiation and membrane attachment protein 11.59 6 3 
304373076 YP_003856285.1 E0TLG4 lipoate-protein ligase A 11.56 6 3 
304373417 YP_003856626.1 E0TLE5 Oligopeptide ABC transporter permease protein 11.40 4 3 
304373069 YP_003856278.1 E0TLF7 CTP synthase 11.38 12 4 
304373372 YP_003856581.1 E0TLA0 Glucose-6-phosphate isomerase A 11.28 6 3 
304373003 YP_003856212.1 E0TL16 aminopeptidase 11.08 8 5 
304373081 YP_003856290.1 E0TLG9 hypothetical protein MHR_0285 10.88 14 6 
304373335 YP_003856544.1 E0TKY9 ATP-dependent serine proteinase, heat shock protein 10.72 12 4 
304373239 YP_003856448.1 E0TKG7 hypothetical protein MHR_0453 10.27 8 3 
304373116 YP_003856325.1 E0TLK4 Peptide chain release factor 1 10.25 5 3 
304372862 YP_003856071.1 E0TK87 hypothetical protein MHR_0059 10.21 3 2 
304373284 YP_003856493.1 E0TKT8 Protein P115 10.21 19 7 
304372946 YP_003856155.1 E0TKN8 aspartyl tRNA synthetase 9.95 6 4 
304372811 YP_003856020.1 E0TJW1 Putative MgpA-like protein 9.54 5 3 
304373045 YP_003856254.1 E0TL58 DNA gyrase subunit B 9.53 6 3 
304373173 YP_003856382.1 E0TK25 30S ribosomal protein S5 9.42 5 2 
304372945 YP_003856154.1 E0TKN7 Histidyl-tRNA synthetase 9.36 3 3 
304372877 YP_003856086.1 E0TKA2 Amino acid or sugar ABC transport system, permease protein 9.28 7 5 
304373296 YP_003856505.1 E0TKV0 mannose-6-phosphate isomerase 9.18 3 2 
304373346 YP_003856555.1 E0TL74 ATP-dependent protease La 8.82 12 6 
304372967 YP_003856176.1 E0TKQ9 Glucokinase 8.75 3 2 
304373443 YP_003856652.1 E0TLP3 ribonucleotide-diphosphate reductase subunit alpha 8.74 10 4 
304373030 YP_003856239.1 E0TL43 Leucyl-trna synthetase protein 8.50 10 5 
304373277 YP_003856486.1 E0TKT1 Transcription termination-antitermination factor nusA 8.44 8 3 
304373441 YP_003856650.1 E0TLP1 Ribonucleoside-diphosphate reductase beta chai 8.43 3 2 
304373147 YP_003856356.1 E0TJZ9 hypothetical protein MHR_0354 8.11 4 2 
304373031 YP_003856240.1 E0TL44 Predicted signaling protein 7.98 8 3 
304373391 YP_003856600.1 E0TLB9 hypothetical 33 kDa chaperonin 7.93 5 3 
304373286 YP_003856495.1 E0TKU0 30S ribosomal protein S12 7.91 4 2 
304373056 YP_003856265.1 E0TL69 Glycerol-3-phosphate dehydrogenase, putative 7.79 3 3 
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Table S34 (continued)      
304373434 YP_003856643.1 E0TLN4 hypothetical protein MHR_0655 7.71 9 5 
304373153 YP_003856362.1 E0TK05 Oligopeptide transport system permease protein 7.69 3 2 
304373198 YP_003856407.1 E0TK50 Glycyl tRNA synthetase 7.42 5 3 
304373458 YP_003856667.1 E0TLQ8 Membrane protein oxaA 7.19 7 3 
304372889 YP_003856098.1 E0TKB4 Heat-inducible transcription repressor hrcA 7.10 3 2 
304373273 YP_003856482.1 E0TKK1 ABC transporter xylose-binding lipoprotein 7.02 2 2 
304373385 YP_003856594.1 E0TLB3 Threonyl-tRNA synthetase 6.54 5 5 
304372867 YP_003856076.1 E0TK92 ABC transporter permease protein 6.50 9 6 
304373115 YP_003856324.1 E0TLK3 ABC transporter ATP-binding protein 6.43 4 2 
304372873 YP_003856082.1 E0TK98 GTP-binding protein LepA 6.34 2 2 
304373365 YP_003856574.1 E0TL93 tRNA modification GTPase mnmE 6.31 3 2 
304373352 YP_003856561.1 E0TL80 Protein translocase subunit secA 6.30 11 4 
304373281 YP_003856490.1 E0TKT5 Predicted kinase, related to dihydroxyacetone kinase 5.88 4 2 
304373218 YP_003856427.1 E0TKE6 Hexosephosphate transport protein 5.81 8 2 
304373438 YP_003856647.1 E0TLN8 Lipoprotein 5.58 7 4 
304372931 YP_003856140.1 E0TKM3 Topoisomerase IV subunit B 5.24 4 2 
304372858 YP_003856067.1 E0TK83 DNA-directed RNA polymerase subunit beta 4.77 8 5 
304373057 YP_003856266.1 E0TL70 hypothetical protein MHR_0260 4.59 4 3 
304373456 YP_003856665.1 E0TLQ6 Lipoprotein 4.52 3 2 
304373151 YP_003856360.1 E0TK03 hypothetical protein MHR_0358 4.50 15 7 
304372932 YP_003856141.1 E0TKM4 Topoisomerase IV subunit A 4.09 3 3 
304373249 YP_003856458.1 E0TKH7 VACB-like ribonuclease II 4.03 2 2 
304372806 YP_003856015.1 E0TJV6 Chromosomal replication initiator protein dnaA 3.47 2 2 
304373114 YP_003856323.1 E0TLK2 ABC transporter permease protein 3.47 9 7 
304372902 YP_003856111.1 E0TKC7 DNA polymerase III gamma and tau subunit 3.23 4 2 
304372965 YP_003856174.1 E0TKQ7 Xylose ABC transporter permease protein 3.19 3 2 
304373023 YP_003856232.1 E0TL36 101 kDa protein 2.86 6 2 
304372845 YP_003856054.1 E0TK70 hypothetical protein MHR_0042 2.73 3 2 
304372829 YP_003856038.1 E0TJX9 hypothetical protein MHR_0024 2.68 2 2 
304373367 YP_003856576.1 E0TL95 hypothetical Y+L amino acid transporter 1 2.27 4 3 
304373357 YP_003856566.1 E0TL85 Glutamyl-tRNA amidotransferase subunit A 1.75 4 3 
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Table S35. MDCK culture M. hyorhinis proteins 
   
NCBI GI NCBI Accession 
UniProt 
Accession Protein Description 
% 
Coverage 
Unique 
Spectra 
Unique 
Peptides 
304373345 YP_003856554.1 E0TL73 Elongation factor Tu 69.90 351 23 
304373112 YP_003856321.1 E0TLK0 FMN-dependent NADH-azoreductase 68.16 318 12 
304372893 YP_003856102.1 E0TKB8 Fructose-bisphosphate aldolase class II transmembrane protein 66.67 97 11 
304372963 YP_003856172.1 E0TKQ5 hypothetical protein MHR_0162 65.55 511 24 
304373258 YP_003856467.1 E0TKI6 Thiol-disulfide isomerase and thioredoxin 64.36 84 5 
304373314 YP_003856523.1 E0TKW8 adenine phosphoribosyltransferase 64.25 111 10 
304373405 YP_003856614.1 E0TLD3 High affinity transport system protein p37 60.71 110 20 
304373244 YP_003856453.1 E0TKH2 Pentitol phosphotransferase enzyme II, B component 60.00 42 4 
304373409 YP_003856618.1 E0TLD7 membrane protease subunits, stomatin/prohibitin-like protein, partial 60.00 20 6 
304373302 YP_003856511.1 E0TKV6 Pyruvate dehydrogenase E1 component beta subunit 59.76 184 18 
304373166 YP_003856375.1 E0TK18 DNA-directed RNA polymerase subunit alpha 57.36 97 14 
304373392 YP_003856601.1 E0TLC0 Glyceraldehyde 3-phosphate dehydrogenase C 57.36 275 18 
304373255 YP_003856464.1 E0TKI3 Enolase 56.89 289 23 
304373113 YP_003856322.1 E0TLK1 FMN-dependent NADH-azoreductase 1 56.19 140 8 
304373086 YP_003856295.1 E0TLH4 30S ribosomal protein S16 54.44 10 4 
304372835 YP_003856044.1 E0TK60 aminopeptidase 54.35 196 20 
304373217 YP_003856426.1 E0TKE5 L-lactate dehydrogenase 53.35 260 14 
304373300 YP_003856509.1 E0TKV4 pyruvate dehydrogenase E3 component dihydrolipoamide dehydrogenase 52.46 181 26 
304373303 YP_003856512.1 E0TKV7 Pyruvate dehydrogenase E1-alpha subunit 52.19 151 17 
304372926 YP_003856135.1 E0TKL8 30S ribosomal protein S9 51.52 29 4 
304373097 YP_003856306.1 E0TLI5 Acetate kinase AckA 51.49 81 16 
304373016 YP_003856225.1 E0TL29 ATP synthase C chain, sodium ion specific lipid-binding protein 51.38 70 3 
304372957 YP_003856166.1 E0TKP9 Triosephosphate isomerase 51.03 30 11 
304373393 YP_003856602.1 E0TLC1 molecular chaperone DnaK 50.25 291 24 
304373108 YP_003856317.1 E0TLJ6 Methyltransferase type 11 50.00 8 5 
304373390 YP_003856599.1 E0TLB8 Trigger factor 49.49 184 23 
304372925 YP_003856134.1 E0TKL7 50S ribosomal protein L13 48.97 9 5 
304373067 YP_003856276.1 E0TLF5 50S ribosomal protein L11 48.67 9 4 
304373308 YP_003856517.1 E0TKW2 Thiol peroxidase 48.26 15 5 
304373187 YP_003856396.1 E0TK39 50S ribosomal protein L2 47.69 38 9 
304373351 YP_003856560.1 E0TL79 Probable purine nucleoside phosphorylase transmembrane protein 47.41 48 11 
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304373349 YP_003856558.1 E0TL77 Deoxyribose-phosphate aldolase 1 45.74 27 7 
365897170 YP_004956716.1 E4PYU7 transcription elongation factor 45.12 12 5 
304373432 YP_003856641.1 E0TLN2 ATP synthase subunit B 44.83 64 12 
304373174 YP_003856383.1 E0TK26 50S ribosomal protein L18 44.72 29 6 
304373178 YP_003856387.1 E0TK30 50S ribosomal protein L5 44.20 41 6 
304373021 YP_003856230.1 E0TL34 Proton-translocating ATPase, beta subunit 42.55 43 13 
304373292 YP_003856501.1 E0TKU6 Pyruvate kinase 41.89 97 15 
304373191 YP_003856400.1 E0TK43 30S ribosomal protein S10 41.35 11 5 
304373259 YP_003856468.1 E0TKI7 prolyl-tRNA synthetase 40.42 58 12 
304373425 YP_003856634.1 E0TLM5 Pyrophosphatephospho hydrolase 40.22 27 6 
304372857 YP_003856066.1 E0TK82 50S ribosomal protein L7/L12 39.84 13 5 
304373096 YP_003856305.1 E0TLI4 Phosphate acetyltransferase 38.99 49 10 
304372890 YP_003856099.1 E0TKB5 Heat shock protein 38.85 34 10 
304373200 YP_003856409.1 E0TK52 Elongation factor Ts 38.51 47 9 
304373227 YP_003856436.1 E0TKF5 Thioredoxin reductase 38.03 44 10 
304372872 YP_003856081.1 E0TK97 Histone-like DNA-binding protein 37.78 12 2 
304373073 YP_003856282.1 E0TLG1 Lipoprotein 37.72 46 16 
304373105 YP_003856314.1 E0TLJ3 Phosphopentomutase 37.63 45 10 
304373301 YP_003856510.1 E0TKV5 
Dihydrolipoamide acetyltransferase component of pyruvate 
dehydrogenase complex 37.50 28 8 
304373006 YP_003856215.1 E0TL19 5'-nucleotidase 37.34 35 11 
304373041 YP_003856250.1 E0TL54 Transcription antitermination protein 36.87 14 5 
304373201 YP_003856410.1 E0TK53 30S ribosomal protein S2 36.23 36 9 
304373222 YP_003856431.1 E0TKF0 Phosphoglycerate kinase 36.07 111 10 
304372918 YP_003856127.1 E0TKL0 Ribose-phosphate pyrophosphokinase 35.89 48 9 
304372865 YP_003856074.1 E0TK90 uncharactized lipoprotein 35.72 144 20 
304373172 YP_003856381.1 E0TK24 50S ribosomal protein L15 35.14 9 5 
304373246 YP_003856455.1 E0TKH4 hypothetical protein MHR_0460 34.86 16 10 
304373185 YP_003856394.1 E0TK37 50S ribosomal protein L22 34.71 24 5 
304372813 YP_003856022.1 E0TJW3 dihydrolipoamide dehydrogenase 34.34 118 14 
304373370 YP_003856579.1 E0TL98 LemA-family protein 33.91 39 4 
304373287 YP_003856496.1 E0TKU1 30S ribosomal protein S7 33.33 13 6 
304373376 YP_003856585.1 E0TLA4 Ribosome recycling factor 33.33 7 3 
304373068 YP_003856277.1 E0TLF6 50S ribosomal protein L1 33.04 31 9 
304373056 YP_003856265.1 E0TL69 Glycerol-3-phosphate dehydrogenase, putative 32.47 17 8 
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304372864 YP_003856073.1 E0TK89 uncharactized lipoprotein 31.91 95 17 
304373182 YP_003856391.1 E0TK34 50S ribosomal protein L29 31.88 4 2 
304372959 YP_003856168.1 E0TKQ1 Serine hydroxymethyltransferase 3 31.82 40 11 
304373243 YP_003856452.1 E0TKH1 Pentitol phosphotransferase enzyme II, A component 31.41 5 3 
304373332 YP_003856541.1 E0TKY6 6-phosphofructokinase 30.96 49 9 
304373350 YP_003856559.1 E0TL78 Thymidine phosphorylase 30.86 28 11 
304373158 YP_003856367.1 E0TK10 Probable transketolase transmembrane protein 30.41 80 17 
304373181 YP_003856390.1 E0TK33 30S ribosomal protein S17 30.00 11 3 
304373443 YP_003856652.1 E0TLP3 ribonucleotide-diphosphate reductase subunit alpha 29.54 39 17 
304373061 YP_003856270.1 E0TLE9 Fatty acid-binding protein DegV-like protein 29.41 11 5 
304373176 YP_003856385.1 E0TK28 30S ribosomal protein S8 29.23 8 3 
304373129 YP_003856338.1 E0TLL7 Nicotinate phosphoribosyltransferase 28.96 14 8 
304372862 YP_003856071.1 E0TK87 hypothetical protein MHR_0059 28.87 16 5 
304373175 YP_003856384.1 E0TK27 50S ribosomal protein L6 28.49 17 3 
304373275 YP_003856484.1 E0TKS9 Translation initiation factor IF-2 28.31 43 11 
304373380 YP_003856589.1 E0TLA8 2,3-bisphosphoglycerate-independent phosphoglycerate mutase 28.27 23 10 
304373242 YP_003856451.1 E0TKH0 hexulose 6 phosphate synthase 28.12 12 8 
304373179 YP_003856388.1 E0TK31 50S ribosomal protein L24 28.04 4 2 
304373305 YP_003856514.1 E0TKV9 50S ribosomal protein L20 27.73 17 4 
304373407 YP_003856616.1 E0TLD5 P60-like lipoprotein 27.66 31 10 
304373156 YP_003856365.1 E0TK08 Oligoendopeptidase F 27.63 44 12 
304373339 YP_003856548.1 E0TKZ3 putative intracellular protease/amidase 27.62 8 3 
304373436 YP_003856645.1 E0TLN6 hypothetical protein MHR_0657 27.55 5 4 
304373003 YP_003856212.1 E0TL16 aminopeptidase 27.15 41 8 
304372900 YP_003856109.1 E0TKC5 Expressed protein 26.92 4 2 
304372949 YP_003856158.1 E0TKP1 Xaa-pro aminopeptidase 26.91 32 6 
304373146 YP_003856355.1 E0TJZ8 cell division protein FtsZ 26.47 22 8 
304373391 YP_003856600.1 E0TLB9 hypothetical 33 kDa chaperonin 26.44 28 8 
304372840 YP_003856049.1 E0TK65 NADH oxidase 26.42 197 12 
304373433 YP_003856642.1 E0TLN3 ATP synthase subunit A 26.23 29 8 
304373049 YP_003856258.1 E0TL62 S-adenosylmethionine synthetase 25.79 24 8 
304373190 YP_003856399.1 E0TK42 50S ribosomal protein L3 25.54 11 4 
304373032 YP_003856241.1 E0TL45 50S ribosomal protein L9 25.52 5 3 
304373189 YP_003856398.1 E0TK41 50S ribosomal protein L4 24.75 23 6 
304372852 YP_003856061.1 E0TK77 5'-nucleotidase 24.68 44 12 
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304373281 YP_003856490.1 E0TKT5 Predicted kinase, related to dihydroxyacetone kinase 24.63 23 9 
304373184 YP_003856393.1 E0TK36 30S ribosomal protein S3 24.28 17 5 
304373240 YP_003856449.1 E0TKG8 Sugar isomerase SgaE 24.18 13 4 
304373288 YP_003856497.1 E0TKU2 translation elongation factor G 24.07 85 13 
304372964 YP_003856173.1 E0TKQ6 xylose ABC transporter ATP-binding protein 23.97 29 8 
304373318 YP_003856527.1 E0TKX2 cell division protease FtsH 23.97 57 10 
304373149 YP_003856358.1 E0TK01 Oligoendopeptidase F 23.32 51 11 
304373428 YP_003856637.1 E0TLM8 TrkA-C domain protein 23.11 9 3 
304373420 YP_003856629.1 E0TLM0 Ribose 5-phosphate isomerase B 22.88 7 3 
304373418 YP_003856627.1 E0TLE6 Lipoprotein 22.62 86 16 
304373312 YP_003856521.1 E0TKW6 Single-stranded DNA-binding protein 22.35 13 4 
304373199 YP_003856408.1 E0TK51 Signal recognition particle protein 22.25 21 9 
304372996 YP_003856205.1 E0TL09 Lipoprotein 22.00 44 13 
304372891 YP_003856100.1 E0TKB6 Arginyl-tRNA synthetase 1 21.95 14 8 
304373143 YP_003856352.1 E0TJZ5 Glycerol-3-phosphate dehydrogenase [NAD(P)+] 21.92 15 6 
304372876 YP_003856085.1 E0TKA1 P59-like protein 21.68 14 7 
304373167 YP_003856376.1 E0TK19 30S ribosomal protein S13 21.31 3 2 
304373019 YP_003856228.1 E0TL32 ATP synthase subunit alpha 21.06 21 8 
304373334 YP_003856543.1 E0TKY8 Membrane nuclease, lipoprotein 20.67 12 6 
304373284 YP_003856493.1 E0TKT8 Protein P115 20.63 68 17 
304373069 YP_003856278.1 E0TLF7 CTP synthase 20.55 29 8 
304373408 YP_003856617.1 E0TLD6 hypothetical protein MHR_0628 20.36 26 10 
304372858 YP_003856067.1 E0TK83 DNA-directed RNA polymerase subunit beta 20.15 58 15 
304372952 YP_003856161.1 E0TKP4 Seryl-trna synthetase protein 20.14 13 5 
304373188 YP_003856397.1 E0TK40 50S ribosomal protein L23 20.12 10 3 
304372859 YP_003856068.1 E0TK84 DNA-directed RNA polymerase subunit beta' 20.00 62 20 
304373029 YP_003856238.1 E0TL42 Fructose permease IIC component 19.48 14 9 
304373320 YP_003856529.1 E0TKX4 Peptidyl-tRNA hydrolase 19.37 9 4 
304373010 YP_003856219.1 E0TL23 GTPase obg 19.14 22 7 
304373458 YP_003856667.1 E0TLQ8 Membrane protein oxaA 18.95 23 9 
304373124 YP_003856333.1 E0TLL2 Expressed protein 18.91 8 3 
304373173 YP_003856382.1 E0TK25 30S ribosomal protein S5 18.83 5 4 
304372946 YP_003856155.1 E0TKN8 aspartyl tRNA synthetase 18.67 21 7 
304373241 YP_003856450.1 E0TKG9 Probable L-ribulose-5-phosphate 3-epimerase ulaE 18.52 18 5 
304373346 YP_003856555.1 E0TL74 ATP-dependent protease La 18.21 33 11 
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304373013 YP_003856222.1 E0TL26 putative acyl carrier protein 18.06 6 2 
304373116 YP_003856325.1 E0TLK4 Peptide chain release factor 1 18.01 11 5 
304372903 YP_003856112.1 E0TKC8 hypothetical protein MHR_0102 17.89 2 2 
304373017 YP_003856226.1 E0TL30 ATP synthase subunit b 17.46 9 2 
304373441 YP_003856650.1 E0TLP1 Ribonucleoside-diphosphate reductase beta chai 17.44 11 4 
304372807 YP_003856016.1 E0TJV7 DNA polymerase III beta subunit 17.38 13 7 
304373335 YP_003856544.1 E0TKY9 ATP-dependent serine proteinase, heat shock protein 16.99 20 7 
304373385 YP_003856594.1 E0TLB3 Threonyl-tRNA synthetase 16.35 17 7 
304373204 YP_003856413.1 E0TK56 Probable 1-acyl-sn-glycerol-3-phosphate acyltransferase 16.34 9 3 
304373414 YP_003856623.1 E0TLE2 Oligopeptide transport system permease protein 16.3 27 8 
304373066 YP_003856275.1 E0TLF4 Putative asparaginyl-trna synthetase protein 16.14 15 5 
304373353 YP_003856562.1 E0TL81 deoxycytidylate deaminase 16.05 11 2 
304373282 YP_003856491.1 E0TKT6 Phosphate acyltransferase 16.01 6 4 
304373286 YP_003856495.1 E0TKU0 30S ribosomal protein S12 15.83 4 2 
304373415 YP_003856624.1 E0TLE3 Oligopeptide ABC transporter ATP binding prote 15.82 15 6 
304372879 YP_003856088.1 E0TKA4 Ag 243-5 protein 15.64 75 6 
304372886 YP_003856095.1 E0TKB1 30S ribosomal protein S4 15.61 5 3 
304373147 YP_003856356.1 E0TJZ9 hypothetical protein MHR_0354 15.48 12 4 
304373431 YP_003856640.1 E0TLN1 hypothetical protein MHR_0652 15.12 16 4 
304373331 YP_003856540.1 E0TKY5 hypothetical protein MHR_0546 14.91 10 6 
304373221 YP_003856430.1 E0TKE9 P3 14.58 54 5 
304373352 YP_003856561.1 E0TL80 Protein translocase subunit secA 14.57 17 11 
304373145 YP_003856354.1 E0TJZ7 Ribosomal RNA small subunit methyltransferase H 14.43 5 2 
304373435 YP_003856644.1 E0TLN5 hypothetical protein MHR_0656 14.38 7 4 
304372811 YP_003856020.1 E0TJW1 Putative MgpA-like protein 14.15 5 3 
304373366 YP_003856575.1 E0TL94 ABC transporter ATP-binding protein 14.13 26 6 
304373045 YP_003856254.1 E0TL58 DNA gyrase subunit B 14.06 11 7 
304373348 YP_003856557.1 E0TL76 uracil phosphoribosyltransferase 14.01 7 3 
304373295 YP_003856504.1 E0TKU9 NH(3)-dependent NAD(+) synthetase 13.99 5 2 
304373157 YP_003856366.1 E0TK09 Elongation factor P 13.98 3 2 
304372898 YP_003856107.1 E0TKC3 Triacylglycerol lipase 13.86 14 3 
304373194 YP_003856403.1 E0TK46 Probable endonuclease 4 13.82 4 2 
304373442 YP_003856651.1 E0TLP2 ribonucleotide reductase stimulatory protein 13.73 3 2 
304373423 YP_003856632.1 E0TLM3 hypothetical protein MHR_0644 13.70 18 6 
304373198 YP_003856407.1 E0TK50 Glycyl tRNA synthetase 13.54 14 5 
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304373357 YP_003856566.1 E0TL85 Glutamyl-tRNA amidotransferase subunit A 13.54 13 6 
304372915 YP_003856124.1 E0TKK7 DNA gyrase subunit A 13.45 13 8 
304372916 YP_003856125.1 E0TKK8 Peptide methionine sulfoxide reductase msrA 13.33 7 2 
304373358 YP_003856567.1 E0TL86 Glutamyl-tRNA amidotransferase subunit B 13.29 10 3 
304373294 YP_003856503.1 E0TKU8 hypothetical protein MHR_0508 13.22 6 2 
304372812 YP_003856021.1 E0TJW2 MgpA-like DHH family phosphoesterase 13.08 7 3 
304373372 YP_003856581.1 E0TLA0 Glucose-6-phosphate isomerase A 12.98 17 5 
304372908 YP_003856117.1 E0TKD3 Hypoxanthine phosphoribosyltransferase 12.64 6 2 
304373368 YP_003856577.1 E0TL96 Neutrophil activating factor 12.50 18 2 
304373144 YP_003856353.1 E0TJZ6 Protein mraZ 12.24 4 2 
304372910 YP_003856119.1 E0TKK2 ABC transporter, ATP-binding protein 12.17 7 2 
304373365 YP_003856574.1 E0TL93 tRNA modification GTPase mnmE 12.16 9 5 
304373081 YP_003856290.1 E0TLG9 hypothetical protein MHR_0285 12.14 17 8 
304373323 YP_003856532.1 E0TKX7 alanyl-tRNA synthetase 11.84 16 7 
304373084 YP_003856293.1 E0TLH2 50S ribosomal protein L19 11.67 5 2 
304373058 YP_003856267.1 E0TL71 Glycerophosphodiester phosphodiesterase family protein 11.62 5 2 
304373249 YP_003856458.1 E0TKH7 VACB-like ribonuclease II 11.53 27 7 
304373057 YP_003856266.1 E0TL70 hypothetical protein MHR_0260 11.15 18 5 
304372933 YP_003856142.1 E0TKM5 Isoleucyl tRNA synthetase 11.10 19 8 
304372836 YP_003856045.1 E0TK61 molecular chaperone DnaJ 11.02 5 4 
304373359 YP_003856568.1 E0TL87 Putative transcriptional regulator 10.80 5 2 
304373220 YP_003856429.1 E0TKE8 Expressed protein 10.64 4 3 
304372907 YP_003856116.1 E0TKD2 Ribosomal RNA small subunit methyltransferase I 10.61 3 2 
304372909 YP_003856118.1 E0TKD4 ABC transporter, ATP-binding protein 10.53 8 2 
304373410 YP_003856619.1 E0TLD8 hypothetical protein MHR_0630 10.40 3 2 
304373326 YP_003856535.1 E0TKY0 hypothetical Phosphatase yidA 10.37 3 2 
304373228 YP_003856437.1 E0TKF6 prolipoprotein diacylglyceryl transferase 10.29 5 2 
304373090 YP_003856299.1 E0TLH8 hypothetical protein MHR_0294 9.98 14 3 
304373065 YP_003856274.1 E0TLF3 Glycosyltransferase 9.97 4 3 
304373115 YP_003856324.1 E0TLK3 ABC transporter ATP-binding protein 9.97 10 3 
304373152 YP_003856361.1 E0TK04 Oligopeptide transport system permease protein 9.91 5 3 
304373273 YP_003856482.1 E0TKK1 ABC transporter xylose-binding lipoprotein 9.43 11 4 
304372899 YP_003856108.1 E0TKC4 Lipoyltransferase and lipoate-protein ligase 9.12 6 4 
304373093 YP_003856302.1 E0TLI1 COF family HAD hydrolase protein 9.09 5 2 
304373367 YP_003856576.1 E0TL95 hypothetical Y+L amino acid transporter 1 8.88 7 4 
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304372932 YP_003856141.1 E0TKM4 Topoisomerase IV subunit A 8.63 13 6 
304373272 YP_003856481.1 E0TKK0 DNA polymerase III alpha subunit 8.58 19 6 
304373239 YP_003856448.1 E0TKG7 hypothetical protein MHR_0453 8.56 2 2 
304373456 YP_003856665.1 E0TLQ6 Lipoprotein 8.37 16 4 
304372873 YP_003856082.1 E0TK98 GTP-binding protein LepA 8.35 5 3 
304373416 YP_003856625.1 E0TLE4 Oligopeptide transport system permease protein 8.33 10 2 
304373114 YP_003856323.1 E0TLK2 ABC transporter permease protein 8.27 34 14 
304373030 YP_003856239.1 E0TL43 Leucyl-trna synthetase protein 8.25 17 5 
304372945 YP_003856154.1 E0TKN7 Histidyl-tRNA synthetase 8.22 7 2 
304373347 YP_003856556.1 E0TL75 hypothetical protein MHR_0562 8.10 5 2 
304373063 YP_003856272.1 E0TLF1 ATP-dependent helicase PcrA 8.09 10 4 
304373411 YP_003856620.1 E0TLD9 Chromosome replication initiation and membrane attachment protein 7.95 10 2 
304373310 YP_003856519.1 E0TKW4 Predicted GTPase, probable translation factor 7.90 4 2 
304373263 YP_003856472.1 E0TKJ1 Phosphotransferase system (PTS) enzyme I 7.88 8 4 
304372902 YP_003856111.1 E0TKC7 DNA polymerase III gamma and tau subunit 7.87 6 4 
304373046 YP_003856255.1 E0TL59 101 kDa protein 7.76 9 5 
304373009 YP_003856218.1 E0TL22 Phosphotransferase enzyme family protein 7.47 3 2 
304372867 YP_003856076.1 E0TK92 ABC transporter permease protein 7.29 6 3 
304372877 YP_003856086.1 E0TKA2 Amino acid or sugar ABC transport system, permease protein 7.22 9 3 
304372931 YP_003856140.1 E0TKM3 Topoisomerase IV subunit B 7.09 6 3 
304373054 YP_003856263.1 E0TL67 Cation-transporting ATPase family protein 6.90 4 3 
304373153 YP_003856362.1 E0TK05 Oligopeptide transport system permease protein 6.86 3 2 
304373076 YP_003856285.1 E0TLG4 lipoate-protein ligase A 6.65 13 3 
304373218 YP_003856427.1 E0TKE6 Hexosephosphate transport protein 6.64 11 4 
304372889 YP_003856098.1 E0TKB4 Heat-inducible transcription repressor hrcA 6.53 4 2 
304373382 YP_003856591.1 E0TLB0 Putative ATP-binding helicase protein 6.49 12 6 
304373434 YP_003856643.1 E0TLN4 hypothetical protein MHR_0655 6.32 3 3 
304373044 YP_003856253.1 E0TL57 Ser/Thr protein phosphatase family protein 6.30 2 2 
304373002 YP_003856211.1 E0TL15 DNA-cytosine methyltransferase family protein 6.14 4 2 
304373043 YP_003856252.1 E0TL56 hypothetical protein MHR_0246 6.13 2 2 
304372920 YP_003856129.1 E0TKL2 uncharactized deoxyribonuclease yabD 6.12 6 2 
304373317 YP_003856526.1 E0TKX1 Lysyl-tRNA synthetase 1 5.89 7 2 
304373127 YP_003856336.1 E0TLL5 methionyl tRNA synthetase 5.88 5 3 
304373101 YP_003856310.1 E0TLI9 aminotransferase class V 5.74 3 2 
304373277 YP_003856486.1 E0TKT1 Transcription termination-antitermination factor nusA 5.21 7 3 
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304373118 YP_003856327.1 E0TLK6 Glutamyl-tRNA synthetase 5.14 6 3 
304373374 YP_003856583.1 E0TLA2 DNA polymerase III alpha subunit 4.46 16 4 
304373328 YP_003856537.1 E0TKY2 Phenylalanyl-tRNA synthetase beta chain 3.98 6 2 
304372814 YP_003856023.1 E0TJW4 valyl-tRNA synthetase 3.76 3 2 
304373438 YP_003856647.1 E0TLN8 Lipoprotein 3.56 5 2 
304373219 YP_003856428.1 E0TKE7 MG2+ ion transporter 3.46 4 2 
304373309 YP_003856518.1 E0TKW3 hypothetical protein MHR_0523 3.33 5 2 
304373151 YP_003856360.1 E0TK03 hypothetical protein MHR_0358 2.87 8 6 
304372846 YP_003856055.1 E0TK71 101 kDa protein 2.74 2 2 
304373150 YP_003856359.1 E0TK02 Lipoprotein 2.55 3 3 
304373095 YP_003856304.1 E0TLI3 Putative lipoprotein 2.28 4 2 
304373089 YP_003856298.1 E0TLH7 hypothetical protein MHR_0293 1.80 4 4 
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304373345 YP_003856554.1 E0TL73 Elongation factor Tu 66.67 378 20 
304372963 YP_003856172.1 E0TKQ5 hypothetical protein MHR_0162 65.77 526 23 
304373302 YP_003856511.1 E0TKV6 Pyruvate dehydrogenase E1 component beta subunit 63.41 243 19 
304373392 YP_003856601.1 E0TLC0 Glyceraldehyde 3-phosphate dehydrogenase C 61.86 224 17 
304372893 YP_003856102.1 E0TKB8 Fructose-bisphosphate aldolase class II transmembrane protein 61.81 49 12 
304373405 YP_003856614.1 E0TLD3 High affinity transport system protein p37 60.94 130 23 
304373112 YP_003856321.1 E0TLK0 FMN-dependent NADH-azoreductase 60.20 224 11 
304373303 YP_003856512.1 E0TKV7 Pyruvate dehydrogenase E1-alpha subunit 60.11 227 19 
304373244 YP_003856453.1 E0TKH2 Pentitol phosphotransferase enzyme II, B component 60.00 17 4 
304373217 YP_003856426.1 E0TKE5 L-lactate dehydrogenase 59.74 425 18 
304373166 YP_003856375.1 E0TK18 DNA-directed RNA polymerase subunit alpha 59.46 85 15 
304373258 YP_003856467.1 E0TKI6 Thiol-disulfide isomerase and thioredoxin 59.41 59 5 
304372835 YP_003856044.1 E0TK60 aminopeptidase 57.83 106 22 
304373097 YP_003856306.1 E0TLI5 Acetate kinase AckA 57.46 93 18 
304373113 YP_003856322.1 E0TLK1 FMN-dependent NADH-azoreductase 1 56.19 89 8 
304373187 YP_003856396.1 E0TK39 50S ribosomal protein L2 55.16 56 12 
304373300 YP_003856509.1 E0TKV4 pyruvate dehydrogenase E3 component dihydrolipoamide dehydrogenase 54.53 167 26 
304373393 YP_003856602.1 E0TLC1 molecular chaperone DnaK 53.43 447 28 
304372926 YP_003856135.1 E0TKL8 30S ribosomal protein S9 51.52 20 4 
304373016 YP_003856225.1 E0TL29 ATP synthase C chain, sodium ion specific lipid-binding protein 51.38 23 3 
304373255 YP_003856464.1 E0TKI3 Enolase 49.56 167 17 
304373096 YP_003856305.1 E0TLI4 Phosphate acetyltransferase 49.06 47 11 
304372925 YP_003856134.1 E0TKL7 50S ribosomal protein L13 48.97 19 5 
304373314 YP_003856523.1 E0TKW8 adenine phosphoribosyltransferase 48.04 25 6 
304373287 YP_003856496.1 E0TKU1 30S ribosomal protein S7 46.79 15 6 
304372890 YP_003856099.1 E0TKB5 Heat shock protein 46.54 18 10 
304373264 YP_003856473.1 E0TKJ2 50S ribosomal protein L21 45.45 9 5 
304373068 YP_003856277.1 E0TLF6 50S ribosomal protein L1 45.22 28 7 
304373390 YP_003856599.1 E0TLB8 Trigger factor 45.17 166 21 
304373351 YP_003856560.1 E0TL79 Probable purine nucleoside phosphorylase transmembrane protein 44.40 39 9 
304373349 YP_003856558.1 E0TL77 Deoxyribose-phosphate aldolase 1 44.39 26 6 
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304372957 YP_003856166.1 E0TKP9 Triosephosphate isomerase 43.21 22 7 
304373174 YP_003856383.1 E0TK26 50S ribosomal protein L18 43.09 45 5 
304373179 YP_003856388.1 E0TK31 50S ribosomal protein L24 42.99 7 3 
304373084 YP_003856293.1 E0TLH2 50S ribosomal protein L19 41.67 9 6 
304373292 YP_003856501.1 E0TKU6 Pyruvate kinase 40.63 74 16 
304373409 YP_003856618.1 E0TLD7 membrane protease subunits, stomatin/prohibitin-like protein, partial 40.00 13 5 
304373185 YP_003856394.1 E0TK37 50S ribosomal protein L22 39.67 25 5 
304373073 YP_003856282.1 E0TLG1 Lipoprotein 39.52 64 17 
304373176 YP_003856385.1 E0TK28 30S ribosomal protein S8 39.23 11 4 
304373175 YP_003856384.1 E0TK27 50S ribosomal protein L6 39.11 43 5 
304373021 YP_003856230.1 E0TL34 Proton-translocating ATPase, beta subunit 38.72 54 12 
304372964 YP_003856173.1 E0TKQ6 xylose ABC transporter ATP-binding protein 38.58 68 17 
304372872 YP_003856081.1 E0TK97 Histone-like DNA-binding protein 37.78 3 2 
304373312 YP_003856521.1 E0TKW6 Single-stranded DNA-binding protein 37.43 11 5 
304373108 YP_003856317.1 E0TLJ6 Methyltransferase type 11 36.72 12 4 
304373003 YP_003856212.1 E0TL16 aminopeptidase 36.01 58 12 
304373041 YP_003856250.1 E0TL54 Transcription antitermination protein 35.86 18 5 
304373335 YP_003856544.1 E0TKY9 ATP-dependent serine proteinase, heat shock protein 35.52 88 20 
304373376 YP_003856585.1 E0TLA4 Ribosome recycling factor 35.48 14 4 
304373222 YP_003856431.1 E0TKF0 Phosphoglycerate kinase 34.58 60 11 
304373246 YP_003856455.1 E0TKH4 hypothetical protein MHR_0460 34.00 24 8 
304373227 YP_003856436.1 E0TKF5 Thioredoxin reductase 33.11 35 10 
304373301 YP_003856510.1 E0TKV5 
Dihydrolipoamide acetyltransferase component of pyruvate 
dehydrogenase complex 33.01 41 10 
304373178 YP_003856387.1 E0TK30 50S ribosomal protein L5 32.60 27 4 
304373308 YP_003856517.1 E0TKW2 Thiol peroxidase 31.98 26 4 
304373167 YP_003856376.1 E0TK19 30S ribosomal protein S13 31.97 7 3 
304373182 YP_003856391.1 E0TK34 50S ribosomal protein L29 31.88 5 3 
304373200 YP_003856409.1 E0TK52 Elongation factor Ts 31.08 40 8 
304373032 YP_003856241.1 E0TL45 50S ribosomal protein L9 31.03 9 3 
304373146 YP_003856355.1 E0TJZ8 cell division protein FtsZ 31.02 12 8 
304373259 YP_003856468.1 E0TKI7 prolyl-tRNA synthetase 30.83 35 10 
304373201 YP_003856410.1 E0TK53 30S ribosomal protein S2 30.54 31 7 
304373288 YP_003856497.1 E0TKU2 translation elongation factor G 30.52 52 15 
304372840 YP_003856049.1 E0TK65 NADH oxidase 30.35 146 12 
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304372857 YP_003856066.1 E0TK82 50S ribosomal protein L7/L12 30.08 22 4 
304373165 YP_003856374.1 E0TK17 50S ribosomal protein L17 30.00 10 4 
304373181 YP_003856390.1 E0TK33 30S ribosomal protein S17 30.00 12 3 
304373370 YP_003856579.1 E0TL98 LemA-family protein 30.00 13 4 
304373184 YP_003856393.1 E0TK36 30S ribosomal protein S3 29.22 19 7 
304373432 YP_003856641.1 E0TLN2 ATP synthase subunit B 29.09 22 8 
304373149 YP_003856358.1 E0TK01 Oligoendopeptidase F 28.74 51 14 
304373186 YP_003856395.1 E0TK38 30S ribosomal protein S19 28.57 10 2 
304372862 YP_003856071.1 E0TK87 hypothetical protein MHR_0059 28.52 13 4 
304373158 YP_003856367.1 E0TK10 Probable transketolase transmembrane protein 28.46 48 14 
304373348 YP_003856557.1 E0TL76 uracil phosphoribosyltransferase 28.02 15 6 
304373305 YP_003856514.1 E0TKV9 50S ribosomal protein L20 27.73 6 3 
304373428 YP_003856637.1 E0TLM8 TrkA-C domain protein 27.56 7 4 
304372949 YP_003856158.1 E0TKP1 Xaa-pro aminopeptidase 26.91 16 6 
365897170 YP_004956716.1 E4PYU7 transcription elongation factor 26.83 8 4 
304372865 YP_003856074.1 E0TK90 uncharactized lipoprotein 26.69 30 14 
304373189 YP_003856398.1 E0TK41 50S ribosomal protein L4 26.44 21 6 
304373191 YP_003856400.1 E0TK43 30S ribosomal protein S10 25.96 8 2 
304373023 YP_003856232.1 E0TL36 101 kDa protein 25.87 59 19 
304373350 YP_003856559.1 E0TL78 Thymidine phosphorylase 25.29 19 9 
304373190 YP_003856399.1 E0TK42 50S ribosomal protein L3 25.11 14 6 
304373010 YP_003856219.1 E0TL23 GTPase obg 24.88 20 8 
304373275 YP_003856484.1 E0TKS9 Translation initiation factor IF-2 24.83 25 10 
304373372 YP_003856581.1 E0TLA0 Glucose-6-phosphate isomerase A 24.68 27 8 
304373086 YP_003856295.1 E0TLH4 30S ribosomal protein S16 24.44 4 2 
304373188 YP_003856397.1 E0TK40 50S ribosomal protein L23 24.39 29 4 
304373418 YP_003856627.1 E0TLE6 Lipoprotein 23.57 65 17 
304373240 YP_003856449.1 E0TKG8 Sugar isomerase SgaE 22.95 17 4 
304373410 YP_003856619.1 E0TLD8 hypothetical protein MHR_0630 22.54 4 3 
304373286 YP_003856495.1 E0TKU0 30S ribosomal protein S12 22.30 6 3 
304372859 YP_003856068.1 E0TK84 DNA-directed RNA polymerase subunit beta' 22.25 49 20 
304373105 YP_003856314.1 E0TLJ3 Phosphopentomutase 22.22 17 5 
304373093 YP_003856302.1 E0TLI1 COF family HAD hydrolase protein 22.08 13 5 
304373318 YP_003856527.1 E0TKX2 cell division protease FtsH 22.04 37 9 
304373129 YP_003856338.1 E0TLL7 Nicotinate phosphoribosyltransferase 21.79 11 5 
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304373425 YP_003856634.1 E0TLM5 Pyrophosphatephospho hydrolase 21.74 19 3 
304373144 YP_003856353.1 E0TJZ6 Protein mraZ 21.09 4 3 
304373242 YP_003856451.1 E0TKH0 hexulose 6 phosphate synthase 20.98 7 4 
304373173 YP_003856382.1 E0TK25 30S ribosomal protein S5 20.63 15 5 
304373183 YP_003856392.1 E0TK35 50S ribosomal protein L16 20.44 11 2 
304373332 YP_003856541.1 E0TKY6 6-phosphofructokinase 20.43 33 6 
304372864 YP_003856073.1 E0TK89 uncharactized lipoprotein 20.36 33 11 
304373198 YP_003856407.1 E0TK50 Glycyl tRNA synthetase 20.31 29 8 
304373019 YP_003856228.1 E0TL32 ATP synthase subunit alpha 20.28 21 9 
304373368 YP_003856577.1 E0TL96 Neutrophil activating factor 20.14 7 2 
304373284 YP_003856493.1 E0TKT8 Protein P115 20.12 36 15 
304373006 YP_003856215.1 E0TL19 5'-nucleotidase 20.10 13 5 
304373147 YP_003856356.1 E0TJZ9 hypothetical protein MHR_0354 19.90 11 5 
304373194 YP_003856403.1 E0TK46 Probable endonuclease 4 19.64 9 3 
304373438 YP_003856647.1 E0TLN8 Lipoprotein 19.24 35 12 
304373081 YP_003856290.1 E0TLG9 hypothetical protein MHR_0285 19.22 35 13 
304373169 YP_003856378.1 E0TK21 Methionine aminopeptidase 18.73 4 3 
304373243 YP_003856452.1 E0TKH1 Pentitol phosphotransferase enzyme II, A component 18.59 8 2 
304373408 YP_003856617.1 E0TLD6 hypothetical protein MHR_0628 18.14 25 11 
304373313 YP_003856522.1 E0TKW7 30S ribosomal protein S6 18.13 4 3 
304373013 YP_003856222.1 E0TL26 putative acyl carrier protein 18.06 5 2 
304372959 YP_003856168.1 E0TKQ1 Serine hydroxymethyltransferase 3 17.94 17 4 
304373156 YP_003856365.1 E0TK08 Oligoendopeptidase F 17.60 20 7 
304373249 YP_003856458.1 E0TKH7 VACB-like ribonuclease II 17.58 19 9 
304373172 YP_003856381.1 E0TK24 50S ribosomal protein L15 17.57 14 3 
304372813 YP_003856022.1 E0TJW3 dihydrolipoamide dehydrogenase 17.07 21 7 
304373380 YP_003856589.1 E0TLA8 2,3-bisphosphoglycerate-independent phosphoglycerate mutase 16.96 22 8 
304372852 YP_003856061.1 E0TK77 5'-nucleotidase 16.74 18 8 
304373416 YP_003856625.1 E0TLE4 Oligopeptide transport system permease protein 16.41 8 4 
304373061 YP_003856270.1 E0TLE9 Fatty acid-binding protein DegV-like protein 16.26 4 3 
304373281 YP_003856490.1 E0TKT5 Predicted kinase, related to dihydroxyacetone kinase 16.18 23 6 
304372886 YP_003856095.1 E0TKB1 30S ribosomal protein S4 16.10 11 4 
304373082 YP_003856291.1 E0TLH0 hypothetical protein MHR_0286 16.05 5 4 
304373029 YP_003856238.1 E0TL42 Fructose permease IIC component 15.90 21 8 
304373407 YP_003856616.1 E0TLD5 P60-like lipoprotein 15.57 15 6 
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304373046 YP_003856255.1 E0TL59 101 kDa protein 15.52 31 12 
304372996 YP_003856205.1 E0TL09 Lipoprotein 15.40 23 10 
304373283 YP_003856492.1 E0TKT7 Ribonuclease III 15.11 3 2 
304373152 YP_003856361.1 E0TK04 Oligopeptide transport system permease protein 15.09 11 5 
304373151 YP_003856360.1 E0TK03 hypothetical protein MHR_0358 14.85 73 29 
304373456 YP_003856665.1 E0TLQ6 Lipoprotein 14.61 18 8 
304373310 YP_003856519.1 E0TKW4 Predicted GTPase, probable translation factor 14.44 9 4 
304373030 YP_003856239.1 E0TL43 Leucyl-trna synthetase protein 14.21 18 8 
304373433 YP_003856642.1 E0TLN3 ATP synthase subunit A 14.20 16 6 
304373221 YP_003856430.1 E0TKE9 P3 13.89 35 7 
304373199 YP_003856408.1 E0TK51 Signal recognition particle protein 13.71 13 4 
304372858 YP_003856067.1 E0TK83 DNA-directed RNA polymerase subunit beta 13.67 24 15 
304373017 YP_003856226.1 E0TL30 ATP synthase subunit b 13.23 5 2 
304372812 YP_003856021.1 E0TJW2 MgpA-like DHH family phosphoesterase 13.08 8 3 
304373116 YP_003856325.1 E0TLK4 Peptide chain release factor 1 13.02 8 3 
304373326 YP_003856535.1 E0TKY0 hypothetical Phosphatase yidA 12.96 6 2 
304373206 YP_003856415.1 E0TK58 Segregation and condensation protein B 12.81 2 2 
304372952 YP_003856161.1 E0TKP4 Seryl-trna synthetase protein 12.80 12 3 
304373170 YP_003856379.1 E0TK22 adenylate kinase 12.61 3 2 
304372946 YP_003856155.1 E0TKN8 aspartyl tRNA synthetase 12.57 12 6 
304373204 YP_003856413.1 E0TK56 Probable 1-acyl-sn-glycerol-3-phosphate acyltransferase 12.45 6 2 
304373414 YP_003856623.1 E0TLE2 Oligopeptide transport system permease protein 12.39 13 8 
304372933 YP_003856142.1 E0TKM5 Isoleucyl tRNA synthetase 12.22 16 9 
304373180 YP_003856389.1 E0TK32 50S ribosomal protein L14 12.20 3 2 
304372910 YP_003856119.1 E0TKK2 ABC transporter, ATP-binding protein 12.17 5 2 
304373056 YP_003856265.1 E0TL69 Glycerol-3-phosphate dehydrogenase, putative 11.95 7 3 
304373439 YP_003856648.1 E0TLN9 hypothetical protein MHR_0660 11.87 17 6 
304373423 YP_003856632.1 E0TLM3 hypothetical protein MHR_0644 11.75 7 3 
304373385 YP_003856594.1 E0TLB3 Threonyl-tRNA synthetase 11.70 14 7 
304372879 YP_003856088.1 E0TKA4 Ag 243-5 protein 11.67 17 4 
304372945 YP_003856154.1 E0TKN7 Histidyl-tRNA synthetase 11.64 9 3 
304372915 YP_003856124.1 E0TKK7 DNA gyrase subunit A 11.63 13 7 
304373226 YP_003856435.1 E0TKF4 Outer membrane protein-P95 11.46 19 7 
304373294 YP_003856503.1 E0TKU8 hypothetical protein MHR_0508 11.16 6 2 
304373295 YP_003856504.1 E0TKU9 NH(3)-dependent NAD(+) synthetase 11.11 5 2 
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304373124 YP_003856333.1 E0TLL2 Expressed protein 10.91 3 2 
304373211 YP_003856420.1 E0TKD9 protein phosphatase 2C 10.89 5 2 
304373360 YP_003856569.1 E0TL88 Glucosamine-6-phosphate isomerase 1 10.87 5 2 
304373110 YP_003856319.1 E0TLJ8 hypothetical protein MHR_0314 10.86 6 2 
304373391 YP_003856600.1 E0TLB9 hypothetical 33 kDa chaperonin 10.58 9 3 
304372898 YP_003856107.1 E0TKC3 Triacylglycerol lipase 10.49 4 2 
304373458 YP_003856667.1 E0TLQ8 Membrane protein oxaA 10.46 14 5 
304373241 YP_003856450.1 E0TKG9 Probable L-ribulose-5-phosphate 3-epimerase ulaE 10.44 9 2 
304373323 YP_003856532.1 E0TKX7 alanyl-tRNA synthetase 10.26 13 8 
304373417 YP_003856626.1 E0TLE5 Oligopeptide ABC transporter permease protein 10.26 3 3 
304373212 YP_003856421.1 E0TKE0 guanylate kinase 9.90 2 2 
304373225 YP_003856434.1 E0TKF3 hypothetical protein MHR_0439 9.85 10 8 
304373365 YP_003856574.1 E0TL93 tRNA modification GTPase mnmE 9.68 9 4 
304373115 YP_003856324.1 E0TLK3 ABC transporter ATP-binding protein 9.65 5 3 
304373209 YP_003856418.1 E0TKD7 Ribulose-phosphate 3-epimerase 9.63 9 2 
304373346 YP_003856555.1 E0TL74 ATP-dependent protease La 9.62 15 7 
304373415 YP_003856624.1 E0TLE3 Oligopeptide ABC transporter ATP binding prote 9.60 13 3 
304373320 YP_003856529.1 E0TKX4 Peptidyl-tRNA hydrolase 9.42 3 2 
304373358 YP_003856567.1 E0TL86 Glutamyl-tRNA amidotransferase subunit B 9.28 4 2 
304373076 YP_003856285.1 E0TLG4 lipoate-protein ligase A 9.25 17 4 
304373090 YP_003856299.1 E0TLH8 hypothetical protein MHR_0294 9.16 6 3 
304373101 YP_003856310.1 E0TLI9 aminotransferase class V 9.14 7 3 
304373048 YP_003856257.1 E0TL61 hypothetical protein MHR_0251 9.07 4 2 
304372968 YP_003856177.1 E0TKR0 hypothetical protein MHR_0167 8.89 8 3 
304373228 YP_003856437.1 E0TKF6 prolipoprotein diacylglyceryl transferase 8.82 3 2 
304373069 YP_003856278.1 E0TLF7 CTP synthase 8.81 12 3 
304373277 YP_003856486.1 E0TKT1 Transcription termination-antitermination factor nusA 8.80 3 3 
304373263 YP_003856472.1 E0TKJ1 Phosphotransferase system (PTS) enzyme I 8.58 12 4 
304373366 YP_003856575.1 E0TL94 ABC transporter ATP-binding protein 8.55 10 4 
304373114 YP_003856323.1 E0TLK2 ABC transporter permease protein 8.35 30 15 
304373218 YP_003856427.1 E0TKE6 Hexosephosphate transport protein 7.88 12 4 
304373338 YP_003856547.1 E0TKZ2 Zinc metalloproteinase C 7.78 9 7 
304372876 YP_003856085.1 E0TKA1 P59-like protein 7.62 4 2 
304373431 YP_003856640.1 E0TLN1 hypothetical protein MHR_0652 7.56 11 2 
304373057 YP_003856266.1 E0TL70 hypothetical protein MHR_0260 7.54 5 3 
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304373045 YP_003856254.1 E0TL58 DNA gyrase subunit B 7.34 7 5 
304373273 YP_003856482.1 E0TKK1 ABC transporter xylose-binding lipoprotein 7.24 8 2 
304372899 YP_003856108.1 E0TKC4 Lipoyltransferase and lipoate-protein ligase 6.99 6 2 
304373282 YP_003856491.1 E0TKT6 Phosphate acyltransferase 6.95 5 3 
304373043 YP_003856252.1 E0TL56 hypothetical protein MHR_0246 6.93 3 2 
304372873 YP_003856082.1 E0TK98 GTP-binding protein LepA 6.84 3 2 
304372918 YP_003856127.1 E0TKL0 Ribose-phosphate pyrophosphokinase 6.75 2 2 
304373150 YP_003856359.1 E0TK02 Lipoprotein 6.66 7 4 
304373331 YP_003856540.1 E0TKY5 hypothetical protein MHR_0546 6.63 11 3 
304373065 YP_003856274.1 E0TLF3 Glycosyltransferase 6.34 3 2 
304373229 YP_003856438.1 E0TKF7 Excinuclease ATPase subunit-like protein 6.28 15 7 
304373153 YP_003856362.1 E0TK05 Oligopeptide transport system permease protein 6.24 4 2 
304373317 YP_003856526.1 E0TKX1 Lysyl-tRNA synthetase 1 6.10 8 4 
304373352 YP_003856561.1 E0TL80 Protein translocase subunit secA 6.10 6 5 
304373230 YP_003856439.1 E0TKF8 hypothetical protein MHR_0444 5.75 4 3 
304372889 YP_003856098.1 E0TKB4 Heat-inducible transcription repressor hrcA 5.40 2 2 
304372836 YP_003856045.1 E0TK61 molecular chaperone DnaJ 5.38 4 2 
304373066 YP_003856275.1 E0TLF4 Putative asparaginyl-trna synthetase protein 5.38 6 2 
304372807 YP_003856016.1 E0TJV7 DNA polymerase III beta subunit 5.35 4 2 
304373037 YP_003856246.1 E0TL50 Cysteinyl-tRNA synthetase 5.25 2 2 
304372965 YP_003856174.1 E0TKQ7 Xylose ABC transporter permease protein 5.24 7 2 
304373089 YP_003856298.1 E0TLH7 hypothetical protein MHR_0293 5.01 16 7 
304373063 YP_003856272.1 E0TLF1 ATP-dependent helicase PcrA 4.91 4 3 
304373404 YP_003856613.1 E0TLD2 Probable ABC transporter ATP-binding protein p29 4.76 2 2 
304373357 YP_003856566.1 E0TL85 Glutamyl-tRNA amidotransferase subunit A 4.37 6 2 
304373382 YP_003856591.1 E0TLB0 Putative ATP-binding helicase protein 4.10 6 4 
304373443 YP_003856652.1 E0TLP3 ribonucleotide-diphosphate reductase subunit alpha 3.88 11 2 
304373334 YP_003856543.1 E0TKY8 Membrane nuclease, lipoprotein 3.82 2 2 
304372845 YP_003856054.1 E0TK70 hypothetical protein MHR_0042 3.55 3 2 
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